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Macrophages are key mediators of innate immunity to infection and are also 
involved in the initiation of adaptive immune responses. Their functions include 
phagocytosis of invading microorganisms, killing of pathogens by the generation of toxic 
mediators such as reactive oxygen intermediates and nitric oxide (NO), and antigen 
presentation to lymphocytes. Activated macrophages also release various cytokines that 
can induce or direct lymphocyte activation. For example, the pro-inflammatory cytokines 
IL-6 and TNF-a promote B and T cell activation, and the heterodimeric cytokine IL-12
drives the differentiation of IFN-y-producing type 1 T helper cells.
Bacterial endotoxin or lipopolysaccharide (LPS), a potent activator of 
macrophages, has been used extensively to study macrophage function. Multiple 
intracellular signalling cascades are triggered following binding of LPS to the recently- 
identified Toll-like receptor 4 (TLR4), resulting in the induction of macrophage 
mediators including cytokines and inducible nitric oxide synthase (iNOS), the enzyme 
that catalyses NO synthesis. Pre-treatment or co-stimulation with interferon (IFN)-y,
which is itself a potent inducer of iNOS, results in modulation of LPS-induced cytokine 
production, including priming for IL-12 production.
The mitogen-activated protein (MAP) kinases are important intracellular 
regulators of a diverse range of cellular functions. In this study, the three major MAP 
kinase subfamilies - extracellular-regulated kinases (ERKs), p38 and c-Jun N- 
terminal/stress-activated protein kinases (JNK/SAPKs) -  are shown to be activated by
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stimulation of macrophages with LPS in the presence/absence of IFN-y. Furthermore,
regulatory roles for the ERK and p38 MAP kinases in the induction of IL-12, IL-6, TNF- 
a and iNOS are demonstrated. p38 MAP kinase activation is required for induction of all
of these macrophage mediators, regulating the induction of IL-12 and iNOS at the 
transcriptional level, and the translation or release of TNF-a. Induction of TNF-a and
iNOS, but not IL-12 p35 or IL-6, is also dependent on ERK MAP kinases. In contrast, 
transcription of the IL-12 p40 gene is negatively regulated by the ERKs to promote the 
formation of bioactive IL-12 heterodimer without excessive production of antagonistic 
p40/p40 homodimers.
The modulation of macrophage activation by pathogens was also examined using 
the immunomodulatory products of two parasites; a surface glycoconjugate of 
intracellular Leishmania parasites and a glycoprotein secreted by an extracellular filarial 
nematode.
Leishmania sp. parasites, which invade and parasitise macrophages, have been 
shown to evade NO-mediated killing by suppressing macrophage IL-12 production and 
thereby preventing the production of IFN-y by Thl cells. In this study, the repeating
phosphodisaccharide (phosphoglycan, PG) component of the Leishmania  surface 
molecule lipophosphoglycan (LPG) is shown to be responsible for the suppression of 
bioactive IL-12 production and a mechanism for this inhibition is proposed. Following 
binding of a synthetic version of this portion of LPG (sPG) to macrophages, probably via 
interaction with either the mannose-fucose receptor (MFR) or complement receptor 3 
(CR3), cellular levels of dual-phosphorylated ERK MAP kinases were enhanced, thereby
suppressing the induction of bioactive IL-12 by preventing synthesis of the p40 subunit at 
the transcriptional level.
The effects on macrophage function of an excretory-secretory product of the 
filarial nematode Acanthocheilonema viteae (ES-62) were also investigated. ES-62 has 
previously been shown to modulate the activation of B and T lymphocytes and the 
differentiation of dendritic cells. In vitro and in vivo exposure of macrophages to ES-62 is 
shown to inhibit induction of IL-12, IL-6 and TNF-a by LPS. ES-62 targets the synthesis
and activation of multiple signalling molecules including tyrosine kinases, MAP kinases 
and transcription factors such as NF-kB and IRF family members. The roles of MAP
kinases in the ES-62-mediated suppression of cytokine induction were also investigated.
The results described provide valuable information about the mechanisms 
underlying the production of cytokines and NO by activated macrophages, and 
demonstrate how pathogens target these responses to evade detection and destruction by 
the host immune system.
Chapter 1 -  General Introduction.
1:1 Macrophages and their roles in innate and adaptive immunity.
Invasion of tissues of healthy, genetically-normal mammals with harmful 
pathogens results in the generation of an immune response to clear the infection. Initially, 
non-specific mechanisms of innate immunity result in local inflammatory responses, 
which are mediated by a variety of cell types, including macrophages, dendritic cells, 
polymorphonuclear leukocytes, mast cells and natural killer cells. These innate immune 
cells co-operate to contain the infection and to remove pathogens by mechanisms 
including phagocytosis and destruction by toxic products. Adaptive immunity is 
established several days after the initial infection and involves the specific recognition of 
pathogens and their products by B and T lymphocytes. This leads to the generation of 
cytotoxic lymphocytes and the production of specific antibodies, which mediate killing of 
infected cells and clearance of the pathogen. The establishment of immune memory is 
another feature of the adaptive response, protecting the individual from subsequent re­
infection with that pathogen.
The long-established theory of self/non-self immune recognition states that an 
immune response is initiated when eells of the immune system recognise foreign (non­
self) antigen (via binding to pattern recognition receptors on cells of the innate immune 
system and lymphocyte antigen receptors). Self-reactive lymphocytes are removed by 
deletion to ensure that the host is tolerant to self-antigens. Recently, this long-held view 
of the immune system has been challenged by the Danger Theory (Matzinger, 1994 and
1998), which is now becoming widely accepted. This new theory suggests that where 
there is no damage caused to an individual by an infectious organism, there is no need to 
mount an immune response to it. However, if infection with pathogens results in distress,
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damage, destruction or necrotic death, endogenous alarm signals from affected cells are 
thought to be detected by dendritic cells, which then activate innate and adaptive 
immunity.
Macrophages play critical roles in immune responses, both as mediators of innate 
immunity and also in the establishment of adaptive immune responses. They provide a 
first line of defence against infection due to their phagocytic activity and toxicity to a 
variety of pathogens, and are thus critical during the early stages of infection. Their 
principle functions (summarised in Figure 1.1) include detection of pathogens and 
pathogen products such as LPS, phagocytosis of infectious microorganisms, toxic killing 
of pathogens by the production of reactive oxygen intermediates and NO release, antigen 
presentation to T cells and production of pro-inflammatory cytokines such as IL-1, IL-6, 
IL-12 and TNF-a. As well as detecting and destroying invading organisms, macrophages 
are responsible for the careful removal of apoptotic and necrotic cells, which might 
represent sources of danger signals.
Macrophages develop from pluripotent haematopoietic stem cells (HSCs) of the 
bone marrow along the myeloid lineage. In mammals, HSCs are found in the foetal liver, 
spleen and bone marrow; after birth and throughout adulthood they are present only in the 
bone marrow. Myelopoiesis proceeds by the action of the colony stimulating factors 
(CSFs). HSCs differentiate in the presence of macrophage-CSF (M-CSF or CSF-1), 
granulocyte/monocyte-CSF (GM-CSF) and IL-3 to become monocytes, which enter the 
bloodstream. Monocytes migrate into tissues e.g. at sites of infection, in response to 
chemotactic molecules released by endothelial cells, and there they mature into 
macrophages (Unanue, 1984). There are two major types of macrophage: those that are
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resident in particular tissues (e.g. liver, lung, skin, CNS, gut, kidney, endocrine organs 
and lymphoid tissue; Gordon, 1986) and those that are recruited to sites of injury or 
infection. The latter group can be further subdivided into inflammatory and activated 
macrophages. Inflammatory macrophages are recruited to non-immunological 
inflammatory sites e.g. following injection with thioglycollate broth; they show increased 
size and competence for phagocytic activity, chemotaxis and antigen presentation 
compared with resident macrophages (Adams and Hamilton, 1984). Macrophages can be 
activated by pathogen products such as lipopolysaccharide (LPS) and cytokines such as 
IFN-y and TNF-a. In addition to the properties displayed by inflammatory macrophages, 
activated macrophages produce toxic oxygen intermediates and secrete regulatory 
moleeules that activate B and T lymphocytes (Beaman and Beaman, 1984).
1:2 Activation of macrophages by LPS.
One of the best characterised and most potent activators of macrophages is 
lipopolysaccharide (LPS). LPS, or bacterial endotoxin, is a surface glycolipid of Gram 
negative bacteria. It is composed of a hydrophilic repeating polysaccharide region (O- 
antigen and core) and a hydrophobic lipid domain, lipid A (see Figure 1.2). The structure 
of LPS varies between species, especially in the 0-antigen region (reviewed by Seydel et 
al, 2000). The function of LPS is largely attributed to the conserved lipid A portion, 
sinee virtually all LPS-induced biological activities are lipid A-dependent (Rietschel et 
al, 1994) and synthetic lipid A has full endotoxic activity.
1:2:1 Induction of pro-inflammatory cytokines and other macrophage mediators by 
LPS.
LPS on intact bacteria or shed from the bacterial surface can be recognised by a 
variety of cells including macrophages and B cells via the lipid A portion of the 
molecule. Activation of these cells by LPS results in the generation of an array of 
mediators that direct an immune response to destroy the invading bacteria. During 
infection, LPS is a potent mediator of local inflammatory responses. The effects of LPS 
include activation of macrophages to produce pro-inflammatory cytokines such as 
interleukin (IL)-l, IL-6, IL-8, IL-12 and tumour necrosis factor (TNF)-a. LPS also 
induces production of other inflammatory mediators such as prostaglandins, oxygen 
radicals, hydrogen peroxide, nitric oxide (NO), leukotrienes and platelet-activating factor 
(PAF). TNF-a and IL-1 stimulate vascular permeability, allowing local accumulation of 
fluid, immunoglobulins and complement proteins. Furthermore, expression of adhesion 
molecules by vascular endothelial cells allows recruitment of circulating neutrophils and 
monocytes to the site of infection. Mediators of innate immunity also direct activation of 
the adaptive immune response e.g. IL-1 and IL-6 activate lymphocytes; IL-12 is critical 
for differentiation of type 1 T helper (Thl) cells. Overstimulation with LPS can have 
toxic systemic effects on the host, such as multiple organ failure, shock and death (Bone, 
1991; Glauser et a/., 1991).
1:2:2 LPS binding and activation of signalling. 
1:2:2:1 CD14 and Toll-like receptors (TLRs).
Unlike the receptors of the adaptive immune system (the TCR and BCR), which 
are generated with random antigen specificity and then clonally selected, cells of the 
innate immune system possess pattern recognition receptors with predetermined 
specificity for a limited number of molecular patterns that are common to a broad range 
of pathogens. These include lipopolysaccharide (LPS) and lipoteichoic acid (LTA) of 
Gram negative and Gram positive bacteria respectively, lipoproteins produced by bacteria 
and parasites, phosphorylcholine (PC) which has been detected in a variety of prokaryotic 
and eukaryotic pathogens, mycobacterial glycolipids, yeast mannans and viral double­
stranded RNAs (reviewed by Medzhitov and Jane way Jr, 1997 and Harnett and Harnett,
1999).
The association of LPS with a variety of serum proteins has been shown to have 
positive and negative effeets on macrophage activation by LPS (Marra et a l, 1992; 
Wright et al, 1992). The best characterised interaction is between LPS and LPS binding 
protein (LBP), a 60 kDa glycoprotein produced by hepatocytes (Ramadori et al, 1990; 
Grube et al, 1994). A role for LBP in LPS recognition and activation of macrophages 
was confirmed by targeted deletion of the LBP gene in mice, which resulted in impaired 
sensitivity to LPS (Jack et al, 1997). LPS aggregates in solution, but LBP disaggregates 
LPS molecules and transports them to the macrophage cell membrane (Schromm et al, 
1996).
The LPS-LBP complex is able to bind to the monocyte/macrophage specific 
surface receptor CD 14, allowing responses to even low doses of LPS (Wright et al, 
1990; Martin et ai, 1992). Targeted deletion of the CD 14 gene in mice demonstrated the 
importance of CD 14 in LPS responsiveness, since only modest amounts of TNF-a and 
negligible IL-1 (3 and IL-6 were induced in these mice (Haziot et ai, 1996). Furthermore, 
stable expression of CD 14 in Chinese hamster ovary (CHO)-Kl fibroblasts conferred 
LPS-responsiveness on these cells (Golenbock et ai, 1993), and the overexpression of a 
human CD14 transgene in mice resulted in hypersensitivity to LPS (Ferrero et al., 1993).
CD 14 exists in two forms: as a glycosylphosphoinositide (GPI)-anchored 
membrane glycoprotein, or in serum as a soluble form (sCD14) that lacks the GPI tail 
(Bazil et ai, 1989). sCD14 is involved in the LPS-mediated activation of non-myeloid 
cells such as endothelial and epithelial cells (Frey et at., 1992; Pugin et ai, 1993), but at 
high concentrations it inhibits LPS action on macrophages (Haziot et ai, 1995). GPI- 
anchored CD14 binds LPS with a stoichiometry of 1:1 (Kitchens and Munford, 1995) and 
is essential for LPS signalling, but it is not capable of transducing signals since it lacks an 
intracellular domain. Therefore it was postulated that it interacts with another LPS 
receptor to achieve activation. The requirement for CD 14 was shown to be bypassed by 
treatment with high doses of LPS (Beaty et al, 1994; Wright et al, 1990), suggesting that 
CD 14 acts to present low doses of LPS to a less abundant receptor.
Recently a family of pattern recognition receptors, the Toll-like receptors (TLRs), 
has been identified and its members have been implicated in the binding of a range of 
pathogen molecules including LPS (reviewed by O ’Neill and Dinarello, 2000 and 
Brightbill and Modlin, 2000). The TLRs were identified on the basis of their homology to
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Drosophila Toll protein, which, as well as being involved in dorsoventral patterning of 
Drosophila embryos during development, is crucial for anti-fungal responses in these 
flies, which possess only innate immunity to pathogens. Similarly, another member of the 
Drosophila Toll family, 18-wheeler (18w), is required for production of an anti-bacterial 
peptide (Eldon et al, 1994; Williams et al., 1997). Toll-like proteins have now been 
identified in a broad range of organisms, including plants (van der Biezen and Jones,
1998).
The first mammalian Toll homologue was identified by Medzhitov et al. (1997). 
They isolated hToll4 (TLR4) mRNA from dendritic cells, yô T cells, Thl and Th2 ap T 
cells and B cells, and demonstrated that a dominant active form of the receptor induced 
cytokine expression when expressed in monocyte cell lines. The murine homologue of 
this receptor was subsequently implicated as the LPS receptor. This was suggested by the 
demonstration that LPS-hyporesponsive C3H/HeJ mice have a point mutation in the gene 
encoding TLR4 that results in the production of inactive receptor (Poltorak et al., 1998). 
Similarly, C57BL/10ScCr mice, which are also LPS-insensitive, have a null mutation in 
the TLR4 gene (Qureshi et al, 1999). Subsequently, Chow et al. (1999) demonstrated 
that transient transfection of HEK 293 cells with human TLR4 conferred sensitivity to 
stimulation with LPS/CD14 complexes on these cells. Furthermore, an LPS antagonist 
blocked TLR-4-mediated activation of an NF-kB reporter construct in a dose-dependent 
manner.
To date, ten mammalian TLRs are known (WIPO, 1998); nine have been 
published (Rock et al., 1998; Chu an g and Ulevitch, 2000; Du et ai, 2000), although 
ligands for only TLR2 and 4 have been identified. TLRs are members of the IL-IR/TLR
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superfamily which also includes the receptors and accessory proteins for IL-1 and IL-18, 
and the Th2 cell-specific marker ST2 (reviewed by Wright, 1999 and O ’Neill and 
Dinarello, 2000). In contrast to the intracellular signalling domain, which shows a high 
degree of conservation between TLR family members, the extracellular portion is 
considerably more diverse. A critical feature of the extracellular domain is the presence 
of leucine-rich repeats (LRRs), which are believed to mediate the response to conserved 
pathogen-associated molecular patterns and thought to play an important role in the 
specificity of host responses to infection.
TLR family members studied so far also achieve transcriptional regulation of 
effector genes through identical signal transduction cascades (see Figure 1.3). In 
Drosophila, production of anti-microbial proteins is dependent on the activation of the 
NF-kB pathway: Rel family members such as Dorsal, Dif and Relish are activated 
following the degradation of the I-kB homologue Cactus. In the same way, mammalian 
TLRs have been demonstrated to signal via NF-kB. Following the binding of ligand to a 
TLR, MyD88, which is itself a member of the IL-IR/TLR superfamily but which lacks an 
extracellular domain, associates with the intracellular signalling domain of the receptor. 
MyD88 acts as an adaptor for the recruitment of IL-lR-associated kinases (IRAKs), 
which activate TNF reeeptor-associated factor 6 (TRAF-6), resulting in nuclear 
translocation of NF-kB and activation of mitogen activated protein (MAP) kinases.
1 2
1:2:2:2 LPS signalling.
The intracellular signalling pathways triggered by LPS are outlined in Figure 1 A. 
Signalling molecules previously identified as targets of LPS via CD 14 are presumably 
regulated through TLR4, although this assumption has not yet been fully confirmed.
Increased tyrosine phosphorylation and activation of Src family kinases Lyn, Hck 
and Fgr occurs within 1 minute of macrophage activation with LPS (Ziegler et al., 1988; 
Stefanova et al, 1991 and 1993; Beaty et al, 1994). LPS has also been shown to induce 
tyrosine phosphorylation of Vav (English et al, 1997) as well as pl45 and She, which are 
often associated with Syk (Crowley et al, 1996). However, activation of Syk by LPS has 
not been shown and Syk-deficient cells respond normally to LPS (Crowley et al, 1997). 
LPS-induced Lyn activation (Stefanova et al, 1993) leads to activation of PI-3-kinase 
(Herrera-Velit and Reiner, 1996) which in turn activates protein kinase C (PKC)-Ç 
(Herrera-Velit et al, 1997). However, macrophages from LynVHck'/Fgr triple knockout 
mice have no major defects in LPS-induced stimulation of NO, IL-1, IL-6 and TNF-a 
secretion, and normal activation of ERR 1/2 and JNK MAP kinases and the transcription 
factor NF-kB (Meng and Lowell, 1997).
LPS is a strong activator of all three subfamilies of mitogen activated protein 
(MAP) kinases -  the extracellular-regulated kinases (ERKs), p38 and the c-Jun N- 
terminal or stress-activated protein kinases (JNKs or SAPKs) (Weinstein et al, 1992; 
Han era/., 1994; Liu et a/., 1994; Raingeaud era/., 1995; Hambleton era/., 1996). These 
serine/threonine kinases have important roles in a range of cell functions including 
protein synthesis, cell cycle control, division and differentiation, and have been suggested
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to regulate cytokine and iNOS production (Davis, 1994; Karin, 1994). The MAP kinase 
kinases (MKKs or MEKs) responsible for dually phosphorylating (Thr-X-Tyr) and 
thereby activating the MAP kinases in response to stimulation with LPS have also been 
identified: MEKs 1 and 2 activate ERKs 1 and 2, MEKs 3 and 6 activate p38, and MEKs 
4 and 7 activate JNKs 1 and 2 (Geppert et al, 1994; Reimann et al, 1994; Buscher et al, 
1995; Sanghera et al, 1996; Swantek et al, 1997; Yao et al, 1997b).
The Ras—>R af^M E K  pathway for activation of ERK MAP kinases is well 
characterised but there are indications that in LPS-stimulated macrophages it is not the 
main activatory pathway for ERK 1/2 (Buscher et al, 1995). Indeed, there is evidence that 
LPS doesn’t even activate the R as^R af pathway (Guthridge et al, 1997). PKC has been 
implicated in the activation of the MEKl/2->ERKl/2 pathway in other systems, but this 
connection has not been established for LPS.
LPS stimulation induces the activity of a number of transcription factors, 
including NF-kB, NF-IL6, members of the CREB/ATFl and AP-1 families, Ets family 
members (including Ets, Elk, Erg and PU.l) and Egr (Sweet and Hume, 1996; Groupp 
and Donavon-Peluso, 1996). These may be activated by phosphorylation by specific 
kinases (e.g. CREB/ATFl, or the AP-1 family member c-Jun) or synthesised de novo 
(e.g. the LPS ‘early response genes’ Jun-B, c-Fos and Egr-1).
As described above, activation of NF-kB family members by TLR4 occurs via 
MyD88, IRAKs and TRAF-6. This leads to activation of IKKa/(3 which phosphorylates I- 
kB; I-kB is then ubiquitinated and degraded, releasing NF-kB to translocate to the nucleus
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(reviewed by Karin, 1999) where it can bind to and regulate the transcription of a variety 
of LPS-inducible genes including IL-12, IL-6, TNF-a and iNOS.
1:2:3 Priming of macrophages by IFN-y.
Pre-incubation or co-stimulation of macrophages with IFN-y has been shown to 
enhance responses to LPS, including IL-12, IL-6, TNF-a and iNOS production (Ma et al, 
1996b; Xie et al, 1993; Martin et al, 1994; Lowenstein et al, 1993; Weisz et al, 1994; 
Sanceau et al, 1991; Darnell et al, 1994). Priming of different responses is achieved by 
distinct mechanisms: for example, while priming for iNOS is achieved by direct targeting 
of pre-existing transcription factors, maximal priming for IL-12 induction may require de 
novo synthesis (Ma et al, 1996b).
The IFN-y receptor is composed of two distinct subunits, IFNGRl and IFNGR2 
(Stark et al, 1998). IFNGRl is the major ligand-binding subunit; both IFNGRl and 
IFNGR2 have critical signalling functions (reviewed by Bach et a l,  1997 and Platanias 
and Fish, 1999). Binding of IFN-y to its receptor results in association of the Janus 
kinases JAKl and JAK2 with the intracellular signalling portions of the receptor. This 
activates the JAKs, which phosphorylate IFNGRl, providing a docking site for the 
cytoplasmic protein signal transducers and activators of transcription 1 (STATl). The 
JAKs phosphorylate STATl, enabling the formation of STATl homodimers, which 
translocate to the nucleus where they bind IFN-y-activated sequence (GAS) elements on 
target genes. Other signalling moleeules activated by IFN-y include the Src tyrosine 
kinase family member Fyn, the tyrosine kinase Pyk-2 which has been linked to ERK-2
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activation, the adaptors CrkL and Crkll, the guanine exchange factor Vav, and the 
tyrosine phosphatases SHP-1 and SHP-2, but their functions in the priming of 
macrophages for cytokine induction by LPS are not clear.
1:3 Regulation of pro-inflammatory cytokine and NO production. 
1:3:1 Interleukin-12 (IL-12) production.
IL-12 was originally identified in the culture supernatants of Epstein-Barr virus 
(EBV)-transformed human B cell lines due to its ability to activate NK cells to produce 
IFN-y, and was initially known as NK cell stimulatory factor (NKSF; Kobayashi et al., 
1989; Stern et ai, 1990). However, it was subsequently found to be produced mainly by 
phagocytic cells (monocytes, macrophages and neutrophils) in response to both Gram 
negative and positive bacteria, bacterial products such as lipopolysaccharide (LPS) and 
lipoteichoic acid (LTA), viruses and intracellular parasites (D'Andrea et al., 1992; 
Cleveland et ai, 1996; Kanangat et al., 1996). Bacterial DNA has also been shown to be 
a potent inducer of IL-12; this activity is dependent on nonmethylated CpG repeats 
(Halpern et al., 1996; Balias et al., 1996). Dendritic cells, polymorphonuclear cells and 
mast cells also produce IL-12 (Smith et al, 1994; Cassatella et al, 1995; Celia et ai, 
1996; Heufler et al., 1996; Kang é ta l,  1996; Koch é ta l,  1996).
Bioactive IL-12 p70 is a heterodimer comprising two glycosylated polypeptides - 
a 35 kDa (p35) chain and a 40 kDa (p40) chain - which are linked by disulphide bonds. 
These subunits are encoded separately, on chromosomes 3 and 5 respectively (Sieburth et
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al, 1992), and regulation of their expression is distinct. p35 is ubiquitously and 
constitutively expressed in a variety of cell types, whereas p40 expression is more 
restricted and highly inducible. It has been hypothesised that the IL-12 heterodimer may 
have been derived from a primordial cytokine and its receptor since p35 shares structural 
similarities with IL-6 and granulocyte-CSF (G-CSF; Merberg et al, 1992), while p40 is 
structurally related to the extracellular portion of the IL-6 and G-CSF receptors (Gearing 
and Cosman, 1991).
The p40 subunit is produced in large excess over p70 heterodimer (1 0 -2 0  times) 
and, in addition to forming bioactive IL-12 heterodimers, it can form homodimers (p402), 
which are antagonistic to bioactive IL-12 (Ling et al, 1995). p35 has also been found in 
complex with the product of EBV-induced gene 3 (EBI3; Devergne et al, 1997) although 
the function of EBI3 and the p35:EBI3 complex are unknown.
The in vivo induction of IL-12 can be either T cell-independent or -dependent. 
Infection with bacteria or intracellular parasites results in rapid IL-12 production by 
direct stimulation of phagocytes; indeed, T cell-deficient SCID mice produce bioactive 
IL-12 upon infection (Gazzinelli et al,  1994; Tripp et al, 1994). However, T cell- 
dependent mechanisms have also been demonstrated. IL-12 production occurred in 
response to presentation of T cell-dependent antigens such as OVA via triggering of 
CD40 molecules on antigen presenting cells and was dependent on TCR ligation 
(DeKruyff et al, 1997; Mamo et al, 1997). CD40-CD40L interaction plays a critical role 
in bioactive IL-12 production by regulating p40 but not p35 mRNA accumulation (Kato 
et al, 1996).
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IL-12 is a key mediator of innate immunity and is also involved in the 
establishment of adaptive immune responses (reviewed by Trinchieri, 1995). It directs the 
differentiation of helper T cells towards a type 1 phenotype, which is characterised by the 
production of IFN-y and down-regulation of IL-4. IL-12 also stimulates IFN-y production 
by NK cells, and thus establishes a positive feedback loop resulting in enhanced 
activation of macrophages, including stimulation of NO production. This is especially 
important for the effective removal of intracellular pathogens such as Listeria 
monocytogenes. Toxoplasma gondii and Leishmania major (reviewed by Ma et ah, 
1996a). Animals treated with neutralising doses of monoclonal antibodies against IL-12 
p40, or lacking either the IL-12 p40 or p35 gene are highly susceptible to such 
intracellular pathogens (Biron and Gazzinelli, 1995; Trinchieri and Scott, 1995).
Both subunits must be co-expressed in the same cell to generate bioactive 
heterodimer and since p35 is constitutively-expressed in a variety of cell types, it was 
originally assumed that p70 generation was mainly controlled at the level of p40 
transcription. However, there is now much evidence of regulation of p35 transcripts 
(Hayes et al, 1995; Snijders et al, 1996; Aste-Amezaga et al,  1998; Kincy-Cain and 
Bost, 1997), and it is therefore more likely that p35 is the limiting subunit. Indeed, the 
formation of antagonistic p402 may predominate even under optimal conditions (Hayes et 
al, 1995; Snijders et al, 1996) and it has therefore been suggested that a temporal 
balance between pdOj and bioactive p70 determines the IL-12 response (Schultze et al,
1999).
Synthesis of both subunits is induced by LPS; IFN-y, which alone can induce low 
levels of p35 but not p40, primes monocytes for transcription of p35 and p40 and is
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thereby synergistic with LPS for bioactive IL-12 production (Ma et a l,  1996b). 
Regulation of p40 production is thought to be largely at the level of transcription. The IL- 
12 p40 promoter has been characterised (reviewed by Ma et al, 1997a) and is 
summarised in Figure 1.5. The human and murine promoters are highly conserved up to 
approximately 400 bp upstream of the transcription start site.
There is an ets element between -211 and -206 and putative PU.l and NF-kB 
elements between -124 and -105. In non-stimulated macrophages, the ets element is 
occupied by PU.l, but this is displaced following stimulation with IFN-y or LPS by a 
transcription factor complex, FI, which binds to the ets element in a complex manner, 
interacting with flanking sequence in the region -292 to -196 (Ma et al, 1997b). FI 
comprises a number of transcription factors, including Ets-2, IRF-1, c-Rel and Glpl09, a 
109 kDa protein highly induced by IFN-y or LPS stimulation. Similarly, an F2 complex is 
induced by IFN-y to interact with this element in the region -243 to -196, but its identity 
has not been established. The NF-kB ‘half-site’ between -116 and -106 has been reported 
to bind p65/p50 and c-Rel/p50 complexes in response to LPS stimulation (Murphy et al, 
1995).
Investigations using knockout mice have indicated that proteins of the IRE family, 
including IRF-1 and IRF consensus sequence binding protein (ICSBP), play significant 
roles in IL-12 expression. IRF-/- and ICSBP-/- mice are deficient in IL-12 production, do 
not efficiently develop Thl immune responses and are hence highly susceptible to 
infection with pathogens such as Listeria monocytogenes. Toxoplasma gondii and 
Leishmania major (Schaxton-KQi'sten et al, 1997; Fehr et al, 1997; Giese et al, 1997; 
Wu et al, 1999; Taki et al, 1997; Lohoff et al, 1997). Wang et a l  (2000) recently
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demonstrated that ICSBP is an important regulator of IL-12 p40 expression. They 
proposed that synthesis of ICSBP occurs following priming with IFN-y (via STAT-1) and 
stimulation with LPS (via NF-kB), and that ICSBP then binds to the Ets element of the 
IL-12 p40 promoter and acts synergistically with IRF-1 (which is also induced by IFN-y 
via STAT-1) to promote transcription.
Other transcription factor binding sites include an IRF-1 site at -730 to -719 and 
a binding site for a nuclear factor originally identified as a regulator of IL-6 production 
(NF-IL6); however, deletion of these regions did not alter the response to IFN-y and LPS 
(Ma et a/., 1996b).
The IL-12 p35 gene has not been so well characterised but, in contrast to p40 
expression, it is thought to require only pre-synthesised activators since its expression is 
not inhibited by treatment with cycloheximide (Aste-Amezaga et al, 1998). Although 
p35 is constitutively expressed, it has been suggested that regulation of p35 expression or 
post-translational modification, which would affect its association with the p40 subunit, 
may contribute to the regulation of p70 production (Snijders et a l,  1996). The murine 
p35 gene and its cDNA have been cloned and sequeneed, and putative promoter elements 
have been identified including Spl, AP-1, ISRE, ICSBP, NF-kB, GATA-1 and GAS 
elements (Schoenhaut et al, 1992; Yoshimoto et al, 1996; Tone et al, 1996). Tone et al 
(1996) showed that transcription can initiate from either of two 5’ exons, resulting in 
mRNA isoforms with different 5’ untranslated regions (UTRs). Subsequently, Babik et 
al  (1999) detected 4 isoforms of p35 mRNA in a murine B cell lymphoma line (A20) and 
bone marrow-derived dendritic cells. Two of these were predominant in non-stimulated 
cells and contained an additional upstream AT G in the 5’ UTR, which resulted in
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abortive translation of p35. Following stimulation with LPS, transcription of the p35 gene 
was not only upregulated, but the initiation of transcription occurred from alternate 
positions, resulting in transcripts lacking the additional upstream ATG. These were 
successfully translated to produce p35 subunit, which could subsequently dimerise with 
p40 to form bioactive IL-12 p70.
Processing of the IL-12 pre-protein subunits represents a further level of IL-12 
regulation. Murphy et al. (2000) recently demonstrated that p40 is processed in the 
normal way for a secretory protein, with cotranslational targeting to the endoplasmic 
reticulum (ER), removal of the signal peptide and partial glycosylation. In contrast, p35 
processing involves two sequential cleavages, which occurred after migration of the 
intact pre-protein into the ER; the second cleavage is accompanied by complex 
glycosylation.
Several cytokines have activatory or suppressive effects on the stimulation of IL- 
12 production by phagocytic cells. While IFN-y and GM-CSF enhance IL-12 (Cassatella 
et ai, 1995; Kubin et al, 1994; D ’Andrea et al, 1993), IL-10, IL-4, IL-13 and TGF-(3 
inhibit IL-12 production by suppressing both p40 and p35 accumulation (Kubin et al, 
1994; D’Andrea et al, 1995). However, IL-4 and IL-13 inhibit IL -12 and TNF-a 
production by monocytes when added simultaneously to the inducing stimulus, but prime 
for IL-12 production in response to various stimuli when added to the culture at least 18 
hours before the stimulus (D’Andrea et al, 1993).
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1:3:2 Interleukin-6 (IL-6) production.
IL-6 is a pleiotropic, pro-inflammatory cytokine with roles in the immune 
response, haematopoiesis and regulation of the acute phase reaction (reviewed by Hirano,
1992). It promotes the growth and proliferation of T cells and has been shown to induce 
IL-2 receptor expression in a T cell line and thymocytes (Noma et ah, 1987; Le et al,
1988). It also synergises with IL-1 for IL-2 and IL-2 receptor alpha chain production (Le 
et al, 1988; Houssiau et al, 1989), plays critical roles in the generation and function of 
cytotoxic T lymphocytes (Takai et al, 1988; Renauld et al, 1989; Liu et al, 1990; Smyth 
et al, 1990), and induces immunoglobulin synthesis by activated B cells (Yoshizaki et 
al, 1982; Muraguchi era/., 1988; Hilbert era/., 1989; Splawski era/., 1990).
IL-6 is produced by many different cell types including macrophages, fibroblasts, 
T and B lymphocytes, synovial cells, endothelial cells, glial cells and kératinocytes, in 
response to a variety of inducers such as IL-1, TNF-a, PDGF, serum and LPS (reviewed 
by Ray et al, 1989a and Hirano, 1992). T cells, for example, can be induced to produce 
IL-6 by mitogens or antigenic stimulation; LPS enhances IL-6 production by monocytes 
and fibroblasts, but glucocorticoids and IL-4 are inhibitory. Various viruses induce IL-6 
production in fibroblasts and in the central nervous system, and HIV has been 
demonstrated to induce IL-6 in monocytes. Disregulation of IL-6 production has also 
been found to contribute to a variety of diseases including autoimmune diseases and 
malignancies (reviewed by Hirano, 1992).
IL-6 is a single chain glycoprotein with a molecular mass ranging from 21 to 28 
kDa (reviewed by Hirano, 1992). Human and murine IL-6 are 66% and 42% homologous
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at the DNA and protein levels respectively; IL-6 is also homologous to G-CSF (Hirano et 
al., 1986). The human IL-6 gene is 5 kb in length and is located on chromosome 7 
(Sehgal et al, 1986); the 7 kb murine gene mapped to chromosome 5 (Mock et al, 1989). 
Both consist of five exons and four introns (Yasukawa et al, 1987; Tanabe et al, 1988). 
The promoter region is highly conserved up to approximately 350 bp upstream of the 
transcription start site (Tanabe et al, 1988), and contains several potential transcriptional 
control elements, such as glucocorticoid responsive elements (GREs), an AP-1 binding 
site, a c-fos serum response element (SRE), a cyclic AMP responsive element (CRE), and 
an NF-kB binding site (Tanabe e ta l,  1988; Ray et al, 1988 and 1989b; see Figure 1.6).
The CRE element, which mediates cAMP inducibility and binds the 
phosphoprotein CREB (Montminy e ta l ,  1986; Silver et al, 1987), is located within a 23 
bp multi-response element (MRE) which is induced by a variety of stimuli (Ray et al, 
1988 and 1989b). A novel 14 bp regulatory element containing an inverted repeat was 
also identified in this region and the nuclear factor that binds to it was cloned and named 
NF-IL6 (Isshiki et al, 1990). NF-IL6 is a leucine zipper protein that shares structural 
homology with CCAAT/enhancer binding protein (C/EBP; Akira et a l,  1990). It is 
induced by stimulation with LPS, IL-1, TNF-a and IL-6 in a variety of tissues (Akira et 
al, 1992). NF-IL6 has been reported to be activated by phosphorylation of its activation 
domain, which is mediated by a Ras-dependent MAP kinase cascade (Trautwein et al, 
1993; Nakajima et al, 1993). NF-IL6 may form homodimers or heterodimerise with 
other C/EBP family members (Kinoshita et al, 1992). Furthermore, Fos and Jun have 
been demonstrated to repress NF-IL6 through association with the leucine zipper region 
(Hsu et al, 1994).
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There have also been numerous reports of regulation of IL-6 production by NF-kB 
(Ray and Ray, 1995; Zhang et al, 1994; Mori et al, 1994; Akira and Kishimoto, 1997). 
Sanceau et al. (1995) showed that triggering of the human IL-6 gene in monocytes by 
IFN-y and TNF-a involves co-operation between the IRF-1, NF-kB and Spl transcription 
factors, and Kannabiran et al. (1997) demonstrated that the transcriptional repressor RBP 
(CBFl) regulates IL-6 gene expression.
Post-translational N- and O-linked glycosylation and phosphorylation of IL-6 pre­
protein represent additional levels of regulation (May et ai,  1988; Santhanam et al.,
1989).
1:3:3 Tumour necrosis factor-a (TNF-a) production.
Tumour necrosis factor (TNF)-a was so named because it was first discovered due 
to its ability to cause necrosis of some tumours (Carswell et ai, 1975). Also known as 
cachectin, it is a pro-inflammatory cytokine, which is produced principally by monocytes 
and macrophages (Beutler and Cerami, 1988; Ziegler, 1988; Old, 1987; Vassalli, 1992; 
MacNaul et ai, 1990); exposure to LPS typically results in up to 10,000-fold induction 
(Beutler et al., 198b). It has also been implicated in the pathogenesis of both acute and 
chronic inflammatory disease (Beutler and Cerami, 1986; Mannel and Echtenacher,
2000). Like IL-6, TNF-a can induce produetion of acute phase proteins and activation of 
B and T cells. It is also capable of stimulating fibroblast proliferation, and activating 
endothelial and synovial cells. Furthermore, it activates macrophages to produce pro-
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inflammatory cytokines: antibodies against TNF-a caused repression of IL-1 and IL-6 
production in response to LPS in vivo (Fong et al, 1989).
Regulation of TNF-a production is complex and stimulus-dependent, and occurs 
at transcriptional and post-transcriptional levels. Human TNF-a is encoded by a single 
gene, which is located on chromosome 6 in the middle of the major histocompatibility 
complex (Spies et al, 1989). It is initially expressed as a 26 kDa transmembrane protein 
which is subsequently cleaved by a metalloproteinase (Black et al,  1997; Moss et al, 
1997). Soluble TNF-a molecules can then form non-covalently linked homotrimers. 
Mature TNF-a is non-glycosylated, and both the membrane-bound and soluble forms are 
biologically active (Perez et al, 1990).
Sequence analysis revealed that the proximal promoter contains multiple 
transcription factor binding sites (see Figure 1.7), including NF-kB (Collart et al, 1990; 
Drouet et al, 1991; Shakhov et al,  1990; Trede et al, 1995), NF-IL6 (also known as 
C/EBPp; Pope et al, 1994; Natsuka et al, 1992) and c-Jun (Newell et al, 1994), which 
have been shown by deletion and mutational analysis to contribute to activation of the 
TNF-a promoter in macrophages (Economou et al, 1989; Pope et al, 1994; Wedel et al, 
1996; Yao et al, 1997a; Udalova et al,  1998). NF-kB binding sites have also been 
identified downstream of the TNF-a gene (Kuprash et al, 1995; Kwon et al, 1996). All 
of these transcription factors can be activated via ERK and JNK MAP kinase pathways 
following LPS stimulation (Nakajima et al, 1993; Trautwein et al, 1993; Scherle et al, 
1998; Foey et al, 1998).
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However, the relative contribution of each transcription factor and the effects of 
synergy between them appear to depend on the differentiation stage of the macrophage. 
NF-IL6 and c-Jun interacted to mediate LPS-induced TNF-a production by the 
monocytic cell line, U937 (Zagariya et al, 1998), but Liu et a l  (2000) demonstrated that 
while NF-kB and c-Jun are involved in LPS-mediated TNF-a production in primary 
human macrophages, NF-IL6 is not. Whilst NF-kB and NF-IL6 have been shown to 
interact through their Rel and b-Zip domains to synergistically activate IL-6 and IL-12 
p40 (Stein et al, 1993; LeClair et al, 1992; Plevy et al, 1997; Matsusaka et al, 1993), 
regulation of TNF-a expression by NF-kB was independent of c-Jun and NF-IL6 (Liu et 
al, 2000). NF-kB p65/p50 heterodimers bound to the kBI and kB3 sites of the human 
TNF-a promoter, while c-Jun bound to an AP-1 site adjacent to kB3, but these 
transcription factors operated independently. Down-regulation of TNF-a production in 
response to a second LPS challenge occurred by competition between NF-kB p50 
homodimers and p65-p50 complexes for binding to the kBI site.
TNF-a expression in LPS-stimulated macrophages has also been shown to be 
regulated by the ERK MAP kinase substrates Ets and Elk-1, which bind to two nuclear 
factor of activated T cells (NFAT)-binding sites that are required for induction of TNF-a 
in lymphocytes (Kramer et al, 1995; Tsai et al, 2000). Egr-1 and Spl binding is also 
induced by LPS, and the coactivators CREB binding protein (GBP) and p300 are required 
for assembly of the LPS-stimulated TNF-a enhancer complex (Tsai et al, 2000).
Message stability is thought to be a particularly significant step in the regulation 
of TNF-a production (Beutler et al, 1986; Shaw and Kamen, 1986). For example, AU- 
rich sequences in the 3’-untranslated region (UTR) of TNF-a mRNA predispose for
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degradation by RNases and regulate the efficiency of translation (Caput et al, 1986; Han 
et al, 1990). In addition, post-translational control mechanisms regulate the proteoloytic 
cleavage of the membrane-bound TNF-a precursor to release soluble TNF-a from the cell 
surface (Kriegler e ta l,  1988).
Cyclic AMP (cAMP) has also been implicated in the regulation of cytokine 
synthesis by LPS-activated macrophages (Benbernou et al, 1997; Eigler et al, 1998, 
Meisel et al, 1996, van der Pouw Kraan et al, 1995). Indeed, prostaglandin E  ^(PGE^), a 
potent physiological inducer of cAMP, and derivatives of cAMP have been shown to 
inhibit IL-12, IL-6 and TNF-a production by LPS-stimulated macrophages (Eigler et al, 
1998; Kambayashi et al, 1995a and b; Panina-Bordignon et al, 1997; van der Pouw 
Kraan et al, 1995). It has been suggested that these inhibitory effects of cAMP are due, 
at least in part, to release of IL-10; however the inhibition of TNF-a production is 
probably a direct effect of cAMP, and largely independent of IL-10, although this is 
controversial (Eigler et al, 1998; Kambayashi et al, 1995a and b; Seldon et al, 1998; 
Procopio e ta l,  1999).
1:3:4 Inducible nitric oxide syntbase (iNOS) production and nitric oxide (NO) 
release.
The generation of the toxic mediator nitric oxide (NO) has been shown to be 
critical in non-specific innate immunity. NO is formed by the action of the NO synthase 
(NOS) enzyme on the substrate L-arginine. Three isoforms of NOS have been identified:
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two are constitutively expressed (cNOS) -  ecNOS and ncNOS expressed by vascular 
endothelium and neuronal cells respectively -  and the third is inducible (iNOS). Whilst 
the cNOS isoforms have limited tissue distribution, multiple cell types have the capacity 
to express iNOS (Oswald et al, 1994). All three are flavoproteins containing bound 
flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), and are dependent 
on NADPH as a cofactor (Hevel et al, 1991; Mayer et al, 1991; Schmidt et al, 1992; 
Stuehr et al, 1991). While cNOS isoforms are only capable of generating small amounts 
of NO, iNOS can catalyse the production of high NO levels. iNOS was first identified in 
murine macrophages; these cells have negligible basal iNOS activity but this can be 
massively enhanced within a few hours by treatment with IFN-y and LPS (Nathan and 
Hibbs, 1991).
NO has been demonstrated to play critical roles in responses to pathogens, acute 
and chronic inflammation, autoimmunity, and apoptosis. For example, inflammatory 
responses were reduced by treatment of rats with the inhibitor of NO generation, L- 
NMMA, but enhanced by treatment with L-arginine (lalenti et al, 1992 and 1993). 
Similarly, patients with ulcerative colitis have increased NO levels (Middleton et al,
1993), and inhibition of NOS ameliorated experimentally-induced chronic ileitis (Miller 
et al, 1993). Rheumatoid arthritis and osteoarthritis patients also have increased NO 
levels in their plasma and synovial fluid (Farrell et al, 1992). Furthermore, in addition to 
killing invading microorganisms, NO is cytotoxic to the cells that produce it and 
neighbouring cells (Moncada, 1992), and has been shown to mediate apoptosis by 
causing DNA damage (Nguyen e ta l,  1992; Cui eta l,  1994).
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The importance of NO in immune responses against pathogens has been most 
extensively studied in relation to infection with Leishmania parasites, which invade and 
parasitise mammalian macrophages. Liew et a l  (1990) showed that L. major 
promastigotes are killed when incubated in vitro at room temperature in PBS containing 
NO. They also demonstrated that injection of L-NMMA into lesions of L. mayor-infected 
CBA mice resulted in a lOAfold increase in parasite burden in the lesion. Furthermore, 
iNOS-deficient mice were highly susceptible to infection and developed visceral disease 
(Wei et al, 1995). Murine peritoneal macrophages can be induced to produce NO in vitro 
by stimulation with IFN-y and LPS (Stuehr and Marietta 1985 and 1987; Ding et al, 
1988; Drapier et al, 1988); this is inhibited by treatment with L-NMMA (Liew et al,
1990). IFN-y-treated macrophages are efficient killers of Leishmania, and this can be 
completely abrogated by L-NMMA treatment (Green et al, 1990; Liew et al, 1990).
NO generation is dependent on substrate and enzyme availability; iNOS 
production is regulated at transcriptional and post-transcriptional/translational levels. The 
human and murine iNOS promoters have been cloned and the functions of human 
(reviewed by Morris and Billiar, 1994) and murine (Xie et al, 1993) promoter/enhancer 
elements have been investigated. The murine iNOS promoter contains at least 24 
elements with homology to transcription factor consensus sequences known to be induced 
by cytokines and microbial products.
Two regions (I and II) of the iNOS gene are required for maximal induction of 
transcription; both regions are necessary for activation by LPS, while region II is critical 
for the response to IFN-y (Lowenstein et al, 1993). Within these regions multiple 
putative transcription factor binding sites have been identified. Region I contains an
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octamer site, an NF-IL6 site and a tumour necrosis factor response element (TNF-RE), 
while region II has an IS RE and a PU-box/IFN element (PIE); both regions also have NF- 
kB binding sites.
The IS RE matches the IFN-regulatory factor element (IRF-E) consensus sequence 
(Martin et al, 1994; Tanaka et al, 1993) which binds IRF-1 (Lorsbach et al, 1993). IRE- 
1 is induced by IFN-y (Fujita et al, 1989; Miyamoto et al, 1988) and regulates the 
transcription of a number of IFN-inducible genes (Reis et al, 1992; Pine, 1992). IRF-1 is 
essential for the induction of iNOS by IFN-y since neither NO release nor iNOS mRNA 
could be detected in macrophages from IRF-1 knock-out mice stimulated with IFN-y in 
the absence/presence of EPS (Kamijo et al, 1994; Martin et al, 1994).
Both the IRF and NF-kB binding domains are necessary for full transcriptional 
activation of the iNOS promoter (Lowenstein et al, 1993). The role of these transcription 
factors in the induction of iNOS expression by IFN-y and EPS has previously been 
investigated in this laboratory (Feng, 1997; see Figure 1.8). IFN-y activates JAKl and 
JAK2, which catalyse the phosphorylation and homodimerisation of STATE ST ATI 
homodimers translocate to the nucleus and induce IRF-1 synthesis; IRF-1 then stimulates 
iNOS expression. An NF-kB pathway transduces the EPS signal, stimulating iNOS 
expression directly by binding to the iNOS promoter, and indirectly by stimulating the 
synthesis of IRF-1 and an IRF-like protein.
iNOS expression is also regulated by post-transcriptional mechanisms such as 
mRNA stability, translation and post-translational modification. For example, TGF-p 
suppresses iNOS production by decreasing message stability, efficiency of translation and
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protein stability (Vodovotz et al, 1993). At least some of the regulatory effects are cell- 
type speeific; iNOS mRNA induction is attenuated by TGF-p in RAW 264.7 cells, but 
enhanced in Swiss 3T3 cells (Morris and Billiar, 1994).
NO generation is also dependent on the availability of the substrate L-arginine, 
which is itself limited by the rate of arginine synthesis and uptake (Nussler et al, 1994; 
Bogle et al, 1992). Furthermore, NADPH is required for the donation of electrons and 
tetrahydrobiopterin (BHJ acts as a cofactor to enhance iNOS activity (Tayeh and 
Marietta, 1989; Kwon et al, 1989). Tetrahydrobiopterin is synthesised from GTP by the 
enzymatic activity of GTP-cyclohydrolase I, which is absent or present at only very low 
levels in unstimulated macrophages but is strongly co-induced with iNOS following 
stimulation with cytokines and LPS (Morris and Billiar, 1994).
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1:4 Aims of the thesis.
Macrophages activated by cytokines such as IFN-y, and microbial products such 
as LPS, produce pro-inflammatory cytokines and NO, which protect the host from a 
variety of infectious organisms, including bacteria, viruses, parasites and fungi. Excessive 
or inappropriate production of these immune mediators can however lead to pathology 
such as chronic inflammation, septic shock and autoimmune disease. A thorough 
understanding of the regulation of these processes is therefore extremely important.
Evasion of the host immune response by infectious organisms is critical to ensure 
their survival in the hostile environment of the host. Immunosuppression and 
immunomodulation are common mechanisms employed by a variety of pathogens, which 
target both innate and adaptive branches of the immune response. For example, a type 1 T 
helper (Thl) cell response is critieal for the suceessful elearance of infection with 
Leishmania parasites, which invade and parasitise macrophages (reviewed by Mattner et 
al, 1997a). However, lipophosphoglycan (LPG) molecules released from the surface of 
these parasites mediate immune evasion by a variety of mechanisms including the 
suppression of IL-12 production by macrophages (Piedrafita et al, 1999). This results in 
a bias in the T helper cell response towards a type 2 (Th2) phenotype. In the absence of 
IFN-y and the presence of IL-4, the production of toxic oxygen intermediates and NO by 
macrophages is suppressed, enabling parasite survival.
Immunomodulation and immunosuppression by filarial nematodes can be 
achieved by the production of excretory-secretory (ES) molecules, which modulate the 
activity of a variety of immune cell types. For example, ES-62, the major ES product of
32
Acanthocheilonema viteae, has been demonstrated to modulate the activation of B and T 
lymphocytes and the differentiation of dendritic cells, and bias the T helper response 
towards a type 2 (Th2) phenotype (Whelan et al, 2000; Harnett et ai, 1999a). The effects 
of ES-62 on macrophage function have not previously been investigated.
Given the critical roles of macrophages in both innate and adaptive immunity, it is 
extremely important to understand how pathogens such as these parasites disrupt normal 
activation of macrophages.
Therefore this project aims to:
1 Dissect the signalling mechanisms underlying the activation of pro-inflammatory 
cytokine (IL-12, IL-6 and TNF-a) and NO production by LPS-stimulated 
macrophages, in particular to establish the roles of the MAP kinases in the 
induction of these macrophage mediators.
2 Determine the signalling mechanisms targeted by a phosphoglycan molecule of 
Leishmania sp. protozoan parasites to suppress IL-12 production by macrophages.
3 Examine the effects of the filarial excretory-secretory glycoprotein ES-62 on 
cytokine and NO production by macrophages, and investigate the signalling 
pathways involved.
These objectives will be investigated in the murine macrophage system, which is 
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Figure 1.1. Major functions of macrophages.
Macrophages have multiple functions in innate immunity as well as in the induction of 
adaptive immune responses. They recognise pathogens and pathogen products via 
receptors including the Toll-like receptors, Fe receptors, complement receptors and 
scavenger receptors. They can phagocytose apoptotic cells, as well as small 
microorganisms, which they kill with toxic intermediates such as oxygen radicals and 
nitric oxide (NO). They digest pathogens and present antigen to T cells via MHC II. 
Furthermore, they produce pro-inflammatory cytokines (such as IL-1, IL-6, IL-8, IL-12 
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Figure 1.2. Structure of bacterial LPS.
LPS is a complex glycolipid, composed of a hydrophilic repeating polysaccharide (O- 
antigen and core) and a hydrophobic lipid A domain. The frequency of structural 
variation between speeies is indicated; the lipid A portion is conserved while the O- 
antigen is highly variable.



















Figure 1 .3 . Conserved IL-IR /TLR  signalling  pathways.
IL-1, IL-18 and LPS trigger similar signalling pathways in target cells. A conserved 
region in the intracellular portion of their receptors, known as the Toll/IL-IR (TIR) 
domain, interacts with MyD88, which is also a member of the IL-IR/TLR 
superfamily. This enables the recruitment of IRAK-1 and IRAK-2, which in turn 
recruit TRAF-6. Activation of the kinases TAB-1 and TAK-1 leads to activation of 
NF-kB and MAP kinase pathways.
(Adapted from O’Neill and Dinarello, 2000)
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Figure 1.4. LPS signalling pathways.
The LBP-LPS complex binds to the macrophage surface receptors CD 14 and TLR4, 
initiating intracellular signalling via TLR4. Multiple signalling pathways are activated, 
including NF-kB and MAP kinase cascades, resulting in the activation or de novo 
synthesis of a variety of transcription factors, which regulate the induction of 
macrophage response genes including those encoding pro-inflammatory cytokines and 
iNOS.
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Figure 1.5. The IL-12 p40 promoter.
The human and mouse IL-12 p40 genes are highly conserved up to approximately 400 
bp upstream of the transcription start site. In unstimulated cells, PU.1 occupies the ets 
element, but this is displaced upon stimulation with IFN-y or LPS by the FI complex, 
which binds at this site and interacts with a large flanking region (Ma et al, 1997b). 
The FI complex includes Ets-2, IRF-1, c-Rel and Glpl09 (a 109 kDa protein, highly 
inducible by IFN-y or LPS). The F2 complex, which responds more to IFN-y than LPS, 
also binds in this region but its identity has not been established. The NF-kB ‘half-site’ 
between -106 and -116 has been reported to bind p50/p65 and p50/c-Rel complexes in 
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Figure 1.6. The IL-6 promoter.
The human and mouse IL-6 genes are approximately 5 kb (mapped to chromosome 7) 
and 7 kb (chromosome 5) respectively, and both consist of 5 exons and 4 introns. 
Highly homologous regions extend approximately 350 bp upstream of the transcription 
start site.
GRE = glucocorticoid response element, GRE = cyclic AMP response element, SRE = 
serum response element, MRE = multi-response element 
(Adapted from Hirano a/., 1992)
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Figure 1.7. The TNF-a promoter.
The 5’ promoter region of the TNF-a gene contains numerous transcription factor 
binding sites, including at least five NF-kB binding sites (-850, -655, -625, -510, -210 
bp). An MHC class Il-like Y box is located at -255 bp, and there are several AP-1 and 
AP-2 binding elements. Multiple transcription factors, including Spl, Egr-1, Ets, NF-AT 
and NF-IL6, have been shown to bind or interact with other factors in the 5’ promoter 
region to regulate the transcriptional machinery. There are further control elements 
downstream of the TNF-a gene, including an additional NF-kB binding site.
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Figure 1 .8 . Transcriptional regulation o f iNOS induction by IFN-y and 
LPS.
Stimulation of macrophages with IFN-y results in IRF-1 synthesis via a JAK-STAT 
pathway. IRF-1 and an IRF-like protein are also produced following stimulation with 
LPS via an NF-kB pathway, iNOS promoter activation is achieved by the binding of 
NF-kB and members of the IRF family of transcription factors.
(Adapted from Feng, 1997)
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High salt buffer (for annealing) 
Klenow (DNA polymerase) 
L-Glutamine 
Penicillin/Streptomycin 
Phosphate buffered saline (PBS) 
Random priming kit 
RNA markers 
RPMI
S-MEM (Calcium-free DMEM) 
BALB/c and 129 mice 
Electrophoresis system 
X-ray film cassettes 
X-OMAT AR autoradiography film 
TMB substrate
Superscript II (reverse transcriptase) 
MAP kinase antibodies 
ABI-prism 7700 SequenceDetector 
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44
Pierce Coomassie protein assay reagent
Promega RNA markers
U0126 (MEK inhibitor)




ExtrAvidin peroxidase conjugate 
Leupeptin
Phenyl methyl sulphonyl fluoride (PMSF) 
Salmonella minnesota Lipopolysaccharide (LPS) 
Sodium ortho vanadate 
TEMED
Scottish Antibody Production Unit HRP-conJugated anti-mouse IgG
HRP-conjugated anti-rabbit IgG 
Transduction Laboratories Anti-phospho-tyrosine RC20
Upstate Biotechnology Anti-phospho-tyrosine 4G10
All other chemicals used in this study are commercially available from Sigma or BDH.
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2:2 Reagents and antibodies.
Reagents were obtained from Sigma (Poole, UK) unless otherwise indicated. IFN- 
Y was a gift from Dr. G. Adolf (Vienna). LPS {Salmonella minnesota) was from Sigma 
(Poole, UK).
Antibodies were obtained from the following sources: MAP kinase antibodies 
(p42/p44 ERK; Thr202/Tyr204 phospho-p42/p44 ERK; p38; Thrl80/Tyrl82 phospho- 
p38; p46/p54 SAPK/JNK; Thrl83/Tyrl85 phospho-p46/p54 SAPK/JNK) were from New 
England Biolabs (Hertfordshire, UK). ELISA antibodies (IL-12 p40 and IL-6 antibody 
pairs, and IL-12 p70 and TNF-a kits) were from PharMingen (San Diego, USA). NF-kB, 
I-KB, IRF-1, IRF-2, Ets-2 and iNOS antibodies were from Santa Cruz Biotechnology 
(Santa Cruz, USA). Horse Radish Peroxidase (HRP)-conjugated anti-mouse IgG and anti­
rabbit IgG antibodies were obtained from the Scottish Antibody Production Unit 
(Lanarkshire, UK). The anti-phospho-tyrosine antibodies 4G10 and RC20 were from 
Upstate Biotechnology (Lake Placid, USA) and Transduction Laboratories (San Diego, 
USA) respectively.
The MAP kinase inhibitors PD 098059 and SB 203580 were obtained from Alexis 
(Nottingham, UK); U0126 was from Promega (Madison, USA).
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2:3 Preparation of synthetic phosphoglycan, sPG.
Synthetic fragments of Leishmania lipophosphoglycan (see Figure 4.2) were 
prepared by Drs. A.V. Nikolaev and A.P. Higson, Department of Chemistry, University 
of Dundee, UK (Nikolaev et al, 1995).
2:4 Purification of ES-62.
ES-62 was purified from secretions from adult Acanthocheilonema viteae worms 
in culture by Ms. D. Rose (Department of Immunology, University of Strathclyde, UK). 
Spent culture medium from A. viteae maintained in RPMI (Gibco BRL, Paisley, UK) at 
37“C, 5% CO2  was passed through filtration units with 0.22 pM membranes (Sigma, 
Poole, UK) to remove microfilariae. The medium was concentrated to a volume of 10ml, 
washed in PBS (pH 7.2), in a stirred cell with a PM 10 membrane (Amicon, Upper Mill, 
UK). A further concentration step was undertaken using Centricon tubes (Amicon) with a 
100 kDa membrane to give a final volume of 0.5 ml. This was applied to a 30 x 1 cm 
Superose 6 column (HR 10/30; Pharmacia Biotech, St. Albans, UK), fitted to an isocratic 
FPLC system (Pharmacia Biotech), previously equilibrated with PBS (pH 7.2) at room 
temperature. The column was eluted at a flow rate of 0.5 ml/min and monitored for 
absorbance at 280 nm. >95% of the protein eluted as a single peak, which was confirmed 
to be ES-62 by SDS PAGE analysis.
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2:5 Macrophages and cell culture.
Macrophages were cultured at 37°C with 5% CO^ in Dulbecco's modified Eagle 
medium (Gibco BRL, Paisley, UK) supplemented with 10% heat-inactivated foetal calf 
serum (FCS; Gibco BRL), 2 mM L-glutamine, 50 U/ml penicillin and 50 pg/ml 
streptomycin (complete DMEM). Cells were cultured in 96-well plates (2x10^ cells/well) 
or in 25 cm^ flasks (4x10^ cells/flask) and rested overnight following isolation or 
passaging before use.
Macrophages were obtained as follows: J774 cells. The murine macrophage cell 
line, J774, was obtained from American Type Culture Collection (Atlanta, USA). 
Peritoneal macrophages. 6-8 week old mice (BALB/c and 129 strains; Harlan Olac, 
Bicester, UK) were injected intraperitoneally with 2 ml thioglycollate broth and after 
three days peritoneal macrophages were removed by peritoneal washing and enriched by 
plastic adherence for 2 hrs. Total spleen cells and splenic macrophages. Spleens were 
removed from mice and gently mashed through a small sieve in medium and aspirated to 
obtain a single cell suspension. Splenic macrophages were selected by plastic adherence 
for 2 hrs. Bone marrow-derived macrophages. Bone marrow cells were removed from the 
femurs of BALB/c mice by gently flushing out the marrow plug with a syringe containing 
medium, and a single cell suspension was created by gentle aspiration. Cells were 
cultured in DMEM containing 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin, 50 
pg/ml streptomycin and 10 ng/ml CSF-1 for 6 days. Adherent cells were washed twice 
and rested before use.
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Macrophages were stimulated with 100 U/ml IFN-y and 1 pg/ml (J774 cells) or 
100 ng/ml (murine macrophages - from BALB/c mice unless otherwise stated) 
Salmonella minnesota LPS (Sigma, Poole, UK). Culture supernatants were assayed for 
cytokine production by ELISA or for NO release by Griess reaction after 24 hrs culture 
unless otherwise stated.
2:6 Griess Reaction.
Nitrite concentrations in culture supernatants were determined by Griess reaction 
(Ding et al., 1998). Briefly, 50 gl culture supernatant was mixed in a 96-well plate with 
an equal volume of Griess Reagent (1% sulphanilic acid, 0.1% napthylene diamine 
dihydrochloride, 5% orthophosphoric acid) at room temperature for 10 mins. The 
absorbance at 570 nm was measured using an MRX microplate reader (Dynex 
Technologies, Chantilly, USA). Sodium nitrite was used as a standard to determine nitrite 
concentrations, which are equivalent to NO production.
2:7 Enzyme-linked immunosorbance assay, ELISA.
ELISA was performed according to the antibody supplier’s recommendations. 
Briefly, Immulon-4 ELISA plates (Dynex Technologies, Chantilly, USA) were coated 
overnight at 4°C with capture antibody in 0.1 M NaHCOj buffer (pH 7.4) and then 
blocked for 2 hrs with 10% calf serum (Gibco BRL, Paisley, UK) in PBS at 37“C. 
Samples and standards were diluted in culture medium and incubated for 1 hr at 37°C or
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overnight at 4°C. Detection antibodies and ExtrAvidin (Sigma) were diluted in blocking 
buffer and incubated for 1 hr each at 37°C. Plates were washed at least five times between 
stages. Finally, plates were developed using TMB substrate (KPL, Gaithersberg, USA) 
and absorbances at 630 nm were determined.
2:8 MTT assay.
Following removal of culture supernatants for cytokine analysis, cell viability was 
assessed by replacing medium and adding 500 gg/ml MTT reagent (Sigma, Poole, UK). 
After 3 hrs at 37“C all medium was removed, the precipitate dissolved in isopropanol, 
and absorbances at 600 nm were determined.
2:9 Osmotic pumps.
ALZET osmotic mini-pumps model 2002 (Charles River UK Ltd., Margate, UK) 
were used as directed by the manufacturer (see also Theeuwes and Yum, 1976) to mimic 
the in vivo release of ES-62. The following procedures were performed by Dr. M. Deehan 
(Department of Immunology, University of Glasgow, UK), Pumps were loaded with 200 
pi of 10, 20, 40 or 80 pg ES-62 or PBS pH7.4, and left overnight at room temperature 
submerged in sterile 0.9% saline solution, according to the manufacturer’s instructions 
(see Figure 2.1). 6-8 week old, male BALB/c mice weighing at least 20g were 
anaesthetised with Halothane-RM (Aventis Pasteur MSD, Maidenhead, UK). The back of 
the neck was swabbed with disinfectant (0.1% benzalkonium chloride) and the area
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shaved. A mid-scapular incision was made and the connective tissue severed to create a 
pocket to insert the mini-pump. The pump was placed with the flow moderator inserted 
first. The wound was sutured and the animal observed until consciousness was regained. 
Animals were sacrificed on day 14 and peritoneal macrophages were removed by 
peritoneal washing and cultured as above.
2:10 Preparation of total cell protein extracts.
Stimulated cells (4x10^25 cm^ flask) were washed twice with ice-cold TBS (25 
mM Tris.Cl, pH 7.4, containing 150 mM NaCl, and 100 mM sodium orthovanadate), and 
harvested with a plastic scraper. The cells were lysed in lysis buffer (25 mM Tris buffer, 
pH 7.4, containing 150 mM NaCl, 1% NP-40, 1 mM sodium ortho vanadate, 1 mM 
EDTA, 2 mM EGTA, 10 mM NaF, 1 mM dithiothreitol (DTT), 50 gg/ml each of 
leupeptin, aprotinin, and phenyl methyl sulphonyl fluoride (PMSF)) by incubation on ice 
for 30 mins. Lysates were then centrifuged at 13,000 xg at 4°C for 10 mins and the 
supernatants were transferred to fresh tubes and stored at -70°C until required. Protein 
concentrations of the lysates were determined using Coomassie Protein Assay Reagent 
(Pierce, Rockford, USA).
2:11 Western blot analysis.
Cell lysates were resolved by SDS-PAGE (Laemmli, 1970) before transfer to 
nitrocellulose using a transblot system (Hoeffer Scientific SE600, San Francisco, USA).
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Nitrocellulose filters were then incubated with wash buffer 1 (0.01 M Tris.Cl buffer, pH 
7.5, containing 0.1 M NaCl and 0.1% Tween-20) containing 2% bovine serum albumin 
(BSA; Sigma, Poole, UK) for at least 1 hr to block non-specific protein binding. Primary 
antibodies were diluted in wash buffer 1 containing 1% BSA, and applied to the filter for 
1 hr at room temperature or overnight at 4°C. Blots were washed twice in wash buffer 1, 
twice in wash buffer 2 (0.01 M Tris.Cl buffer, pH 7.5, containing 0.5 M NaCl and 0.1% 
Tween-20) and finally twice in wash buffer 1 again; each wash was for 10 mins. 
Following washing, the blots were incubated with the appropriate HRP-conjugated 
secondary antibody (diluted up to 1:5000 in wash buffer 1 containing 1% BSA) for 1 hr 
at room temperature. After washing again as before, immuno-reactive bands were 
visualised by the Enhanced Chemiluminescence (ECL) system (Amersham, Little 
Chalfont, UK) and exposed to X-OMAT film (Kodak, New York, USA).
2:12 Preparation of nuclear protein extracts.
Treated cells (4xl0V25 cm^ flask) were washed twice with ice-cold TBS and then 
resuspended in 400 gl ice-cold buffer A (10 mM HEPES buffer, pH 7.9, containing 10 
mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and 100 gM 
sodium ortho vanadate). Cells were allowed to swell on ice for 15 mins, after which 25 gl 
of a 10% solution of Nonidet P-40 (NP-40; Fluka, Poole, UK) was added and the cells 
were vortexed vigorously for 15 secs. The homogenate was centrifuged at 13,000 xg for 
30 secs and the resulting nuclear pellet was resuspended in 100 gl ice-cold buffer B (20 
mM HEPES buffer, pH 7.9, containing 0.4 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT, 1 mM PMSF and 100 gM sodium orthovanadate) and rocked vigorously at 4°C for
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15 mins. The nuclear extract was centrifuged for 5 mins at 13,000 xg at 4°C, and the 
supernatant collected and frozen in aliquots at -70°C until use.
2:13 EMSA/Band shift assay.
Synthetic oligonucleotide probes were designed by Dr. X.-Q. Wei (Department of 
Immunology, University of Glasgow, UK). After dissolving in distilled water, annealing 
was carried out in high salt buffer (H buffer; Gibco BRL, Paisley, UK) by boiling at 
100°C for 10 mins followed by slow cooling for several hours. Double stranded 
oligonucleotides were labelled with [a-^^P]-dATP (Amersham, Little Chalfont, UK) using 
a random priming kit containing dCTP, dGTP, dTTP, H buffer and Klenow DNA 
polymerase (Gibco BRL) and incubating at 37°C for 2 hrs. Probes were purified on an 
8% non-denaturing polyacrylamide gel using TBE as running buffer. The gels were then 
exposed to X-OMAT film (Kodak, New York, USA) to detect labelled probe and gel 
pieces were incubated in TE buffer overnight at 37°C.
Binding reactions were initiated by pre-incubation of 10 gg nuclear protein extract 
with 200 ng double-stranded poly (dl-dC).(dl-dC) (Pharmacia Biotech, St. Albans, UK) 
in reaction buffer (20 mM HEPES buffer, pH 7.9, containing 40 mM KCl, 1 mM MgCl, 
0.1 mM EGTA, 0.5 mM dithiothreitol, 10% glycerol and 0.1% NP-40) in a volume of 30 
gl for 20 mins on ice. For antibody super-shift assays, 1 gl antibody was added during this 
pre-incubation period. The appropriate radiolabelled synthetic oligonucleotide DNA 
probe (0.5 ng) was then added, and the mixture incubated on ice for a further 20 mins. 
The resultant DNA-protein complexes were resolved by non-denaturing 6% PAGE. The
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gels were fixed (in 20% methanol, 10% acetic acid, 10% glycerol) for 20 min and then 
dried and visualised by autoradiography. The sequences of the oligonucleotide probes 
used in this work are provided in Table 2.1.
2:14 Preparation of RNA extracts.
Stimulated macrophages (4xlOV25 cm^ flask) were washed twice with ice-cold 
PBS before the addition of 1 ml RNAzoF^ B (Biogenesis, Poole, UK). After incubation 
on ice for a few minutes the contents were removed to an E ppendorf tube. 200 gl 
chloroform was added and samples were incubated for a further 10 mins on ice. 
Following centrifugation (13,000 xg for 15 mins) the upper phase was removed and an 
equal volume of isopropanol was added. RNA was precipitated by incubation on ice for 
30 mins and separated by centrifugation (13,000 xg for 20 mins). The RNA pellet was 
washed with ethanol, dried, dissolved in DEPC water and heated to 68°C for 2 mins 
before use. The concentration of RNA in samples was estimated by UV spectroscopy.
2:15 Northern blot analysis.
IL-12 p40 and p-actin cDNA probes were provided by Dr. X.-Q. Wei 
(Department of Immunology, University of Glasgow, UK). These cDNA probes were 
labelled with [a-32p]-dATP using a commercial random priming kit (Gibco BRL, 
Paisley, UK) according to the manufacturer’s instructions, and purified on a NICK 
column (Amersham, Little Chalfont, UK) using TE buffer. The labelled cDNA was then 
denatured by heating for 10 mins at 96°C and chilled on ice.
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Total macrophage RNA (10 gg in 3 pi DEPC-treated water) was denatured in 7 gl 
sample buffer (71% formamide, 7% 20x MOPS buffer (400mM MOPS pH 7.0, 122 mM 
NaAc, 20 mM EOT A) and 8% formaldehyde) for 2 mins at 68°C. Samples were chilled 
on ice and mixed with 16% nucleic acid gel loading buffer (50% glycerol, 1 mM EDTA, 
0.25% bromophenol blue, 0.25% xylene cyanol).
Electrophoresis was carried out through a 1.5% agarose gel containing 5% 20x 
MOPS buffer and 2.8% formaldehyde. Samples and RNA markers (Promega, Madison, 
USA) were loaded and gels were run in Ix MOPS buffer at a constant voltage for 3-5 hrs. 
Following electrophoresis, agarose-formaldehyde gels were rinsed twice in distilled water 
and the RNA was transferred on to a nylon membrane by capillary blotting (Southern, 
1975) overnight at room temperature. The blot was rinsed in 2x SSC (0.3 M NaCl, 42 
mM sodium citrate, pH 7.2), air dried and oven baked at 120°C for 20 mins and UV- 
linked.
The nylon membrane was incubated in pre-hybridisation buffer containing 7% 
SDS, 40 mM NaH^PO^, 1 mM EDTA and 100 mg/ml ssDNA for 3 hrs at 65°C. The 
labelled probe was then added and incubated for 18 hrs in a hybridisation oven. The filter 
was then washed sequentially, twice in 2x SSC and 0.1% SDS for 30 mins and twice in 
0.2x SSC and 0.1% SDS for 60 mins at 65°C. The membrane was dried between filter 
paper for 10 mins at room temperature and exposed to X-ray film (Kodak, New York, 
USA) for 1-3 days.
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2:16 TaqMan real-time RT-PCR.
TaqMan real-time RT-PCR (Gibson et al. 1996) was performed according to the 
manufacturer’s instructions (PE Biosystems, Foster City, USA) and as described by 
Overbergh et al. (1999). The principle of this method is outlined in Figure 2.2.
RNA (1-5 pg) was reverse transcribed using 100 U Superscript II RT (Life 
Technologies, Gaithersberg, USA) at 42°iC for 50 mins in the presence of 50 mM Tris- 
HCl (pH8.3), 75 mM KCl, 3 mM MgCl„ 5 mM DTT, 0.5 mM dNTPs and 5 pM 
01igo(dT),6 (Gibco BRL, Paisley, UK).
Primers and fluorogenic probes (see Table 2.2) were designed using the 
PrimerExpress"^^ vl.O program and purchased from PE Biosystems. The fluorogenic 
probes contained a reporter dye (FAM) covalently attached at the 5’ end and a quencher 
dye (TAMRA) covalently attached at the 3’ end, and were HPLC purified. Extension 
from the 3’ end was blocked by attachment of a 3’ phosphate group.
PCR reactions were performed in the ABI-prism 7700 Sequence Detector, which 
contains a Gene-Amp PCR system 9600 (PE Biosystems). PCR amplifications were 
performed in a total volume of 25 pi, containing 0.5 pi cDNA sample, 50 mM KCl, 10 
mM Tris-HCl (pH 8.3), 10 mM EDTA, 200 pM dATP, dCTP, dGTP and 400 pM dUTP, 
5 mM MgCl2 , 300 nM each primer (see Table 2.2), 0.625 U AmpliTaqGold'^’^  and 0.25 U 
AmpErase Uracil N-GIycosylase (PE Biosystems). Each reaction also contained 200 nM 
detection probe (see Table 2.2). Each PCR amplification was performed in triplicate
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wells, using the following conditions: 2 mins at 50”C and 10 mins at 94°C, followed by a 
total of 40 or 45 two-temperature cycles (15 secs at 94°C and 1 min at 60°C).
Data analysis was performed using the Sequence Detection software (PE 
Biosystems) which calculates the threshold cycle, Ct (see Figure 2.3). This represents the 
PCR cycle at which an increase in fluorescence above a threshold can first be detected. 
Samples were normalised by their reference reporter (HPRT) by subtracting the Ct value 
of HPRT from the Ct value of the gene of interest; this value is ACt. To obtain a value for 
fold increase relative to HPRT the formula 2'^^‘ was used (samples have been checked to 
ensure 100% efficiency). Multiplication of this value by 100 gives expression of the gene 
of interest as a percentage of HPRT. The positive error is the standard deviation of the 
difference, s = V(s/ 4- Sj )^, where s, and Sg are the standard deviations of the Cts of HPRT 
and the gene of interest.
2:17 Densitometry and statistical analysis.
Data presented are representative of at least two independent experiments. 
Cytokine and NO measurements are displayed as means and standard deviations of 
triplicate culture unless otherwise indicated. Densitometry was performed using the 
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Figure 2.1. ALZET osmotic mini-pumps.
ALZET osmotic mini-pumps are composed of three concentric layers - the drug 
reservoir, the osmotic sleeve, and the rate-controlling, semi-permeable membrane. The 
drug reservoir is impermeable, blocking the exchange of material between the reservoir 
and the surrounding osmotic sleeve, which contains a high concentration sodium 
chloride solution. The difference in osmotic pressure between the osmotic sleeve and 
the implantation site drives delivery of the test solution, which is loaded into the drug 
reservoir before use. Water enters the sleeve along the osmotic gradient, compresses the 
flexible reservoir, and displaces the test solution through the flow moderator at a 
constant rate. The mass delivery rate of the test substance can be varied by adjusting the 
concentration of the test solution loaded into the reservoir.
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Table 2.1 - EMSA Oligonucleotide Probes.
NF-kB from iNOS 
promoter
5’ CCC AAC TGG GGA CTC TCC CTT TGG 3’
NF-kB from IL-12 
p40 promoter
5’ CAA AAC ATT CTG GGG GAA TTT TAA GA 3’
IRF-E from iNOS 
promoter
5 ’ GAG TGT GAA TAT TTG ACT TTG ATA AT 3 '
Fragment of FI site 
from IL-12 p40 
promoter
5 ’ GAG AGA TAG TAA TTT GTG TTT AGA TGA TGG GTA 
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Figure 2.2. TaqMan real-time RT-PCR.
The TaqMan probe consists of an oligonucleotide with a 5’ reporter dye (R) and a 3’
quencher (Q). When the probe is intact, the proximity of the quencher to the reporter
results in suppression of reporter fluorescence. As PCR proceeds, the polymerase enzyme
cleaves the probe with its 5’-3’nuclease activity. The reporter and quencher become
separated, resulting in increased reporter fluorescence. The 3’ end of the probe is blocked
to prevent extension of the probe during PCR.
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Table 2.2 - TaqMan Primers and Probes.
Primers: F = forward, R = reverse
Probes: 5’ FAM (6-carboxy-fluorescein) labelled, 3’ TAMRA (6-carboxy-tetramethyl 
rhodamine; quencher) labelled
Murine IL-12 p40 F Primer: 5’ GGA ATT TGG TCC ACT GAA ATT TTA AA 3’
R Primer: 5’ CAC GTG AAC CGT CCG GAG TA 3’
Probe: 5’ FAM -  AAC AAG ACT TTC CTG AAG TGT GAA GCA CCA 
AAT - TAMRA 3’
Murine IL-12 p35 F Primer: 5’ AAG ACA TCA CAC GGG ACC AAA 3’
R Primer: 5’ CAG GCA ACT CTC GTT CTT GTG TA 3’
Probe: 5’ FAM -  CAG CAC ATT GAA GAC CTG TTT ACC ACT GGA - 
TAMRA 3'
Murine TNF-a Purchased from PE-Applied Biosystems UK (Warrington, UK)
Murine TLR2 F Primer: 5’ AAG ATG CGC TTC CTG AAT TTG 3’
R Primer: 5’ TCC AGC GTC TGA GGA ATG C 3’
Probe: 5’ FAM -  CGT TTT TAG CAC CCG GAT CCC TGT ACT G -  
TAMRA 3’
Murine TLR4 F Primer: 5’ AGG AAG TTT CTC TGG ACT AAC AAG TTT AGA 3’ 
R Primer: 5’ AAA TTG TGA GCC ACA TTG AGT TTC 3’
6 1
Probe: 5’ FAM -  GCC AAT TTT GTC TCC ACA GCC ACC A - TAMRA
3’
Murine HPRT F Primer: 5’ GCA GTA CAG CCC CAA AAT GG 3’
R Primer: 5’ AAC AAA GTC TGG CCT GTA TCC AA 3’
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Figure 2.3. Typical TaqMan Amplification Plots.
The amplification plot shows how the fluorescence emission (normalised Reporter, Rn) 
varies with the PCR cycle number. Initially, the fluorescent signal is below the detection 
limit of the Sequence Detector. In the second stage, the signal can be detected as it 
continues to increase in direct proportion to the amount of specific amplified product. 
As PCR continues, the ratio of polymerase enzyme to PCR product decreases and hence 
the amount of PCR product ceases to increase exponentially, until eventually the Rn 
reaches a plateau. The Ct (threshold cycle) is determined during the exponential phase 
(threshold indicated by black line). Two triplicate samples are shown (C4-C6 and CIO- 
C12).
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3:1:1 Mitogen-activated protein (MAP) kinases.
Mitogen-activated protein (MAP) kinases are key signalling molecules involved 
in the regulation of a diverse range of cellular functions including protein synthesis, cell 
cycle control, division and differentiation, and cell motility (Davis, 1994; Karin, 1994; 
Madhani and Fink, 1998). In mammals there are three major subfamilies of MAP kinases 
-  the extracellular regulated kinases (ERKs), p38, and the c-Jun N-terminal kinases 
(JNKs) which are also known as stress activated protein kinases (SAPKs). The signalling 
cascades leading to activation of these three MAP kinase subfamilies are summarised in 
Figure 3.1.
MAP kinases are characterised by the presence of a Threonine-X-Tyrosine motif 
in the activation loop of the protein. Each MAP kinase is activated by dual 
phosphorylation of the threonine and tyrosine residues by a MAP kinase kinase 
(MAPKK, MKK or MEK), which is itself activated by dual serine phosphorylation by a 
MAP kinase kinase kinase (MAPKKK). For example, the classical MAP kinase pathway 
is the ERK cascade. Binding of growth factors to their cell surface receptors results in 
recruitment of tyrosine kinases and adaptor molecules to the intracellular signalling 
domain of the receptor. Recruitment of the Grb2 and Sos proteins results in activation of 
the small GTPase Ras, which catalyses the activation of the MAPKKK Raf; Raf then 
phosphorylates M EK l/2, which activates ERK l/2 MAP kinases. MAP kinases
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phosphorylate their downstream targets on serine and threonine residues; these include 
the transcription factors Elk-1, ATE-2 and c-Jun.
All three subfamilies of MAP kinases (ERKs, p38 and JNKs) have been shown to 
be activated following stimulation of macrophages with LPS (Weinstein et al, 1992; Han 
et al, 1994; Liu et al, 1994; Raingeaud et a l, 1995; Hambleton et a l, 1996), and the 
roles of some of these in pro-inflammatory cytokine and NO^have been demonstrated 
(Geppert et al, 1994; Swantek et al, 1997; Bhat et al, 1998; Lu et a l, 1999; Zhu et al, 
2000).
Selective inhibitors of MAP kinase activation are useful pharmacological tools for 
dissecting the roles of these signalling molecules. PD 098059 is a selective and potent 
inhibitor of the ERK MAP kinase cascade, which mediates its effects by binding to and^the 
activation of the ERK-specific MAP kinase kinase, MEK-1 (Alessi et a l, 1995; Dudley et 
al, 1995). It has no effect on any of the components of the INK or p38 MAP kinase 
cascades (Pang et al, 1995). U0126 also targets MEK-1, but it blocks MEK-1 activity rather 
than its activation, and is therefore slightly more effective since it also removes any basal 
MEK-1 activity present in cells prior to stimulation (Favata et a l, 1998; DeSilva et al, 
1998). Similarly, the compound SB 203580 has been reported to be a selective and potent 
inhibitor of p38 MAP kinase activity, which does not affect either ERK or JNK MAP 
kinases (Cuenda et al, 1995). Unfortunately, there is currently no known selective inhibitor 
of JNK MAP kinases.
66
3:1:2 Aim of this study.
The aim of this study was to investigate the involvement of ERK and p38 MAP 
kinases in the regulation of EL-12, IL-6, TNF-a and NO production. This was achieved by 
stimulating murine macrophages (J774 cell line, peritoneal macrophages, splenic 
macrophages and bone marrow-derived macrophages) with LPS in the presence/absence 
of IFN-y. MAP kinase activation was assayed by Western Blotting and by employing 
specific inhibitors of the MAP kinase isoforms to investigate their roles in cytokine and 
NO production. Cytokine production was measured by ELISA, Northern Blotting and 
TaqMan real-time PCR; NO release was assayed by Griess Reaction. Furthermore, 
putative downstream targets were also examined by Western Blotting and EMSA (Band 
Shift assay) to provide clues to the mechanisms underlying MAP kinase-mediated 
regulation of cytokine and NO production.
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3:2 Results.
3:2:1 Cytokine and NO production by macrophages.
To verify the effects of stimulation, macrophages were cultured with IFN-y and/or 
LPS for 24 hours. Culture supernatants were then harvested and assayed for the 
production of IL-12, IL-6, TNF-a by ELISA, and NO release by Griess Reaction (see 
Materials and Methods).
3:2:1:1 IL-12 production.
An ELISA antibody pair was used for the detection of IL-12 p40 subunit, which 
will in fact detect a number of p40-containing species including p40 monomer, bioactive 
p70 heterodimer and p40/p40 homodimers. Production of the p40 subunit of IL-12 was 
induced upon stimulation of J774 macrophages with LPS (Figure 3.2A) in a dose- 
dependent manner (Figure 3.2B). Co-stimulation with IFN-y reduced LPS-induced IL-12 
production (Figure 3.2). In contrast, IFN-y was synergistic with LPS for the induction of 
IL-12 p40 from thioglycollate-elicited peritoneal macrophages from BALB/c and 129 
mice, which produced only low levels of IL-12 p40 in response to LPS alone (Figure 
3.3). IFN-y treatment alone did not induce IL-12 production from either J774 cells 
(Figure 3.2A) or murine peritoneal macrophages (Figure 3.3). IL-12 p40 was detected in 
culture supernatants by ELISA from 8 hours after stimulation with IFN-y + LPS and was 
maximal by 12 hours (Figure 3.4).
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Macrophages derived from BALB/c bone marrow by culture in the presence of 
CSF-1 for 6 days also produced IL-12 p40 in response to stimulation with LPS or IFN-y + 
LPS (Figure 3.5). Removal of CSF-1 by washing and replacement with normal full 
medium 2 hours prior to stimulation abolished the response to LPS stimulation and 
reduced IFN-y + LPS-induced IL-12 p40 production (Figure 3.5), indicating that these 
cells need CSF-1 to enable them to respond^to activatory signals.
IL-12 p40 production following treatment of spleen cells from BALB/c mice with 
LPS or IFN-y + LPS was also measured (Figure 3.6A). IFN-y had no significant effect on 
LPS-induced p40 production. This IL-12 can be attributed to splenic macrophages since 
removal of non-adherent cells by washing and replacement with fresh medium led to 
similar levels of IL-12 p40 stimulation (Figure 3.6B). The contribution of splenic B cells, 
which can also produce IL-12 (reviewed by Ma et al, 1997a), could therefore be 
considered negligible.
To confirm whether stimulation induces production of bioactive IL-12 
heterodimer, not simply p40 monomer, IL-12 p70 levels in culture supernatants were 
measured by ELISA. Peritoneal macrophages produced IL-12 p70 in response to 
stimulation with IFN-y + LPS (Figure 3.7); p70 levels were typically 10- to 20-fold lower 
than p40 levels, consistent with previous reports.
To investigate at what level regulation of IL-12 production occurs, IL-12 p40 and 
p35 mRNA were detected by TaqMan real-time PCR. IL-12 p40 mRNA expression was 
induced by IFN-y + LPS stimulation; it was detectable by 4 hours after stimulation, and 
maximal by 10 hours, after which levels slowly decreased (Figure 3.8A). Similar
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expression kinetics were found by Northern Blotting (not shown). Transcripts for the 
‘constitutively’-expressed p35 subunit of IL-12 were also enhanced by IFN-y + LPS 
treatment (Figure 3.8B); p35 mRNA was detectable by 4 hours but peaked earlier than 
p40, at 8 hours, before declining to near basal levels by 16 hours. Therefore, the 
regulation of both p40 and p35 is important for generation of bioactive IL-12. 
Interestingly, the induction of p40 mRNA was much greater than that of the p35 subunit 
(~ 10-fold); this may explain why the p40 subunit is produced in vast excess over 
bioactive p70.
3:2:1:2 IL-6 production.
J774 cells and peritoneal macrophages from BALB/c mice produced IL-6 in 
response to LPS stimulation; although IFN-y alone did not induce IL-6, it was synergistic 
with LPS for IL-6 production by peritoneal macrophages (Figure 3.9A and B). In 
contrast, bone marrow-derived macrophages (cultured and stimulated in the presence of 
CSF-1) produced IL-6 following LPS stimulation, but this was reduced by co-stimulation 
with IFN-y (Figure 3.9C).
3:2:1:3 TNF-a production.
TNF-a release by murine peritoneal macrophages was induced by stimulation 
with LPS alone; IFN-y, both on its own and in combination with LPS, had little effect on 
TNF-a production (Figure 3.10A). Bone marrow-derived macrophages behaved in a
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similar manner to peritoneal macrophages when stimulated in the presence of CSF-1 
(Figure 3.10B). In the absence of CSF-1 they responded poorly to LPS (Figure 3.10B). 
However, co-stimulation with IFN-y resulted in similar levels of TNF-a induction to 
stimulation in the presence of CSF-1, indicating that IFN-y may be providing the 
additional signals that these cells need to respond to LPS (Figure 3.10B). In a timecourse 
experiment, TNF-a was detected in peritoneal macrophage culture supernatant at 4 hours 
after stimulation and production was maximal by 12 hours (Figure 3.11).
To verify whether the induction of TNF-a occurs at the level of transcription, 
TNF-a mRNA was detected by TaqMan real-time PCR. Stimulation with IFN-y and LPS 
resulted in a rapid and sustained increase in TNF-a mRNA (Figure 3.12). Induction was 
maximal by 2 hours after stimulation and mRNA levels remained elevated until at least 
10 hours, before starting to fall by 16 hours after stimulation. Therefore, induction of 
TNF-a production does occur at the level of transcription.
3:2:1:4 NO production.
NO is produced by the catalytic action of iNOS on the substrate L-arginine. It is 
highly reactive and is therefore rapidly converted to nitrite (NO2 ') in solution; this can be 
assayed by Griess Reaction. Analysis of culture supernatants in this way showed that 
1774 cells produced NO in response to stimulation with IFN-y; this was enhanced by 
stimulation with LPS, which alone induced very low levels of NO release (Figure 3.13 A). 
Similar results were obtained with murine peritoneal macrophages from BALB/c and 129 
strains (Figure 3.13B and C). NO was detectable in peritoneal macrophage supernatants
71
from between 8 and 12 hours post-stimulation and maximal by about 16 hours (Figure 
3.14). Total spleen cells from both mouse strains produced NO in response to stimulation 
with IFN-y -t- LPS (Figure 3.15A), but NO production by splenic macrophages was not 
detected. IFN-y + LPS also induced NO release from BALB/c bone marrow-derived 
macrophages (Figure 3.15B).
3:2:1:5 Cell viability of treated macrophages.
The viability of J774 cells and murine peritoneal macrophages was assessed by 
MTT assay to determine whether treatment with IFN-y and/or LPS is toxic to the cells 
and might account for some of the differences in cytokine production. Macrophage 
viability was largely unaltered by stimulation with IFN-y or LPS (Figure 3.16A and B), 
although occasionally a small decrease in viability was observed following stimulation 
with both IFN-y and LPS. A decrease in the viability of bone marrow-derived 
macrophages following stimulation in the presence of CSF-1 was also seen (Figure 
3.16C). Culture of bone marrow-derived macrophages in the absence of CSF-1 resulted 
in a dramatic decrease in the viability of non-stimulated macrophages, but this was 
partially rescued by stimulation with either IFN-y or LPS, or both (Figure 3.16C). 
However, in general the observed differences in cytokine production were not a 
consequence of alteration of macrophage viability.
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3:2:2 Roles of MAP kinases in cytokine and NO production by macrophages in 
response to stimulation with IFN-y and LPS.
Although there are some reports of regulation of cytokines and iNOS by MAP 
kinases (Bhat et al, 1998; Badger et al, 1998), the role of the different MAP kinase 
subfamilies in mediating activation of macrophages by LPS is still unclear. Therefore, the 
activation of MAP kinases by stimulation of macrophages with LPS in the 
absence/presence of IFN-y was examined, and the importance of the MAP kinases for 
induction of EL-12, IL-6, TNF-a and NO was dissected.
3:2:2:1 Activation of MAP kinases by stimulation with IFN-y and/or LPS.
The LPS-mediated activation of ERK, p38 and JNK MAP kinases in J774 cells 
and murine peritoneal macrophages was investigated by Western Blotting, using specific 
antibodies against their dual-phosphorylated (bioactive) forms. LPS strongly stimulated a 
rapid (within 1 min) and transient increase in the levels of activation of both ERKl (3.7 
fold) and ERK2 (3.2 fold), which peaked at 10 minutes but remained elevated for at least 
60 minutes above the low basal levels of ERK activation observed in unstimulated J774 
cells (Figure 3.17A). IFN-y co-treatment enhanced LPS-stimulation of ERK activation in 
these cells (not shown). Although there was no basal ERK MAP kinase activity in murine 
peritoneal macrophages, LPS strongly stimulated both ERKl and ERK2 within 10 
minutes (Figure 3.18A). In contrast, IFN-y only weakly stimulated ERK activity and 
slightly suppressed LPS-stimulated ERK phosphorylation. It is interesting to note that in 
J774 cells, there was roughly equivalent activation of both ERK isoforms (Figure 3.17A),
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whereas in peritoneal macrophages there was more phospho-ERKl than phospho-ERK2 
(Figure 3.ISA). In both cell types there was more total ERK2 than ERKl protein (Figures 
3.17Aand3.18A).
Little or no activation of p38 MAP kinase was detected in unstimulated 1774 cells 
(Figure 3.17B). LPS strongly activated p38, which was maximal at 10 minutes and 
sustained for up to 60 minutes. Likewise, p38 was activated following stimulation of 
murine peritoneal macrophages with either LPS or IFN-y + LPS for 10 minutes (Figure 
3.18B). Similarly, although SAPK/JNK MAP kinases were found not to be significantly 
activated in either unstimulated 1774 cells (Figure 3.17C) or peritoneal macrophages 
(Figure 3.18C), LPS, following a lag period of up to 10 minutes, strongly stimulated both 
p46 and p54 JNK MAP kinases in J774 cells (Figures 3.17C). Activation of both 
isoforms was maximal at 30 minutes and declined towards basal levels within 60 
minutes. Moreover, p46 and p54 JNK were both stimulated in murine peritoneal 
macrophages by either LPS or IFN-y + LPS within 10 minutes; IFN-y was synergistic 
with LPS for p54 JNK activation (Figure 3.18C). These results clearly show that LPS 
stimulates all three MAP kinase subfamilies in macrophages, but with differential 
activation kinetics.
3:2:2:2 Effects of selective inhibitors of the ERK and p38 MAP kinase signalling 
cassettes on LPS-stimulated MAP kinase activity.
The ERK and p38 inhibitors (PD 098059 and SB 203580 respectively) were used to 
investigate whether the induction of IL-12, IL-6, TNF-a and NO by LPS or IFN-y + LPS is
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mediated or regulated by these MAP kinases. First, the effects of these reagents on the dual 
phosphorylation of their target and heterologous MAP kinases were examined in J774 cells 
and peritoneal macrophages from BALB/c mice, to verify their specificity. In J774 cells, as 
expected, PD 098059 (20 pM) profoundly inhibited both the basal and stimulated ERK 
MAP kinase activation, but had no effect on phosphorylation of p38 or SAPK/JNK (Figure 
3.20). Indeed, higher concentrations of PD 098059 completely abrogated ERK MAP kinase 
activation (not shown). Treatment with PD 098059 also dramatically reduced basal 
phospho-ERK and suppressed IFN-y + LPS-induced ERK activation in peritoneal 
macrophages (Figure 3.21). Conversely, SB 203580 inhibited p38, but not ERK or JNK 
phosphorylation in J774 cells (Figure 3.20). Pre-incubation of cells with SB 203580 led to 
an increase in both basal and stimulated ERK (particularly ERKl) activation in J774 cells 
(Figure 3.20) and peritoneal macrophages (Figure 3.21), suggesting that p38 may act, at 
least in part, to exert inhibitory effects on ERK signalling in J774 cells. This finding is 
consistent with the proposed regulatory cross-talk postulated to occur amongst the different 
MAP kinase signalling cassettes (Zhang et al, 1997; Zhu et al, 2000; Singh et al, 1999).
3;2:2;3 Effects of inhibition of MAP kinases on cytokine and NO production by 
macrophages.
To investigate whether ERK and p38 MAP kinases are involved in LPS-induced 
cytokine and NO production by macrophages, J774 cells and murine peritoneal 
macrophages were pre-treated with either PD 098059 or SB 203580 for 1 hour prior to 
stimulation, and cytokine and NO levels in 24 hour culture supernatants were measured
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as before. Cell viability, as determined by MTT assay, was not altered by treatment with 
PD 098059 or SB 203580 at the concentrations shown (Figure 3.22).
3:2:2:3:1 Regulation of IL-12 production by ERK and p38 MAP kinases.
Pre-treatment of J774 cells with PD 098059 enhanced LPS-induced IL-12 p40 
production in a dose-dependent manner (Figure 3.23A), indicating that ERK MAP 
kinases negatively regulate p40 production in these cells. 20 gM PD 098059 had maximal 
effect, so the inhibitor was used at this concentration in subsequent experiments. PD 
098059 pre-treatment had the same effect on IFN-y + LPS-induced IL-12 p40 production 
by murine peritoneal macrophages (Figure 3.23B). Similarly, p40 production was 
enhanced by pre-incubation with U0126, which was more potent than PD 098059 (Figure 
3.23C).
To determine whether this regulation by ERK MAP kinases occurs at the level of 
transcription, IL-12 p40 transcript was detected by Northern Blot analysis of total RNA 
from 1774 cells stimulated with LPS following pre-incubation for 1 hour with PD 
098059. IL-12 p40 mRNA levels were enhanced by PD 098059 treatment (Figure 3.24), 
indicating that ERK MAP kinases negatively regulate the transcription of the p40 subunit 
or message stability. Similar results were obtained by TaqMan real-time PCR analysis of 
RNA from IFN-y + LPS-stimulated peritoneal macrophages (Figure 3.25).
Levels of p70 heterodimer in culture supernatants were also measured to 
determine whether the enhancement of p40 by inhibition of ERK MAP kinases results in
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increased production of bio active IL-12. Interestingly, p70 induction was not enhanced 
by pre-treatment with PD 098059 or U0126 (Figure 3.26), indicating that enhancement of 
p40 production is not sufficient to increase production of bioactive heterodimer. This 
suggests that these MAP kinases might be required for either p35 production or assembly 
of the two subunits to form bioactive heterodimer, or simply that the p35 subunit is 
limiting.
To investigate these possibilities, p35 mRNA levels were assayed by TaqMan to 
determine whether ERK MAP kinases regulate p35 production. PD 098059 pre-treatment 
did not alter IFN-y + LPS-stimulated p35 induction (Figure 3.27), indicating that ERK 
MAP kinases are neither positive nor negative regulators of IL-12 p35 induction. It would 
therefore appear that the availability of the p35 subunit limits the formation of bioactive 
IL-12.
The role of p38 MAP kinases was similarly investigated by pre-treating cells with 
SB 203580. This resulted in decreased production of IL-12 p40 by LPS-stimulated J774 
cells and IFN-y -f LPS-stimulated murine peritoneal macrophages (Figure 3.28). 
Inhibition was dose-dependent and a concentration of 5 pM SB 203580 was chosen for 
subsequent experiments. IL-12 p70 levels were also suppressed by SB 203580 pre­
treatment (Figure 3.29); the extent of p70 inhibition was comparable to that of p40 (82% 
and 86% inhibition of p40 and p70 respectively).
Northern Blot analysis of total RNA from J774 cells stimulated with LPS following 
pre-incubation for 1 hour with SB 203580 revealed that regulation of IL-12 p40 induction 
by p38 MAP kinases occurs at the level of transcription or message stability, since treatment
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with SB 203580 resulted in delayed and overall reduced IL-12 p40 mRNA production 
(Figure 3.30). Similar results were obtained by TaqMan analysis of RNA from IFN-y + 
LPS-stimulated peritoneal macrophages pre-treated with SB 203580 (Figure 3.31). IL-12 
p35 message was also measured by TaqMan analysis; inhibition of p38 activity by pre­
treatment with SB 203580 also suppressed p35 mRNA levels (Figure 3.32).
Taken together, these results suggest that p38 MAP kinases are required for 
transcription of both the IL-12 p40 and p35 genes, while ERK MAP kinases negatively 
regulate p40 but not p35 transcription. The modulation of transcripts by both inhibitors 
correlated with their effects on p40 protein production, indicating that the ERK and p38 
MAP kinases exert most or all of their regulatory influence at the transcriptional level.
J774 cells and murine peritoneal macrophages were treated with PD 098059 or 
U0126 as well as SB 203580 to investigate whether the inhibitors cancel one another out 
and hence whether the ERK and p38 MAP kinases act antagonistically on the same 
signalling pathway. However, neither PD 098059 nor U0126 treatment restored IL-12 
p40 inhibition by SB 203580 (Figure 3.33). In fact, U0126 treatment further decreased 
IL-12 p40 beyond the level of SB 203580 reduction (Figure 3.33B). This suggests that 
ERK MAP kinases can only negatively regulate IL-12 p40 production in the presence of 
a p38 signal.
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3:2:2:3:2 Regulation of IL-6 production by p38, but not £RK, MAP kinases.
Induction of IL-6 in J774 cells and murine peritoneal macrophages was not 
altered when ERK MAP kinase activation was suppressed by pre-treatment with PD 
098059 (Figure 3.34). In contrast, SB 203580 pre-treatment resulted in inhibition of IL-6 
production (Figure 3.35), indicating that while ERK MAP kinases do not regulate IL-6 
production in LPS- or IFN-y+ LPS-stimulated macrophages, p38 does mediate induction 
of IL-6.
3:2:2:3:3 Regulation of TNF-a production by ERK and p38 MAP kinases.
Treatment of J774 cells with either PD 098059 or SB 203580 prior to LPS 
stimulation resulted in dose-dependent suppression of TNF-a production (Figure 3.36A 
and 3.37A), demonstrating that both MAP kinase subfamilies are required to transduce 
LPS signals for TNF-a production. Similar results were obtained in murine peritoneal 
macrophages stimulated with IFN-y and LPS (Figure 3.36B and 3.37B).
TaqMan analysis was performed to determine whether this regulation of TNF-a 
production occurs at the level of transcription or message stability. Pre-treatment with PD 
098059 did not alter TNF-a mRNA levels at timepoints up to and including 8 hours after 
stimulation with IFN-y and LPS (Figure 3.38A), indicating that ERK MAP kinases 
regulate a later stage of synthesis of this cytokine. At 18 hours, TNF-a mRNA was 
slightly enhanced in the PD 098059-treated cells. SB 203580 pre-treatment resulted in a 
reduction in TNF-a transcript levels at intermediate timepoints (6 and 8 hours; Figure
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3.38B), suggesting that p38 MAP kinase regulates TNF-a production, at least in part, at 
the level of transcription or message stability.
3:2:2:3:4 Regulation of NO production by ERK and p38 MAP kinases.
Similarly, both ERK and p38 MAP kinases appear to be required for induction of 
NO release, since treatment with either PD 098059 or SB 203580 resulted in dose- 
dependent reduction of NO induction in J774 cells and murine peritoneal macrophages 
(Figure 3.39). Treatment with PD 098059 (up to 50 gM) only partially inhibited NO 
generation in J774 cells (Figure 3.39A), but NO production was completely abolished by 
incubation with 10 pM SB 203580 (Figure 3.39B). These results were confirmed by 
Western Blot analysis of iNOS expression which showed that whilst PD 098059 (20 pM) 
only partially blocked the induction of iNOS protein expression (41%), SB 203580 (5 
pM) almost completely abrogated LPS-induction of iNOS expression (Figure 3.40). 
Taken together, these results suggest that whilst both p38 and ERK MAP kinases appear 
to play positive roles in the LPS-mediated induction of iNOS, p38 activation is more 
critical, and appears to be necessary and sufficient for effector induction.
3:2:3 Roles of MAP kinases in activation of transcription factor synthesis and 
binding.
Having clearly demonstrated roles for ERK and p38 MAP kinases in LPS-induced 
cytokine and NO production, the next step was to attempt to identify their downstream
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targets to provide further clues to their mechanisms of action. To analyse the transcription 
factors targeted by ERK and p38 MAP kinases, cellular protein levels were measured by 
Western Blotting of total cell lysates, and binding of nuclear proteins to promoter 
sequences was assayed by EMSA (Band Shift).
3:2:3:1 Effects of MAP kinase inhibitors on NF-kB nuclear translocation and DNA 
binding.
The transcription factor NF-kB is involved in the induction of the IL-12 p40, IL-6, 
TNF-a and iNOS genes. In unstimulated cells, NF-kB is held in the cytoplasm by I-kB; 
LPS stimulation results in activation of I-kB kinases (IKKs) which phosphorylate I-kB, 
labelling it for ubiquitination and degradation, thereby liberating NF-kB which 
translocates to the nucleus (reviewed by Karin, 1999). I-kB degradation was not 
prevented by treatment with either PD 098059 or SB 203580 (Figure 3.41), indicating 
that neither ERK nor p38 MAP kinases achieve modulation of transcription by regulating 
the entry of NF-kB into the nucleus.
The translocation of NF-kB to the nucleus of J774 cells and binding to promoter 
sequences following stimulation with LPS was investigated by EMSA to determine 
whether ERK and p38 MAP kinases mediate their effects on cytokine and NO synthesis 
by modulating NF-kB activity. Cells were pre-treated with PD 098059 or SB 203580 for 
1 hour prior to LPS stimulation for a further hour. Nuclear protein extracts were 
incubated for 30 minutes with a ^^P-labelled oligonucleotide probe representing an NF-kB 
binding site from either the iNOS or the IL-12 p40 promoter, prior to separation on a
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polyacrylamide gel and visualisation by exposure to X-ray film (see Materials and 
Methods).
LPS stimulated binding of NF-kB to both the iNOS and IL-12 p40 promoter 
sequences, with identical patterns of binding complexes (Figure 3.42). Two binding 
complexes were detected in both resting and LPS-stimulated cells. The lower molecular 
weight complex (b) was predominant in resting cells and was not dramatically altered 
upon LPS stimulation. In contrast, a higher molecular weight complex (a) bound at only 
low levels in unstimulated cells, but binding was strongly induced by LPS stimulation. 
Supershift assay using specific antibodies against different NF-kB isoforms was 
performed to identify the components of these complexes. p65, p50 and c-Rel isoforms 
were present in the higher molecular weight complex (a), which most likely represents 
p65-p50 and c-Rel-p50 heterodimers. The lower molecular weight complex comprised 
p50-p50 homodimers. Binding patterns were not altered by pre-treatment of cells with 20 
|xM PD 098059 or 5 pM SB 203580, suggesting that neither ERK nor p38 MAP kinases 
regulate NF-kB translocation to the nucleus and binding to promoter sequences. Similar 
patterns of NF-kB binding were observed using nuclear protein extracts from IFN-y + 
LPS-stimulated murine peritoneal macrophages (not shown).
3:2;3:2 Effects of MAP kinase inhibitors on binding to the IRF-E promoter 
sequence.
The iNOS promoter contains a binding site, known as the interferon regulatory 
factor (IRF) element (IRF-E), for members of the IRE family of transcription factors.
82
IRF-1 has also been identified as a member of the large FI binding complex that 
regulates IL-12 p40 promoter activity. Therefore the MAP kinase inhibitors PD 098059 
and SB 203580 were used to investigate whether ERK or p38 MAP kinases target 
synthesis of IRF proteins and their binding to promoter sequences.
There was no detectable IRF-1 in unstimulated peritoneal macrophages, but 
induction of IRF-1 synthesis occurred within 1 hour of stimulation with IFN-y + LPS and 
was maximal by 4 hours (Figure 3.43A upper panel). In contrast, another IRF family 
member, IRF-2, which has been shown to be a negative regulator via interaction with IRF 
elements (Harada et al, 1989; Yamamoto et al, 1994), was expressed constitutively in 
resting cells and was not altered by stimulation (Figure 3.43A lower panel). Pre-treatment 
with PD 098059 for 1 hour prior to, or addition of PD 098059 1 hour after, IFN-y + LPS 
stimulation enhanced IRF-1 synthesis by 4 hours post-stimulation; similar treatment with 
SB 203580 did not alter IFN-y + LPS-induced IRF-1 synthesis (Figure 3.43B). These 
results indicate that ERK but not p38, MAP kinases negatively regulate IRF-1 synthesis; 
neither MAP kinase subfamily regulates IRF-2 production (not shown).
The binding activity of J774 cell nuclear lysates to a ^^P-labelled oligonucleotide 
probe containing the IRF-E from the iNOS promoter was measured by EMSA. Two 
complexes (a and b) bound at low levels in samples from resting cells and stimulation 
with LPS for 2 hours enhanced this binding activity (Figure 3.44A). By 3 hours post­
stimulation this activity had diminished but was still above basal levels. This indicates 
that iNOS expression is induced by the transient binding of IRF family members to the 
IRF-E. Perhaps surprisingly, treatment with PD 098059 alone for 1 hour enhanced IRF-E 
binding and while PD 098059 pre-treatment did not alter LPS-induced binding at 2 hours,
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it did result in sustained induction of binding at 3 hours after LPS stimulation. In contrast, 
although SB 203580 alone enhanced binding of complex a, pre-incubation with SB 
203580 resulted in an overall suppression of complex b binding and promoted complex a 
binding at 3 hours. Thus, it appears that binding to the iNOS IRF-E is negatively 
regulated by ERK MAP kinases and modulated by p38 MAP kinases.
3:2:3:3 Effects of MAP kinase inhibitors on binding of transcription factors to the 
IL-12 p40 promoter.
The FI complex of transcription factors, which includes IRF-1, Ets-2, c-Rel and 
Glpl09, is an important inducer of IL-12 p40 transcription (Ma et al, 1997b). It binds to 
an Ets consensus site in a complex manner, interacting with flanking sequences in a 
region of approximately 96 bp. A ^^P-labelled oligonucleotide probe representing a 
portion of this FI binding region was used to investigate the binding activity of nuclear 
extracts from LPS-stimulated J774 cells. Two binding complexes were present in 
unstimulated cells; 2 hours LPS treatment enhanced this activity and resulted in the 
induction of a third complex (Figure 3.44B). By 3 hours post-stimulation, binding activity 
had returned to basal levels. Treatment with neither PD 098059 nor SB 203580 altered 
this pattern of FI binding activity, indicating that neither MAP kinase subfamily achieves 
its regulation of IL-12 p40 transcription by altering binding to the FI promoter site. 
Moreover, Western Blotting showed that treatment with neither PD 098059 nor SB 




The recent identification of TLR4 as the LPS receptor has clarified the 
understanding of macrophage signal transduction pathways triggered by LPS stimulation. 
LPS molecules form aggregates in solution, which must be disrupted for recognition of 
these bacterial products by macrophages. This is achieved by the serum protein LBP 
which associates with LPS, enabling it to interact with CD 14 on the macrophage surface. 
CD 14 is unable to transduce signals across the plasma membrane so the LPS-LBP-CD14 
complex must interact with TLR4. Ligation of the TLR4 receptor results in association 
and activation of tyrosine kinases and tyrosine phosphatases which regulate activation of 
multiple signalling pathways including NF-kB and MAP kinase cascades (see Figures 1.3 
and 1.4). Multiple transcription factors are influenced, either by modifications such as 
phosphorylation or by induction of de novo synthesis. Ultimately this results in induction 
of genes encoding pro-inflammatory cytokines such as IL-12, IL-6 and TNF-a, and other 
innate immune mediators such as iNOS, which catalyses NO production.
In this study, consistent with many previous reports, stimulation of murine 
macrophages from a variety of sources (J774 macrophage cell line, thioglycollate-elicited 
peritoneal macrophages, splenic macrophages and bone marrow-derived macrophages) 
with LPS resulted in induction of IL-12 (both subunits), IL-6 and TNF-a (Figures 3.2 - 
3.12). IFN-y alone was a poor inducer of these cytokines, but it had various effects on the 
induction of cytokine production by LPS. For example, while it was synergistic with LPS 
for IL-12 p40 production by peritoneal and bone marrow-derived macrophages (Figures 
3.3 - 3.5), it was inhibitory for 1774 cells (Figure 3.2) and did not alter p40 production by 
splenic macrophages (Figure 3.6). Similarly, it enhanced IL-6 production by peritoneal
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macrophages but had the opposite effect on bone marrow-derived macrophages (Figure
3.9). These effects may represent the differential abilities of macrophages sourced from
distinct locations to process IFN-y signals, or reflect differential macrophage maturation.
Indeed, the priming effect of IFN-y on LPS-induced IL-12 production has been shown in
some cells to be dependent on IFN-y pre-incubation (Ma et al, 1996b). Furthermore, the
effects of IFN-y on bone marrow-derived cells were also dependent on the
absence/presence of CSF-1 in the culture medium (Figures 3.5 and 3.10). In the absence
of CSF-1, bone marrow-derived macrophages could not respond to the LPS signal to
produce IL-12 and TNF-a, but this ability was restored by IFN-y. However, IFN-y was
presence
not synergistic with LPS for IL-12 production in these cells in the -absenee- of CSF-1. 
Therefore, the effects of IFN-y appear to be dependent on multiple factors such as the 
tissue microenvironment of the macrophages and the maturation status of the 
macrophage.
Low levels of iNOS expression and NO production were also induced by LPS 
stimulation (Figures 3.13 - 3.15). However, the effect of treatment with IFN-y alone was 
much more significant, and the combination of IFN-y and LPS produced the strongest 
induction of NO synthesis. Overall, while LPS stimulation was most critical for induction 
of cytokine synthesis, IFN-y induced NO more strongly. The combination of IFN-y and 
LPS was most effective for the stimulation of cytokine and NO production by peritoneal 
macrophages.
MAP kinases have previously been reported to be important downstream 
mediators of LPS signals (Weinstein et al, 1992; Hambleton et al, 1995 and 1996; Han
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et al, 1994; Zhu et al, 2000). Consistent with these reports, the three major subfamilies 
of MAP kinases (ERKs, p38 and JNKs) were shown in this study to be activated upon 
treatment of macrophages with LPS or IFN-y + LPS (Figures 3.17 and 3.18).
Interestingly, in J774 cells, LPS stimulation resulted in roughly equal 
phosphorylation of both ERK isoforms, whereas in peritoneal macrophages stimulated 
with LPS in the absence or presence of IFN-y, the ERKl isoform was more strongly 
activated. However, ERK2 was expressed at much higher levels than ERKl in J774 cells, 
whereas both isoforms were present at similar levels in peritoneal macrophages. This 
suggests that LPS stimulation preferentially targets the activation of ERKl, although 
ERK2 activation is also induced. Since treatment with the inhibitor of the ERK MAP 
kinase pathway, PD 098059, suppressed the dual phosphorylation of both ERK isoforms 
(Figures 3.20 and 3.21), this inhibitor cannot be used to dissect the individual functional 
significance of the two ERK isoforms.
The roles of ERK and p38 MAP kinases in the induction of IL-12, IL-6, TNF-a 
and NO by LPS and IFN-y + LPS were investigated using the inhibitors PD 098059 and 
SB 203580 (Figures 3.23 -  3.40). Synthesis of all of these macrophage mediators was 
shown to be induced in a p38-dependent manner; ERK MAP kinases were also required 
for the induction of TNF-a and iNOS, but were negative regulators of IL-12 p40 
production (summarised in Figure 3.46).
It has been reported that the anti-inflammatory cytokine IL-10 is produced by 
LPS-stimulated monocytes in a p38-dependent manner (Foey et al, 1998) and it is 
therefore possible that the suppression of cytokine and iNOS production observed
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following SB 203580 treatment could be due to the induction of IL-10. However, IL-10 
release was not detected under any of the conditions tested (not shown), suggesting that 
the ERK and p38 MAP kinases do not exert any of their regulatory effects on IL-12, IL-6, 
TNF-a or NO via generation/suppression of IL-10.
Induction of IL-12 p40 transcription by LPS was shown to be mediated by p38 
and negatively regulated by ERK MAP kinases (Figures 3.23 -  3.25 and 3.28 -  3.31). 
The requirement for a p38 signal supports the recent demonstration that mice deficient in 
MEK3, the kinase upstream of p38, are defective in IL-12 production (Lu et al, 1999). 
Furthermore, in the absence of p38 MAP kinase activation, inhibition of ERK 
phosphorylation did not enhance IL-12 p40 production (Figure 3.33), suggesting that the 
suppressive action of the ERKs is dependent on a positive p38 signal. ERK MAP kinases 
could target either a regulator of p38 activity or a p38 substrate. However, since treatment 
with PD 098059 suppressed ERK activation but did not alter p38 (Figure 3.20), this 
eliminates a target upstream of p38. Therefore the ERKs must negatively regulate a target 
downstream of p38 to limit p40 monomer production. This may serve to prevent 
excessive formation of inhibitory p40 homodimers and thus maintain an appropriate 
balance between p70 heterodimers and p40 homodimers. This suggests that the balance 
of p38 and ERK MAP kinase signals is critical for the regulation of IL-12 p40 
production.
The synergy of IFN-y with LPS for IL-12 p40 production by peritoneal 
macrophages (Figures 3.3 and 3.4) can also be explained in terms of negative regulation 
by ERK MAP kinases, since IFN-y stimulation reduced LPS-stimulated ERK activation 
in these cells (Figure 3.18). In contrast, ERK activation in J774 cells was slightly
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enhanced by IFN-y co-stimulation (not shown); hence there was no synergy between IFN- 
y and LPS in these cells, rather a slight reduction in IL-12 p40 production (Figure 3.2).
p35 transcription was also p38-dependent but, unlike p40, it was not regulated by 
ERK MAP kinases (Figures 3.27 and 3.32). Thus, LPS stimulation of macrophages 
results in the activation of p38 MAP kinase, which induces transcription of both the p40 
and the p35 IL-12 genes, resulting in the production of bioactive IL-12. Simultaneous 
activation of ERK MAP kinases prevents excessive production of the p40 subunit and the 
formation of antagonistic p40 homodimers.
IL-6 was regulated in the same way as the p35 subunit of IL-12 i.e. induction of 
IL-6 by LPS was p38-dependent but ERK-independent (Figures 3.34 and 3.35). This is 
interesting since these two molecules are homologous and IL-12 p35 has been suggested 
to have been derived from an IL-6-like primordial cytokine (Merberg et al, 1992). p38 
MAP kinase has recently been suggested to stabilise IL-6 mRNA (Winzen et al, 1999); 
this mechanism may also contribute to the p38-dependent regulation of IL-12 p35.
Induction of the TNF-a and iNOS genes was dependent on the activation of both 
ERK and p38 MAP kinases (Figures 3.36, 3.37 and 3.40). This is consistent with similar 
reports in the literature (Geppert et al, 1994; Bhat et al, 1998; Larsen et al, 1998; 
Badger et al, 1998; Zhu et al, 2000), although the production of iNOS and NO does not 
appear to be dependent on these MAP kinases in some cells (DaSilva et al, 1997; Guan 
et al, 1997). In this study however, the dependence of iNOS transcription on both ERK 
and p38 MAP kinase signals in macrophages was underlined by the inhibition of NO 
production following treatment with PD 098059 or SB 203580 (Figure 3.39). Treatment
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with PD 098059 did not alter TNF-a message levels (Figure 3.38), indicating that ERK 
MAP kinases do not regulate TNF-a transcription or message stability, but must act at a 
later stage of synthesis such as translation or release from the cell. p38 MAP kinase does 
appear to partially regulate TNF-a at the message level, but is also likely to act at later 
stages of TNF-a generation.
The different macrophage effectors exhibited different sensitivities to the 
inhibitors. For example, treatment of peritoneal macrophages with 5 pM SB 203580 
resulted in significant inhibition of IL-6 and NO, but reduced IL-12 p40 levels (in the 
same samples) even more dramatically and effectively abolished TNF-a production. This 
indicates that while p38 MAP kinase is required for optimal induction of all of these 
cytokines and iNOS by IFN-y + LPS, it would appear to be absolutely necessary for TNF- 
a production in these cells. Similarly, p38 MAP kinase signals seem to be critical for IL-6 
production by J774 cells, but perhaps less important for IL-12 p40 induction.
It has been suggested that ERK activation is negatively regulated by p38 (Singh et 
al, 1999). The enhanced phosphorylation of ERK that accompanied inhibition of p38 by 
SB 203580 (Figures 3.20 and 3.21) seems to support this hypothesis. However, Hall- 
Jackson et a l  (1999) recently demonstrated that SB 203580 can activate Raf in vivo in a 
p38-independent manner. Thus, it is possible that the enhanced ERK activation occurred 
as a result of SB 203580 treatment rather than as a consequence of removal of a 
suppressive signal. Although p38 is unquestionably required for induction of IL-12 p35, 
IL-6, TNF-a and iNOS, since enhanced ERK activation could not explain the effects of 
SB 203580 on the induction of these proteins, there is therefore a possibility that the 
reduction of IL-12 p40 production by treatment with SB 203580 could be due, at least in
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part, to increased negative regulation by ERK MAP kinases. However, mice deficient in 
p38 MAP kinase kinase 3 (MKK3/MEK3) were defective in IL-12 p40 production by 
macrophages and dendritic cells (Lu et al, 1999), supporting the proposed requirement of 
p38 MAP kinase for IL-12 p40 production.
The relevance of INK activation for the induction of cytokine and NO production 
by LPS could not be demonstrated by such inhibitor studies because a specific inhibitor 
of this MAP kinase subfamily is not currently available. Alternative techniques could be 
employed to investigate this, such as stimulation of INK MAP kinase-deficient 
macrophages obtained either by transient transfection with dominant negative INK or 
antisense oligonucleotides, or from knock-out animals. Indeed, Constant et a l  (2000) 
recently showed that IFN-y + LPS-stimulated peritoneal macrophages from JNKl- 
deficient mice produce more IL-12 and NO than control mice, while Swantek et a l  
(1997) demonstrated that a kinase-defective INK mutant blocked the translation of TNF- 
a.
The effects of inhibition of ERK and p38 MAP kinases on various transcription 
factors that regulate cytokine and iNOS expression were investigated in an attempt to 
identify the downstream targets of the ERK and p38 pathways. Treatment with neither 
PD 098059 nor SB 203580 altered the degradation of I-kB|3 or the binding of NF-kB to 
iNOS or IL-12 p40 promoter sequences (Figures 3.41 and 3.42), suggesting that 
regulation of LPS-induced cytokine and NO production by these MAP kinase subfamilies 
occurs independently of the NF-kB pathway.
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In contrast, EMSA analysis indicated that regulation of iNOS transcription by p38 
may be achieved by members of the IRF family of transcription factors. SB 203580 
treatment disrupted binding to the IRF-element (IRF-E) from the iNOS promoter (Figure 
3.44A). The identity of the IRF family members involved remains to be established. IRF- 
1 synthesis was not altered by SB 203580 treatment (Figure 3.43B), indicating that p38 
could act further downstream e.g. to phosphorylate IRF-1, or on other IRF family 
members such as IRF-2, ICSBP, ICS AT or novel IRF proteins.
IRF family members could also play important roles in the regulation of IL-12 
p40. PD 098059 treatment enhanced IFN-y + LPS-induced IRF-1 synthesis in peritoneal 
macrophages (Figure 3.43B), suggesting a mechanism for the negative regulation of IL- 
12 p40 expression via suppression of IRF-1 synthesis by ERK MAP kinases. Neither 
inhibitor altered binding to the FI site from the IL-12 p40 promoter (Figure 3.44B), 
indicating that neither ERK nor p38 MAP kinases regulate the assembly of the FI 
complex. Therefore it is unlikely that ERK and p38 target IRF-1 within this complex, but 
there are other IRF-binding sites present on the p40 promoter that represent potential 
targets. However the oligonucleotide used for FI binding represents only a portion of this 
large site so further investigation is required to confirm this. Nuclear translocation of Ets, 
another component of the FI complex, was not altered by treatment with PD 098059 or 
SB 203580 (Figure 3.45), suggesting that Ets does not transduce p38 or ERK signals.
92
3:4 Summary of this study.
In summary therefore, ERK and p38 MAP kinases play critical roles in the 
induction of pro-inflammatory cytokines and iNOS by LPS-stimulated macrophages. 
While p38 MAP kinase transduces positive signals, ERKs can either positively or 
negatively regulate effector induction. These MAP kinases are likely to exert their 
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Figure 3.1. MAP kinase cascades.
Binding of ligands to cell surface receptors results in recruitment of tyrosine kinases and 
adaptor molecules to the intracellular signalling portion of the receptor, leading to 
activation of small GTP-binding proteins such as Ras and Rac, These catalyse the 
activation of three MAP kinase cascades - the ERK, p38 and INK MAP kinase pathways. 
MAP kinas^ kinases (MAPKKKs) activate MAP kinase kinases (MAPKKs or MEKs), 
which in turn activate MAP kinases by dual phosphorylation of a threonine and a tyrosine 
in the TXY motif in the activation loop. The MAP kinases act by phosphorylating target 






0 0 0 “
7 5 0 “
CM 5 0 0 “
_ j
2 5 0 “
medium IFN-y LPS IFN-y
6 0 0 -  
5 0 0 -  
400  
300  
2 0 0 “  




E £ £ £













Figure 3.2. IL-12 p40 production by the J774 murine macrophage cell line.
J774 cells (2xlOVwell in a 96-well plate) were stimulated with 100 U/ml IFN-y and/or 1 
pg/ml LPS (A), or treated with various concentrations of LPS in the absence/presence of 
100 U/ml IFN-y (B).
IL-12 p40 (monomer, active p70 heterodimer, p40/p40 homodimer) in culture 
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Figure 3.3. IL-12 p40 production by murine peritoneal macrophages.
Thioglycollate-elicited peritoneal macrophages from BALB/c (A) and 129 (B) mice 
(2xlOVwell in a 96-well plate) were stimulated with 100 U/ml IFN-y and/or 100 ng/ml 
LPS for 24 hours. IL-12 p40 (monomer, active p70 heterodimer, p40/p40 homodimer) 
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Figure 3.4. Timecourse of IL-12 p40 production by peritoneal macrophages.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xlOVwell in a 96- 
well plate) were cultured for the times indicated with 100 ng/ml LPS in the 





i  4 0 -  
?  3 0 -
;  2 0 -
_l
medium IFN-y LPS IFN-y
□  CSF-1 
^  no CSF-1
LPS
Figure 3.5. IL-12 p40 production by bone marrow-derived macrophages.
Bone marrow-derived macrophages were obtained from bone marrow cells by culture in 
medium containing CSF-1 for 6 days. For stimulation in the absence of CSF-1, medium 
was removed and replaced with medium lacking CSF-1 two hours prior to stimulation. 
Macrophages (2xlOVwell in a 96-well plate) were stimulated with 100 U/ml IFN-y 
and/or 100 ng/ml LPS in the presence/absence of CSF-1; IL-12 p40 in 24 hour culture 
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Figure 3.6. IL-12 p40 production by splenic cells.
Spleens were removed from BALB/c mice and cells were prepared as indicated below 
and stimulated with 100 U/ml IFN-y and/or 100 ng/ml LPS.
A. Total spleen cells were plated (2xlOVwell in a 96-well plate) and stimulated.
B. In the same experiment, total spleen cells were plated (2xlOVwell in a 96-well plate) 
and splenic macrophages were allowed to adhere for 2 hours. Wells were washed to 
remove non-adherent cells and medium was replaced prior to stimulation.
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Figure 3.7, IL-12 p70 production by murine peritoneal macrophages.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xlOVwell in a 96- 
well plate) were stimulated with 100 U/ml IFN-y and/or 100 ng/ml LPS for 24 hours. 



















_ J 100 5 15 20
Duration of stimulation (hours)
Figure 3.8. Induction of IL-12 p40 and p35 mRNA.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4xl0V25 cm^ flask) 
were cultured for the times indicated with 100 U/ml IFN-y and 100 ng/ml LPS. RNA 
was purified and IL-12 p40 and p35 message levels were detected by TaqMan real-time 
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Figure 3.9. IL-6 production by J774 cells, murine peritoneal macrophages and 
bone marrow-derived macrophages.
J774 cells (A), peritoneal macrophages from BALB/c mice (B) and bone marrow- 
derived macrophages (obtained by culture of bone marrow cells with CSF-1 for 6  days; 
C) from BALB/c mice (2xl0Vwell in a 96-well plate) were stimulated with 100 U/ml 
IFN-y and/or LPS (J774 cells, 1 pg/ml; murine macrophages, 100 ng/ml) for 24 hours; 
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Figure 3.10. TNF-a production by peritoneal macrophages and bone marrow- 
derived macrophages.
Thioglycollate-elicited peritoneal macrophages (A) and bone marrow-derived 
macrophages (obtained by culture of bone marrow cells with CSF-1 for 6  days; B) from 
BALB/c mice (2xlOVwell in a 96-well plate) were cultured with 100 U/ml IFN-y and/or 
100 ng/ml LPS. For stimulation of bone marrow-derived macrophages in the absence of 
CSF-1, medium was removed and replaced with fresh medium lacking CSF-1 two hours 
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Figure 3.11. Timecourse of TNF-a production by peritoneal macrophages.
Thioglycollate-elicited peritoneal macrophages fromBALB/c mice (2 xlOVwell in a 96- 
well plate) were cultured for the times indicated with 100 U/ml IFN-y and 100 ng/ml 
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Figure 3.12. Induction of TNF-a mRNA.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4x10^25 cm^ flask) 
were cultured for the times indicated with lOOU/ml IFN-y and 100 ng/ml LPS. RNA was 
purified and TNF-a message was detected by TaqMan real-time PCR. Transcript levels 




8 0  1
60 -
40 -
2 0  -
0 ------ i----------— I—












Figure 3.13. NO production by J774 cells and murine peritoneal macrophages.
J774 cells (A) and peritoneal macrophages from BALB/c (B) and 129 (C) mice 
(2xlOVwell in a 96-well plate) were stimulated with 100 U/ml IFN-y and/or LPS (J774 




4 0  -
30  Hf 2 .H
1 0 -
0
I I I—11 It—11 I
T
T
I ■ '  I '  '  I '  ' I '  '  I '  '  I '  '  1 '  ' I '  '  I
medium 1 2 4  8 12 16 2 0  24  
LPS stimulation 
(time in hours)
'  I '  '  I ■ ■ r ‘ ‘ V 1  I I I
1 2 4  8 12 1 6 2 0 2 4  
IFN-y + LPS stimulation 
(time in hours)
Figure 3.14. Timecourse of NO production by peritoneal macrophages.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xl0Vwell in a 96- 
well plate) were cultured for the times indicated with 100 ng/ml LPS in the 
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Figure 3.15. NO production by splenic cells and bone marrow-derived 
macrophages.
Total spleen cells (A) and bone marrow-derived macrophages (B) from BALB/c mice 
(2xlOVwell in a 96-well plate) were stimulated with 100 U/ml IFN-y and/or 100 ng/ml 
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Figure 3.16. Viability of macrophages following stimulation with IFN^ and/or LPS.
J774 cells (A), and peritoneal macrophages (B) and bone marrow-derived macrophages 
(in the presence/absence of CSF-1; C) from BALB/c mice (2xlOVwell in a 96-well 
plate) were stimulated with 100 U/ml IFN-y and/or LPS (J774 cells, 1 pg/ml; murine 
macrophages, 100 ng/ml) for 24 hours. Cell viability following stimulation was assessed 
by MTT assay.
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Figure 3 .1 7 . A ctivation  of MAP kinases in J774 ce lls .
J774 cells (4xlOV25 cm^ flask) were stimulated with 1 |ig/ml LPS for the times 
indicated. Total protein lysates were prepared and equal amounts of protein were 
separated by SDS PAGE. Gels were blotted on to nitrocellulose and probed with 
antibodies specific for the active (dual-phosphorylated) isoforms of ERK (pERKl/2; A), 
p38 (pp38; B) and JNK (pJNK 1/2; C) MAP kinases (upper panel of each pair). Blots 
were stripped and reprobed with antibodies that detect total amounts of each MAP 
kinase as a protein loading control (lower panel of each pair). Densitometric values 
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Figure 3 .1 8 .  Act ivat ion  o f  MAP kinases  in peritoneal macrophages.
Peritoneal macrophages (4xlOV25 cm^ flask) were stimulated with 100 U/ml IFN-y 
and/or 100 ng/ml LPS for 10 minutes. Total protein lysates were prepared and equal 
amounts of protein were separated by SDS PAGE. Gels were blotted on to 
nitrocellulose and probed with antibodies specific for the active (dual-phosphorylated) 
isoforms of ERK (A), p38 (B) and JNK (C) MAP kinases (upper panel of each pair). 
Blots were stripped and reprobed with antibodies that detect total amounts of each 
MAP kinase as a protein loading control (lower panel of each pair).
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Figure 3.19. Inhibitors of MAP kinase cascades.
MAP kinases (MAPKs) are activated by dual phosphorylation on a tyrosine and a 
threonine residue by MAP kinase kinases (MAPKKs or MEKs). These are activated by 
phosphorylation by MAP kinase kinase kinases (MAPKKKs) e.g. Raf activates MHKl/2 
which activate ERK 1/2. The targets of specific inhibitors of MAP kinase pathways are 
also indicated. ERK activation can be prevented by treatment with PD 098059, which 
targets the activation of M EKl/2, or U0126, which inhibits M EKl/2 activity. p38 activity 


















Figure 3 .2 0 .  Effects  o f  the MEK and p38 MAP kinase inhibitors PD 
098059  and SB 203580  on ERK, p38 and JNK MAP kinase act ivat ion in 
J774 ce l l s .
J774 cells (4x10^/25 cm^ flask) were pre-treated with either the inhibitor of the ERK 
MAP kinase pathway, PD 098059 (20|liM ; PD), or the p38 inhibitor, SB 203580 (5|iM; 
SB) for 1 hour prior to stimulation with 1 gg/ml LPS for 10 minutes. Total protein 
lysates were purified and assayed by Western Blotting using anti-phospho-ERK (A), - 
p38 (B) and -JNK (C) antibodies (upper panels). The blots were then stripped and 
reprobed with anti-ERK (A), -p38 (B) and -JNK (C) antibodies as a loading control 
(lower panels).






Figure 3 .2 1 .  Effects  o f  the MEK and p38 MAP kinase inhibitors PD 
098059  and SB 203580  on ERK MAP kinase act ivat ion in peritoneal  
macrophages.
Peritoneal macrophages (4xlOV25 cm^ flask) were stimulated for 4 hours with 100 U/ml 
IFN-y and 100 ng/ml LPS, in the absence/presence of PD 098059 (PD; 20 gM) or SB 
203580 (SB; 5 gM) which was added at the times indicated relative to IFN-y + LPS 
stimulation. Total protein lysates were purified and assayed by Western Blotting using 
anti-phospho-ERK antibody (upper panel). The blot was then stripped and reprobed with 
anti-ERK antibody as a loading control (lower panel).
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Figure 3.22. Effect of inhibition of ERK and p38 MAP kinases on cell viability of 
peritoneal macrophages.
The viability of peritoneal macrophages (originally plated at 2xlOVwell in a 96-well 
plate) following pre-treatment with 20 pM PD 098059 or 5 pM SB 203580 for 1 hour 
prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS was assessed by MTT 
assay.
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Figure 3.23. Effect of inhibition of ERK MAP kinases on IL-12 p40 production by 
macrophages.
J774 cells (A) or murine peritoneal macrophages (B and C) (2xl0Vwell in a 96-well 
plate) were pre-treated for 1 hour with the inhibitors of the ERK MAP kinase pathway, 
PD 098059 (PD; 20 |llM  or as indicated) or U0126 (1 \iM), prior to stimulation with 1 
pg/ml LPS (A) or 100 U/ml IFN-y and 100 ng/ml LPS (B and C). IL-12 p40 in 24 hour 
culture supernatants was measured by ELISA. * p < 0.05, ** p < 0,01
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Figure 3 .2 4 .  E ffect  o f  inhib it ion of  ERK MAP kinase act ivat ion on IL- 
12 p40 mRNA induction.
J774 cells (4xl0V25 cm^ flask) were pre-treated with 20 pM PD 098059 (PD) for 1 
hour prior to stimulation with 1 pg/ml LPS for the times indicated. Northern Blot 
analysis (A) was performed using purified total RNA hybridised with a cloned murine 
IL-12 p40 cDNA probe. After stripping, a cloned murine p-actin cDNA probe was used 
as a loading control. Densitometric values (B) are IL-12 p40:p-actin ratios derived 
from the data, expressed relative to basal levels.
117
A IL-12 p402 5 0 1
^  200 “
6  1 5 0 -
Q .  1 0 0 -
5 0 -
0 #
0 155 1 0 2 0
B
Duration of stimulation (hours)
IFN-y + LPS 
PD-h IFN-y + LPS
4 0  “1
30  -
1 00 5 15 2 0
Duration of stimulation (hours)
Figure 3.25. Modulation of IL-12 p40 mRNA and protein production by inhibition 
of ERK MAP kinase activation.
Peritoneal macrophages (4x10925 cm^ flask) were pre-treated with 20 pM PD 098059 
for 1 hour prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS for the times 
indicated. Total RNA was purified and TaqMan real-time PCR analysis was performed 
to measure IL-12 p40 transcript levels, which are expressed relative to HPRT mRNA 




7 5 0 0 -
□  IFN-y + LPS 














4 0 0 -
_j
2 0 0 -





Figure 3.26. Effect of inhibition of ERK MAP kinases on IL-12 p70 production by 
peritoneal macrophages.
BALB/c peritoneal macrophages (2xlOVwell in a 96-well plate) were pre-treated for 1 
hour with the inhibitors of the ERK MAP kinase pathway, PD 098059 (PD; 20 pM) or 
U0126 (1 pM), prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS. IL-12 p40 
and bioactive p70 m 24 hour culture supernatants were measured by ELISA.
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Figure 3.27. Effect of inhibition of ERK MAP kinase activation on IL-12 p35 
mRNA induction.
Peritoneal macrophages (4x10^25 cm^ flask) were pre-treated with 20 pM PD 098059 
for 1 hour prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS for the times 
indicated. Total RNA was purified and TaqMan real-time PCR analysis was performed 
to measure IL-12 p35 transcript levels, which are expressed relative to HPRT mRNA.
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Figure 3.28. Effect of inhibition of p38 MAP kinase on IL-12 p40 production hy 
macrophages.
J774 cells (A) or murine peritoneal macrophages (B) (2xl0Vwell in a 96-well plate) 
were pre-treated for 1 hour with the inhibitor of the p38 MAP kinase pathway, SB 
203580 (SB; 5 pM or as indicated), prior to stimulation with 1 pg/ml LPS (A) or 100 
U/ml IFN-y and 100 ng/ml LPS (B). IL-12 p40 in 24 hour culture supernatants was 
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Figure 3.29. Effect of inhibition of p38 MAP kinase on IL-12 p70 production by 
peritoneal macrophages.
BALB/c peritoneal macrophages (2xlOVwell in a 96-well plate) were pre-treated for 1 
hour with the inhibitor of the p38 MAP kinase pathway, SB 203580 (SB; 5 pM), prior to 
stimulation with 100 U/ml IFN-y and 100 ng/ml LPS. IL-12 p40 and bioactive p70 in 24 
hour culture supernatants were measured by ELISA (A); the effect of SB on IL-12 p70 
is also shown enlarged (B).
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Figure 3 .3 0 . E ffect of inhib ition  o f p38 MAP kinase activ ity  on IL-12 
p40 mRNA induction.
J774 cells (4x10^/25 cm^ flask) were pre-treated with 5 pM SB 203580 (SB) for 1 hour 
prior to stimulation with 1 pg/ml LPS for the times indicated. Northern Blot analysis 
(A) was performed using purified total RNA hybridised with a cloned murine IL-12 p40 
cDNA probe. After stripping, a cloned murine p-actin cDNA probe was used as a 
loading control. Densitometric values (B) are IL-12 p40:p-actin ratios derived from the 
data, expressed relative to basal levels.
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Figure 3.31. Modulation of IL-12 p40 mRNA production by inhibition of p38 MAP 
kinase activity.
Peritoneal macrophages (4xlOV25 cm^ flask) were pre-treated with SB 203580 (SB; 5 
pM) for 1 hour prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS for the 
times indicated. Total RNA was purified and TaqMan real-time PCR analysis was 
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Figure 3.32. Effect of inhibition of p38 MAP kinase activity on IL-12 p35 mRNA 
induction.
Peritoneal macrophages (4x10^25 cm^ flask) were pre-treated with SB 203580 (SB; 5 
|xM) for 1 hour prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS for the 
times indicated. Total RNA was purified and TaqMan real-time PCR analysis was 
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Figure 3.33. Effect of inhibition of both ERK and p38 MAP kinases on IL-12 
production.
J774 cells (A) and murine peritoneal macrophages (B) (2xl0Vwell in a 96-well plate)
were pre-treated with the ERK inhibitor PD 098059 (PD; 20 pM) or U0126 (1 pM) in
the presence/absence of the p38 inhibitor SB 203580 (SB; 5 pM or as indicated) for 1
hour prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS. IL-12 p40 in 24 hour
culture supernatants was measured by ELISA.
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Figure 3.34. Effect of inhibition of ERK MAP kinases on IL-6 production.
J774 cells (A) and murine peritoneal macrophages (B) (2xlüVwell in a 96-well plate) 
were pre-treated for 1 hour with the inhibitor of the ERK MAP kinase pathway, PD 
098059 (PD; 20 pM or as indicated), prior to stimulation with 1 pg/ml LPS (A) or 100 

































Figure 3.35. Effect of inhibition of p38 MAP kinase on IL-6 production.
J774 cells (A) and murine peritoneal macrophages (B) (2xlOVwell in a 96-well plate) 
were pre-treated for 1 hour with the inhibitor of the p38 MAP kinase pathway, SB 
203580 (SB; 5 pM or as indicated), prior to stimulation with 1 pg/ml LPS (A) or 100 
U/ml IFN-y and 100 ng/ml LPS (B). IL - 6  in 24 hour culture supernatants was measured 
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Figure 3.36. Effect of inhibition of ERK MAP kinases on TNF-a production.
J774 cells (A) and murine peritoneal macrophages (B) (2xlOVwell in a 96-well plate) 
were pre-treated for 1 hour with the inhibitors of the ERK MAP kinase pathway, PD 
098059 (PD; 20 pM or as indicated) or U0126 (1 pM), prior to stimulation with 1 pg/ml 
LPS (A) or 100 U/ml IFN-y and 100 ng/ml LPS. TNF-a in 24 hour culture supernatants 


































Figure 3.37. Effect of inhibition of p38 MAP kinase on TNF-a production.
J774 cells (A) and murine peritoneal macrophages (B) (2xl0Vwell in a 96-well plate) 
were pre-treated for 1 hour with the inhibitor of the p38 MAP kinase pathway, SB 
203580 (SB; 5 pM or as indicated), prior to stimulation with 1 pg/ml LPS (A) or 100 
U/ml IFN-y and 100 ng/ml LPS (B). TNF-a in 24 hour culture supernatants was 
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Figure 3.38. Effects of inhibition of ERK and p38 MAP kinases on TNF-a mRNA
induction.
Peritoneal macrophages (4x10^/25 cm^ flask) were pre-treated with 20 pM PD 098059 
(PD) or 5 pM SB 203580 (SB) for 1 hour prior to stimulation with 100 U/ml IFN-y and 
100 ng/ml LPS for the times indicated. Total RNA was purified and TaqMan real-time 
PCR analysis was performed to measure TNF-a transcript levels, which are expressed 
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Figure 3.39. Effects of inhibition of ERK and p38 MAP kinases on NO release.
J774 cells (A and B) and murine peritoneal macrophages (C) (2xlOVwell in a 96-well 
plate) were pre-treated for 1 hour with the inhibitor of the ERK MAP kinase pathway, 
PD 098059 (PD; 20 |iM or as indicated), or the p38 inhibitor, SB 203580 (SB; 5 pM or 
as indicated), prior to stimulation with 1 pg/ml LPS (A and B) or 100 U/ml IFN ^ and 
100 ng/ml LPS (C). NO in 24 hour culture supernatants was assayed by Griess Reaction. 
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Figure 3 .4 0 . E ffects of inhib ition  of ERK and p38 MAP kinases on iNOS 
induction.
J774 cells (4xlOV25 cm^ flask) were pre-treated for 1 hour with the inhibitor of the 
ERK MAP kinase pathway, PD 098059 (20 pM; PD), or the p38 inhibitor, SB 203580 
(5 pM; SB), prior to stimulation with 1 pg/ml LPS for 16 hours. Total protein lysates 
were purified and assayed for iNOS by Western Blotting using an anti-iNOS antibody.
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Figure 3 .4 1 .  Effects  of  inhib it ion of  ERK and p38 MAP kinases on I-kB 
degradation fo l low in g  s timulation with IFN-y + LPS.
Peritoneal macrophages (4xl0V25 cm^ flask) were stimulated for 4 hours with 100 
U/ml IFN-y and 100 ng/ml LPS, in the absence/presence of PD 098059 (PD; 20 pM) or 
SB 203580 (SB; 5 pM) which was added at the times indicated relative to IFN-y + LPS 
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Figure 3 .4 2 .  Effects  o f  inhibit ion o f  ERK and p38 MAP kinases on NF- 
kB binding to iNOS and IL-12 p40 promoter sequences .
J774 cells (4xlOV25 cm^ flask) were pre-treated with either PD 098059 (PD; 20 pM) or 
SB 203580 (SB; 5 pM) for 1 hour prior to stimulation with 1 pg/ml LPS for 1 hour. 
Nuclear protein was purified and analysed by EMSA for NF-kB binding to ^^P-labelled 
oligonucleotide probes containing NF-kB binding sites from iNOS (A) and IL-12 p40 
(B) promoters. Supershift was performed by pre-incubating nuclear protein samples 
with antibodies against NF-kB isoforms for 30 minutes prior to addition of the probe, 
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Figure 3 .4 3 .  Effects  o f  inhibit ion o f  ERK and p38 MAP kinases on lRF-1 
synthesis  fo l low ing  s timulation with IFN-y + LPS.
A. Peritoneal macrophages (4x10^25 cm^ flask) were stimulated with 100 U/ml IFN-y 
and 100 ng/ml LPS for the times indicated.
B. Peritoneal macrophages (4xl0V25 cm^ flask) were stimulated for 4 hours with 100 
U/ml IFN-y and 100 ng/ml LPS, in the absence/presence of PD 098059 (20 pM) or SB 
203580 (5 pM) which was added at the times indicated relative to IFN-y + LPS 
stimulation.









Figure 3 .4 4 .  Effects  o f  inhibit ion of  ERK and p38 MAP kinases  on 
transcription factor  binding to the iNOS IRF-E binding site and a portion  
of  the IL-12 p40 promoter.
J774 cells (4xl0V 25 cm^ flask) were pre-treated with either PD 098059 (PD; 20 pM) or 
SB 203580 (SB; 5 pM) for 1 hour prior to stimulation with 1 pg/ml LPS for the times 
indicated. Nuclear protein was purified and analysed by EMSA for binding to ^^ P- 
labelled oligonucleotide probes containing the IRF-E binding site from the iNOS 
promoter (A) and a portion of the IL-12 p40 promoter that is involved in binding of the 
FI complex (B). ‘a’, ‘b’, ‘c ’ and ‘d’ indicate binding complexes.
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Figure 3 .4 5 .  Effects  of  inhibit ion o f  ERK and p38 MAP kinases on LPS-  
induced Ets-2 production.
J774 cells (4xlOV25 cm^ flask) were pre-treated with either PD 098059 (PD; 20 pM) or 
SB 203580 (SB; 5 pM) for 1 hour prior to stimulation with 1 pg/ml LPS for 1 hour. 
Nuclear protein was purified and analysed by Western Blotting using an anti-Etsl/2 
antibody.
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Figure 3.46. Roles of ERK and p38 MAP kinases in the induction of cytokine and 
iNOS production by LPS.
Stimulation of macrophages with LPS in the presence/absence of IFN-y results in 
activation of ERK and p38 MAP kinases by dual phosphorylation. p38 MAP kinase 
activity is required for synthesis of both subunits of IL-12, as well as IL-6, TNF-a and 
iNOS. Induction of TNF-a and iNOS is also ERK MAP kinase-dependent. IL-6 and IL- 
12 p35 are not regulated by ERK MAP kinases. IL-12 p40 production is negatively 
regulated by ERK MAP kinases, which appear to suppress the p38 signal. IL-12 p40 can 
heterodimerise with the p35 subunit to form bioactive IL-12, or form inhibitory 
homodimers. iNOS catalyses the production of NO from L-arginine.
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4:1:1 Leishmania parasites - infection and disease.
It is estimated that 12 million people worldwide are infected with parasites of the 
genus Leishmania, and a further 350 million are at risk (WHO 2000b). Infection occurs 
mainly in the Tropics since the survival of the parasite is limited by the geographical 
distribution of its vector (the sandfly) and its susceptibility to cold climates.
Infection of humans with Leishmania parasites results in a spectrum of diseases 
known collectively as leishmaniasis (reviewed by Grimaldi et a l, 1989). Visceral 
leishmaniasis, or kala azar, is the most severe form of the disease and is fatal if left 
untreated. It is characterised by fever, weight loss, swelling of the spleen and liver, and 
anaemia. Mucocutaneous leishmaniasis, or espundia, produces lesions that can lead to 
extensive and disfiguring destruction of mucous membranes of the nose, mouth and 
throat cavities. Cutaneous leishmaniasis, the most common form, is characterised by 
large numbers of skin ulcers on the exposed parts of the body such as face, arms and legs, 
and can cause serious disability and permanent scarring, d isease- is particularly prevalent 
and lethal among immunosuppressed patients, and Leishmania/¥LIV co-infection is 
increasingly common (WHO 2000b).
Parasites are transmitted between mammalian hosts (humans, domestic and wild 
animals) by sandflies {Phlebotomus and Lutzomyia spp.) when these insects take a 
bloodmeal.
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4:1:2 The lifecycle of Leishmania parasites.
The digenetic lifecycle of Leishmania consists of alternating phases in the 
digestive tract of the sand fly vector and in macrophages of the mammalian host 
(reviewed by Turco and Descoteaux, 1992; see Figure 4.1). Sandflies acquire Leishmania 
parasites from vertebrate hosts in the amastigote form by ingestion in a bloodmeal. 
•Metacyclogenesis,lh e  process of development from dividing non-infectious amastigotes 
to resting, flagellated, infectious promastigotes takes place as parasites move through the 
midgut to the anterior end of the gut and into the mouthparts. When the sandfly feeds 
again, promastigotes are injected into another mammalian host where they invade and 
parasitise macrophages. This is achieved by direct association of surface molecules with 
macrophage receptors, or indirectly via association with molecules present in serum, such 
as C3, which then bind their receptors on the macrophage (reviewed by Bogdan and 
Rollinghoff, 1998). Internalisation occurs via formation of a phagosome, which fuses 
with secondary lysosomes to form a phagolysosome. Inside the phagolysosome, the 
parasites transform to obligate intracellular amastigotes and multiply, before being 
released and ingested by the sandfly vector to continue the cycle.
4:1:3 Evasion of the host immune response.
At all stages of the lifecycle parasites are exposed to attack from the vector or the 
host (reviewed by Turco and Descoteaux, 1992). To survive in the sandfly they must 
protect against the lytic effects of the insect’s gut enzymes. In the mammalian host they
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must combat the effects of normal serum in the bloodstream, and degradative enzymes 
and toxic oxygen products in the macrophage phagolysosome.
Effective immunity against Leishmania infection is dependent on the induction of 
a parasite-specific Thl cell response (Scott et al, 1988; Boom et al, 1990; Heinzel et al, 
1991; Reiner and Locksley, 1995). In the absence of significant IL-4 production, IFN-y 
produced by Thl cells and NK cells stimulates the iNOS-catalysed production of NO by 
macrophages, resulting in killing of Leishmania parasites (Liew et a l, 1990; Wei et al, 
1995; Stenger et a l, 1996). The genetic predisposition of naturally-occurring mouse 
strains to mount a Th response with a type 1 (Thl) or type 2 (Th2) bias is believed to 
underlie the resistance versus susceptibility to Leishmania infection respectively. C3H 
and C57BL/6 mice, which naturally resolve their lesions, exhibit a dominant Thl profile, 
while BALB/c mice, which develop progressive disease, show a dominant Th2 phenotype 
(Scott, 1991; Heinzel et al, 1989).
Leishmania parasites employ a number of mechanisms to aid their survival and 
promote establishment and maintenance of infection, including the suppression of IL-12 
production (reviewed by Mattner et al, 1997a). IL-12 is critical for the establishment of 
Thl responses and the induction of IFN-y production, and thus the synthesis of iNOS. It 
is therefore a key determinant in the outcome of Leishmania infections. Indeed, IL-12- 
deficient, like iNOS-deficient, mice have been shown to be susceptible to Leishmania 
infection (Satoskar et a l, 2000; Mattner et a l, 1996 and 1997b; Wei et a l, 1995). 
Furthermore, treatment of susceptible BALB/c mice with recombinant IL-12 resulted in a 
curative response to L. major infection due to IFN-y production and inhibition of Th2 
cytokines (Heinzel et al, 1993; Sypek et a l, 1993). In contrast, neutralisation of either
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IL-12 or IFN-y led to an adverse outcome in normally resistant mice (Sypek et a l, 1993; 
Belosevic e? a/., 1989).
Since macrophages are the major producers of IL-12 and it is these cells that 
Leishmania invades, the inhibition of macrophage IL-12 production is thought to be an 
important parasite survival strategy. In the absence of IFN-y, NO production by 
macrophages is significantly reduced and therefore the parasites survive and are able to 
multiply. Indeed, Reiner et al. (1994) and Carrera et at. (1996) showed that Leishmania 
promastigotes evade IL-12 induction by macrophages from both resistant C57BL/6 and 
susceptible BALB/c mice.
4:1:4 Leishmania lipophosphoglycan and its role in immune evasion.
Multiple virulence determinants produced by Leishmania parasites have been 
identified with a capacity to modulate the immune response (reviewed by Bogdan and 
Rollinghoff, 1998). These include molecules expressed on the parasite surface such as 
lipophosphoglycan (LPG), glycoinositol phospholipids (GIPLs) and the 
metalloproteinase gp63, as well as secreted factors such as proteophosphoglycans (PPGs) 
which are secreted by amastigotes into the parasitophorous vesicles of the host cell.
Leishm ania  parasites are covered with a thick glycocalyx, which consists 
predominantly of a single molecule called lipophosphoglycan (LPG); as many as 10  ^
copies of LPG may be present on a single promastigote (Orlandi and Turco, 1987). LPG 
is a multifunctional molecule with roles at various stages of the Leishmania lifecycle,
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both in the sandfly vector and in the mammalian host (reviewed by Turco and 
Descoteaux, 1992). In the sandfly it is involved in the binding of parasites to the midgut 
and, subsequently, detachment of the parasite to allow transmission. Metacyclogenesis 
includes structural modification of LPG, allowing parasites to move through the gut 
towards the mouthparts; LPG also protects against hydrolytic enzymes in sandfly gut. In 
the vertebrate host, it has been implicated in the resistance of the parasite to complement- 
mediated lysis, its binding to and uptake by macrophages, modulation of macrophage 
signal transduction pathways leading to suppression of effector molecule production and 
resistance to oxidative attack.
The importance of LPG in the successful establishment and maintenance of 
infection was suggested by the demonstration that mice vaccinated with LPG displayed a 
reduced parasite burden upon challenge infection with L, major, and had increased 
numbers of L. mq/or-reactive T cells compared with non-vaccinated mice (Handman and 
Mitchell, 1985). Further evidence was provided from studies in which several LPG- 
deficient strains of Leishmania were shown to be unable to survive in host macrophages; 
for example, an avirulent clone of L. major that lacked LPG was phagocytosed by 
macrophages and killed within 18 hours (Handman et al, 1986). The ability of LPG to 
confer resistance to killing was confirmed by passive transfer of purified LPG from a 
virulent strain into avirulent promastigotes, which were then able to survive in 
macrophages (McNeely and Turco, 1990).
The structure of LPG is shown in Figure 4.2. It comprises a monoalkyl lipid that 
anchors LPG to the plasma membrane, a hexasaccharide core and a phosphoglycan 
region with a neutral cap. The functions of LPG have been investigated and variously
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attributed to the different LPG portions. The effects of LPG on macrophage function are 
summarised in Figure 4.3. LPG is a potent inhibitor of many protein kinase C (PKC)- 
mediated events which are deleterious to Leishmania promastigotes (reviewed by Turco 
and Descoteaux, 1992). PKC is a multifunctional serine-threonine kinase, which is 
composed of an ATP-binding catalytic domain and a regulatory domain that contains 
sites involved in calcium, diacylglycerol (DAG) and phospholipid binding (reviewed by 
Nishizuka, 1986). Upon binding to membranes, a conformational change occurs and the 
catalytic and regulatory domains of PKC dissociate. A study by Giorgione et at. (1996) 
indicated that LPG bound on the outside of the plasma membrane inhibits PKCa 
activation by causing it to bind to the inner membrane without the induction of a 
conformational change.
LPG inhibits the oxidative burst via its suppression of PKC; monoalkyl lipid 
fragments exhibit the most potent inhibitory activity, although phosphoglycan was also 
demonstrated to inhibit purified PKC activity (McNeely and Turco, 1987 and 1990; 
McNeely et al, 1989). Furthermore, the phosphoglycan portion is a highly effective 
scavenger of hydroxyl radicals and superoxide ions, thereby limiting the consequences of 
oxidative attack (Chan et al, 1989). LPG also inhibits the PKC-mediated induction of the 
immediate early gene c-fos, thus preventing the formation of Fos-Jun complexes, which 
are important for the transcriptional regulation of a number of macrophage effector genes 
(Descoteaux et a l, 1991). PKC-dependent mechanisms mediate the activation of 
macrophages by TNF-a and IFN-y (Fan et al, 1988; Hamilton et al, 1985; Schutze et al, 
1990) and these have therefore also been implicated as LPG targets. Furthermore, LPG 
causes the down-regulation of TNF receptors (Descoteaux et al, 1991). In addition, LPG 
is thought to inhibit chemotaxis via a PKC-dependent mechanism, thereby preventing
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accumulation of blood monocytes at sites of infection (Frankenburg et al, 1990; Laskin 
et al, 1987).
LPG also activates HIV-1 replication in monocytes and T cells (Bernier et a l, 
1995 and 1998) and has been demonstrated to target protein tyrosine kinase- and protein 
kinase A-dependent pathways and NF-kB binding (Bernier et a l, 1998) to achieve up- 
regulation of HIV-1 long terminal repeat (LTR)-driven transcription.
The critical role of macrophages in the activation of T helper cells is also 
impaired by Leishmania infection. The expression of major histocompatibility complex 
(MHC) class II molecules and the production of IL-1 are both defective in L. donovani- 
infected macrophages, and LPG has been implicated in these deficiencies (Reiner, 1987; 
Reiner et al, 1987; Frankenburg et al, 1990).
Proudfoot et a l (1996) showed that glycoinositol phospholipids (GIPLs) and LPG 
are both capable of inhibiting NO synthesis following activation of macrophages with 
IFN-y. GIPLs are thought to act via suppression of production of iNOS, the enzyme that 
catalyses NO synthesis; although LPG may also act in this way, it is believed to achieve 
NO suppression in vivo predominantly via inhibition of IL-12 and hence IFN-y 
production.
Reiner et a l  (1994) demonstrated that non-infective amastigotes induce IL-12 
production by bone marrow-derived macrophages, whereas infective promastigotes do 
not. Furthermore, Sartori et a l  (1997) showed that both procyclic and metacyclic 
promastigotes were capable of inhibiting IL-12 production induced by Staphylococcus
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aureus. The composition of glycans on the surface of the parasites has been linked to this 
ability to modulate IL-12 production. GIPLs are present on both amastigotes and 
promastigotes whereas LPG is present predominantly on the promastigote stage of the 
parasite (Mengeling et al., 1997). Consistent with this theory, IL-12 production is 
induced by glycoconjugates of GIPLs, but suppressed by LPG glycoconjugates 
(Piedrafita et al, 1999).
In a previous investigation in this laboratory using the J774 murine macrophage 
cell line, Piedrafita et a l (1999) demonstrated that a synthetic version of the PG portion 
of LPG (sPG), which consists of an average of 10 repeats of the Galactose-Mannose- 
phosphate subunit (see Figure 4.2), is able to mimic LPG-mediated suppression of IL-12 
p40 production. Thus, the phosphoglycan portion, and not the glycophosphoinositol lipid 
anchor, is critical for this activity. sPG suppressed IL-12 p40 at the transcriptional level, 
but did not inhibit IL - 6  or TNF-a production by these macrophages.
4:1:5 Aim of this study.
The aim of this investigation was to build on the discoveries described in the 
previous chapter to determine the signalling mechanisms underlying the sPG-mediated 
suppression of IL-12. The effects of sPG on the activation of MAP kinases and their 
regulation of IL-12 p40 production were examined.
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4:2 Results.
4:2:1 Effects of sPG on cytokine and NO production by macrophages.
First, the effects of sPG on the production of cytokines and NO by LPS- 
stimulated J774 cells and IFN-y + LPS-stimulated murine peritoneal macrophages were 
analysed. Unless otherwise indicated, cells were stimulated in the absence/presence of 
sPG for 24 hours, and cytokines and NO in culture supernatants were measured by 
ELISA and Griess reaction respectively. A shorter PG fragment, called sPG3, which has 
an average of approximately 4.5 Gal-Man-phosphate repeats and lacks the terminal 
phosphate group (see Figure 4.2), was also tested.
4:2:1:1 Effect of sPG on IL-12 production.
sPG treatment inhibited LPS-induced IL-12 p40 production in a dose dependent 
manner (Figure 4.4A). A dose of 50 |xM resulted in 57% inhibition and was selected for 
further experiments. Interestingly, the truncated version of sPG, sPG3, also inhibited IL- 
12 production, and with a similar potency (Figure 4.4B); 50 pM sPG3 inhibited IL-12 
p40 production by 57%. This indicates that a high degree of polymerisation of the Gal- 
Man repeats is not necessary for inhibition of IL-12, and also that the terminal phosphate 
group is not critical.
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The time of addition of sPG relative to LPS stimulation was important (Figure 
4.5). Addition 1 hour before or 10 minutes after LPS was as effective as simultaneous 
treatment. However, sPG added 30 minutes after LPS resulted in less significant 
inhibition of IL-12, and by 1 hour after LPS stimulation sPG was totally ineffective.
sPG also inhibited the production of IL-12 p40 induced by treatment of murine 
peritoneal macrophages with IFN-y + LPS. Of particular interest, this suppression was 
independent of the strain of mouse used; sPG inhibited IL-12 p40 production by 
macrophages from both the Lew/zmawia-susceptible BALB/c and the resistant 129 strains 
to a similar extent (Figure 4.6).
The biological relevance of these data was confirmed by the demonstration that 
sPG treatment also reduced levels of IL-12 p70 heterodimer in culture supernatants 
(Figure 4.7). Thus, the PG portion of LPG reduces bioactive IL-12 production by 
inhibiting production of the p40 subunit.
4:2:1:2 Effects of sPG on macrophage viability and TNF-a and NO production.
Analysis of macrophage viability by MTT assay confirmed that sPG does not 
inhibit IL-12 production by simply killing cells (Figure 4.8). TNF-a and NO levels in 
culture supernatants were also measured to assess whether sPG acts specifically to inhibit 
IL-12 production, or generally, for example to inhibit transcription. sPG did not inhibit 
the production of TNF-a or NO by J774 cells or murine peritoneal macrophages (Figure 
4.9). These data are consistent with previous experiments using sPG, which showed that
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it had no effect on IL - 6  or TNF-a production (Piedrafita et a l, 1999). Therefore, sPG 
specifically targets the production of IL-12 by macrophages.
4:2:2 Effects of sPG on MAP kinase activity.
The signalling mechanisms underlying the sPG-mediated suppression of LPS- 
induced IL-12 p40 production are unknown, although a previous study (Piedrafita et al, 
1999) suggested that suppression of p40 transcription is not due to reduced NF-kB 
availability. The requirement of p38 MAP kinase activity for transcription of the IL-12 
p40 gene, and the negative regulation of this signal by ERK MAP kinases was 
demonstrated in the previous chapter. Hence, these MAP kinases represent putative 
mediators of IL-12 suppression by sPG. Therefore, the effects of sPG on MAP kinase 
activation and the modulation of IL-12 production by treatment with PD 098059 were 
investigated.
First, MAP kinase activation in J774 cells and peritoneal macrophages following 
treatment with sPG and stimulation with LPS or IFN-y -f LPS was assessed by Western 
Blotting using antibodies specific for the active dual-phosphorylated forms of the ERKs, 
p38 and SAPK/JNK.
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4:2:2:1 Modulation of ERK MAP kinase activation.
Treatment with sPG alone enhanced the activation of both ERK MAP kinase 
isoforms in J774 cells (Figure 4.10). Increased ERK2 activation was detectable by 30 
seconds and ERKl was enhanced by 1 minute after treatment. Activation of both ERK 
isoforms was maximal by 5 minutes and remained enhanced throughout a 30 minute 
timecourse. sPG also enhanced the EPS-induced activation of ERKs (Figure 4.11). As 
before, enhanced ERK phosphorylation was detectable by 30 seconds after stimulation. 
Activation of ERKl was maximal by 5 minutes and ERK2 peaked at about 1 minute after 
stimulation. Thereafter, phosphorylation of both ERK isoforms declined towards basal 
levels by 1 0  minutes.
Similar results were obtained in murine peritoneal macrophages (Figures 4.12 and 
4.13). Stimulation for 10 minutes with IFN-y + LPS in the presence of sPG resulted in the 
enhanced phosphorylation of both ERK isoforms (Figure 4.12). Another experiment 
showed sustained enhaneement of phosphorylation of both ERK isoforms throughout an 
8  hour timecourse of stimulation (Figure 4.13).
4:2:2:2 Modulation of p38 and JNK MAP kinase activation.
Enhanced dual phosphorylation of p38 MAP kinase was detected in 1774 cells 
treated with sPG alone or sPG + LPS for 20 minutes; sPG3 also enhanced p38 production 
(Figure 4.14). Similar results were observed following stimulation of murine peritoneal 
macrophages for 10 minutes with IFN-y + LPS in the absence/presence of sPG (Figure
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4.15A). In contrast, dual phosphorylation of JNK MAP kinases at this timepoint was not 
altered by sPG treatment (Figure 4.15B).
4:2;2;3 Effects of inhibition of ERK MAP kinase activation on sPG-mediated 
suppression of IL-12.
Since ERK MAP kinases transduce negative signals for the regulation of IL-12 
p40 production, the enhancement of ERK activation by sPG could provide a mechanism 
for the sPG-mediated suppression of IL-12 production. To test this hypothesis the MEK 
inhibitor PD 098059 was used to investigate whether sPG could still inhibit IL-12 when 
ERK activation was blocked. As predicted, sPG was unable to suppress IL-12 p40 
production following the pre-incubation of J774 cells or murine peritoneal macrophages 
with 20 |iM PD 098059 for 1 hour prior to stimulation (Figure 4.16 and 4.17). However, 
neither PD 098059 nor U0126 pre-treatment rescued sPG-mediated suppression of 
bioactive IL-12 p70 production (Figure 4.18).
Taken together, these data demonstrate that sPG, and thus LPG, achieves its 




Many of the mechanisms employed by Leishm ania  sp. parasites to evade 
detection and killing by the host immune system are mediated by the major component of 
the parasite glycocalyx, LPG. In this study, a synthetic version of a portion of Leishmania 
LPG was used to investigate how this molecule suppresses the induction of IL-12, a key 
cytokine in the clearance of Leishmania infection.
Concurrent with a previous report from this laboratory (Piedrafita et a l, 1999), 
the data presented here demonstrate that the phosphoglycan (PG) portion of LPG is 
capable of suppressing IL-12 p40 production and that this results in lower levels of 
bioactive IL-12 p70 production (Figures 4.4 -  4.7). Interestingly, the results of this study 
and the previous report (Figure 4.9 and Piedrafita et al, 1999) demonstrate that sPG does 
not mimic all the functional properties of LPG; while it was capable of suppressing IL-12 
production, sPG did not alter NO induction. This provides further evidence that different 
structural regions of LPG make distinct contributions to the activity of this 
multifunctional molecule.
Many of the functions of LPG have been attributed to the PG portion. Indeed, 
delipidated PG of naturally-extracted LPG exacerbated infection in both resistant and 
susceptible mouse strains (Mitchell and Handman, 1986). The hexasaccharide core of 
LPG was not required for inhibition of IL-12, neither was the lipid anchor. Similarly, 
inhibition of macrophage microbicidal activity and IL-1 production is achieved by the PG 
portion of LPG, not the lipid anchor (Frankenburg et al, 1990; Giorgione et a l, 1996). 
Preliminary data from this laboratory also showed that vaccination with sPG exacerbated
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infection in mice challenged with L, major or L. mexicana (D. Piedrafita, personal 
communication). In contrast, inhibition of iNOS by GIPLs is dependent on the lipid 
anchor (Proudfoot et al, 1995).
A regulatory role for LPG in the induction of iNOS, which results in the inhibition 
of NO production has been demonstrated, and this activity has been located to the 
phosphoglycan region (Proudfoot et al, 1996; Liew et al, 1997). sPG, however, did not 
alter NO production (Figure 4.9), indicating that these Gal-Man-phosphate repeats are not 
sufficient for this regulation of iNOS. A higher degree of polymerisation is present in 
LPG molecules and the PG is modified by the attachment of side chains, which vary 
according to species. It is therefore likely that these additional elements are responsible 
for modulation of iNOS. Although it appears that sPG is incapable of disrupting iNOS 
directly, inhibition of IL-12 by sPG would be expected to result in suppression of NO 
production by macrophages in vivo due to reduced IFN-y production by T and NK cells.
The observation that sPG similarly inhibited IL-12 production by macrophages 
from both resistant (129) and susceptible (BALB/c) mouse strains (Figure 4.6) is 
consistent with demonstrations of IL-12 suppression by L. major promastigotes in 
BALB/c versus C3H and C57BL/6 strains (Carrera et al, 1996). Therefore susceptibility 
to Leishmania infection is not due to a defect in IL-12 production or sensitivity to 
inhibition of IL-12. Rather, it has been proposed that susceptibility to infection may 
represent a loss of responsiveness of T cells to IL-12. This is suggested by the finding 
that T cells from BALB/c mice down-regulate IL-12R more rapidly than T cells from 
resistant mice (Guler et al, 1996).
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LPG has been shown to associate with macrophages by both complement- 
dependent and -independent interactions. It interacts directly via binding to mannose- 
fucose receptors, MFRs, and complement receptor 3, CR3 (reviewed by Bogdan and 
Rollinghoff, 1998). It also interacts indirectly via association with serum proteins such as 
complement factor 3 (C3) and C-reactive protein (GRP) which then bind their own 
receptors on the macrophage surface. Parasites subsequently enter macrophages by 
phagocytosis. It is tempting to speculate that sPG would interact with the MFR via its 
galactose-mannose subunits; indeed galactose and fucose (6 -deoxy-galactose) are 
structurally very similar. This might also explain why such a small number of repeats are 
sufficient for binding and achieving IL-12 inhibition.
Alternatively, there is evidence in the literature to back up the suggestion that sPG 
inhibits IL-12 through interaction with CR3. Marth and Kelsall (1997) demonstrated that 
the induction of IL-12 by a variety of stimuli in human monocytes was specifically down- 
regulated following exposure to antibodies against CR3 as well as natural CR3 ligands 
iC3b and Histoplasma capsulatum. Thus sPG/LPG could suppress LPS/IFN-y-induced 
IL-12 production via binding to and signalling through CR3. Indeed, this receptor has 
been shown to associate with CD 14 in neutrophils following LPS stimulation, suggesting 
that it may be involved in regulation of LPS signals (Zarewych et al, 1996). The recently 
identified TLRs, which recognise a variety of pathogen molecules, also represent 
candidate sPG/LPG receptors.
Sequential development of promastigotes from the non-infective (procyclic) form 
to the highly infective (metacyclic) form is accompanied by modification of LPG, in 
particular an increase in the number of phosphodisaccharide repeats (McConville et al,
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1992). While the metacyclic form inhibits IL-12 production from PBMCs; procyclic LPG 
induces high levels of IL-12 production from PBMCs (Sartori et a l, 1997). It has been 
suggested that the ability of promastigotes to inhibit IL-12 production by macrophages 
could depend, at least in part, on the presence of longer phosphodisaccharide repeats of 
PG. Consistent with this, Piedrafita et al. (1999) showed that a range of synthetic 
fragments of PG (L1-L5) containing up to three Gal-Man repeats were not effective 
inhibitors of IL-12. In this study however, a truncated version of sPG (sPG3), which had 
an average of 4.5 repeats, was capable of inhibiting IL-12 production (Figure 3.4B). This 
indicates that the binding of sPG and inhibition of IL-12 are dependent on neither a high 
degree of polymerisation of Gal-Man-phosphate repeats, nor a terminal phosphate group. 
The apparent differences between these studies could be explained by the presence of 
(CH2 )gCH=CH2  side chains on the L1-L5 molecules, which may have interfered with the 
binding of the Gal-Man subunit of such short molecules, thus preventing the inhibition of 
IL-12.
The inhibition of IL-12 by sPG also explains the apparent anomaly of the R2D2 
donov'flni
mutant of L. major which is deficient in LPG but still able to inhibit IL-12 release by 
murine macrophages (Carrera et at., 1996). R2D2 parasites have incomplete LPG 
assembly but are still able to synthesise repeating phosphodisaccharide (Toison et al, 
1989).
It has been suggested that induction of IL-10 production by LPS and/or LPG 
could account for suppression of IL-12 production. However, no IL-10 was detected in 
culture supernatants of 1774 cells or peritoneal macrophages stimulated with any 
combination of sPG, IFN-y and LPS (not shown). This is consistent with a previous
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report, which showed that L. major promastigotes were capable of reducing IL-12 p40 
production by macrophages from IL-10 knock out mice (Carrera et a l, 1996). Thus, IL- 
10 is not likely to be responsible for the down-regulation of IL-12 synthesis in L. major- 
infected macrophages or the inhibition of IL-12 production by macrophages exposed to 
sPG.
The results described in this chapter present a mechanism for the suppression of 
IL-12 p40 production by Leishmania LPG, resulting in lower levels of bioactive IL-12 
p70 release. sPG treatment, both on its own and in combination with macrophage 
stimulatory signals, enhanced the activation of both the ERKl and ERK 2 isoforms 
(Figures 4.10 -  4.13). Furthermore inhibition of ERK MAP kinase activation by pre­
treatment with the MEKl inhibitors PD 098059 and U0126 rescued macrophages from 
sPG-mediated IL-12 p40 suppression (Figures 4.16 and 4.17). Taken together, these 
results suggest that sPG achieves inhibition of IL-12 p70 production by enhancing the 
negative regulation of p40 transcription by ERK MAP kinases.
Interestingly, pre-treatment with neither PD 098059 nor U0126 -pre-treatment 
rescued bioactive IL-12 production (Figure 4.18), indicating that increased production of 
the p40 subunit was not enough to rescue p70 production. Since ERK MAP kinases do 
not appear to regulate p35 production (see Figure 3.27), this suggests that sPG may also 
target production of the p35 subunit in an ERK-independent manner, or it may influence 
the assembly or release of bioactive cytokine. Nevertheless, these results demonstrate a 
mechanism for the suppression of IL-12 p40 production by sPG, resulting in lower levels 
of bioactive IL-12 p70 production.
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The enhancement of p38 activation (Figures 4.14 and 4.15) may at first sight be a 
little confusing since p38 transduces positive signals for IL-12 production. However, sPG 
achieved suppression of IL-12 despite enhanced p38 activation. This is consistent with 
the hypothesis that p38 activation is required for negative regulation by ERKs, which act 
to disrupt p38 signals.
The upstream mechanisms of ERK activation and the downstream targets of this 
MAP kinase responsible for regulating IL-12 p40 production remain to be identified. It is 
possible that sPG alters the binding of different isoforms of NF-kB in a MAP kinase- 
independent manner, and that this leads for example to the preferential binding of 
inhibitory p50 homodimers. However, results presented in the previous chapter 
demonstrated that NF-kB does not transduce p38 or ERK MAP kinase signals. Consistent 
with this, a previous report suggested that sPG does not inhibit IL-12 by down-regulating 
the nuclear translocation of NF-kB and its binding to promoter sequences (Piedrafita et 
al, 1999). Similarly, binding of the FI binding complex, another potential target of sPG, 
did not appear to be altered by inhibition of ERK or p38 MAP kinases (Figure 3.43B). 
However, IRE synthesis was enhanced by inhibition of ERK activation, as was binding of 
IRE family members to the iNOS promoter sequence, suggesting that ERK MAP kinases 
mediate their downstream functions by modulating transcriptional regulation by IRE 
proteins. Hence, this family of transcription factors, which are important regulators of IL- 
12 production, represent the most likely downstream targets of ERK MAP kinases 
activated by sPG.
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4:4 Summary of this study.
In summary therefore, this investigation has enabled the development of a model 
for the suppression of IL-12 production by Leishmania LPG (Figure 4.19). LPG binds to 
macrophages via its disaccharide repeats and transduces signals leading to the enhanced 
activation of ERK MAP kinases. ERKs negatively regulate LPS-induced IL-12 p40 
transcription by disrupting p38 MAP kinase signalling. Production of the p35 subunit of 
IL-12 may also be suppressed by LPG in an ERK-independent manner. The inhibition of 
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Figure 4.1. Leishmania lifecycle.
Typical lifecycle of Leishmania sp. parasites. Extracellular flagellated promastigotes 
reproduce in the midgut of Phlebotomus and Lutzomyia sandflies. In a process called 
metacyclogenesis they cease dividing, detach from epithelial cells and migrate to the 
insect mouthparts. When the sandfly feeds, metacyclic promastigotes are injected into 
the skin of the mammalian host (e.g. human) and enter the bloodstream. Parasites invade 
macrophages and differentiate into non-flagellated amastigotes in the phagolysosome. In 
this hostile environment, amastigotes are able to proliferate and are released by lysis of 
the host cell to infect other macrophages. Infected macrophages are ingested by feeding 
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Figure 4.2. Chemical structures of Leishmania LPG, sPG and sPG3.
LPG comprises a monoalkyl lipid, a hexasaccharide core, a phosphoglycan (PG) region 
and a neutral cap (adapted from Mengeling et a l,  1997). The R side chain and the 
oligosaccharide cap structure vary according to species (most prevalent L. donovani cap 
shown). The synthetic version, sPG represents the PG (highlighted red) region and is a 
polymer of galactose-mannose-phosphate repeated an average of 10 times (Nikolaev et 
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Figure 4.3. Suppression of macrophage function by Leishmania LPG.
Leishmania parasites inhibit activation of macrophage responses to evade detection and 
suppress the host’s immune attack against them. The parasite surface molecule 
lipophosphoglycan (LPG) has been shown to interfere with many macrophage signalling 
pathways to suppress gene expression and limit the effects of other macrophage 
responses such as the oxidative burst (reviewed by Turco and Descoteaux, 1992).
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Figure 4.4. Effects of sPG and sPG3 on IL-12 p40 production by J774 cells.
J774 cells (2xl0^/well in a 96-well plate) were stimulated with 1 pg/ml LPS in the 
presence of different concentrations of sPG, or the shorter fragment sPG3, for 24 hours 
and IL-12 p40 (monomer, active p70 heterodimer, p40/p40 homodimer) in culture 
supernatants was measured by ELISA. * p < 0.05
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Figure 4.5. Time-dependent inhibition of LPS-induced IL-12 p40 production by 
sPG.
J774 cells (2xlOVwell in a 96-well plate) were stimulated with 1 pg/ml LPS in the 
presence of 50 pM sPG for 24 hours. sPG was added at the times indicated relative to 
LPS stimulation, and IL-12 p40 (monomer, active p70 heterodimer, p40/p40 




7 5 0 -
E
a.








6 0 0 -
£
O)Q.




2 0 0 -
T
m edium  IFN-y LPS IFN-y
□  control
M sPG
D  control 
M  sPG
LPS
Figure 4.6. Effect of sPG on IL-12 p40 production by peritoneal macrophages.
Thioglycollate-elicited peritoneal macrophages from Lew/zma«ifl-susceptible BALB/c 
(A) and -resistant 129 (B) mice (2xl0Vwell in a 96-well plate) were stimulated with 100 
U/ml IFN-y and/or 100 ng/ml LPS in the presence/absence of 50 jaM sPG. IL-12 p40 
(monomer, active p70 heterodimer, p40/p40 homodimer) in 24 hour culture supernatants 
was assayed by ELISA. ** p < 0.01
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Figure 4.7. Effect of sPG on IL-12 p70 production by peritoneal macrophages.
Thioglycollate-elicited peritoneal macrophages from Leishmania-susceptihle BALB/c 
mice (2 x l 0 Vwell in a 96-well plate) were stimulated with 1 0 0  U/ml IFN-y and/or 1 0 0  
ng/ml LPS in the presence/absence of 50 pM sPG. Bioactive IL-12 p70 in 24 hour 
culture supernatants was assayed by ELISA. * p < 0.05
167
0 .20
I  0 .1 5 4
oN 
un
g  0 .1 0 -
F











Figure 4.8. Effects of sPG treatment on cell viability.
Thioglycollate-elicited peritoneal macrophages (2 xlOVwell in a 96-well plate) were 
stimulated with 100 U/ml IFN-y and/or 100 ng/ml LPS in the presence/absence of 50 pM 
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Figure 4.9. Effects of sPG on TNF-a and NO production by peritoneal 
macrophages.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xlOVwell in a 96- 
well plate) were stimulated with 100 U/ml IFN-y and/or 100 ng/ml LPS in the 
presence/absenee of 50 pM sPG. TNF-a and NO in 24 hour culture supernatants were 
assayed by ELISA and Griess Reaction respectively.
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Figure 4 .1 0 .  E ffec t o f  sPG on ERK MAP kinase activation  in J774 c e l l s .
J774 cells (4xl0V25 cm^ flask) were stimulated for the times indicated with 50 pM sPG. 
Dual phosphorylated ERK MAP kinases were detected by Western Blotting of total 
protein lysates (A, upper panel). Total ERK MAP kinase protein was also detected as a 
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Figure 4 .1 1 .  E ffec t  o f  sPG on LPS-induced ERK MAP kinase activation  
in J774 c e l ls .
J774 cells (4xl0V25 cm^ flask) were stimulated for the times indicated with 1 ng/ml 
LPS in the absence/presence of 50 pM sPG. Dual phosphorylated ERK MAP kinases 
(pERK) were detected by Western Blotting of total protein lysates (A, upper panel). 
Total ERK MAP kinase protein was also detected as a loading control (A, lower panel). 





Figure 4 .1 2 .  E ffec t  o f  sPG on ERK MAP kinase activation  in murine 
peritoneal m acrophages.
Peritoneal macrophages from BALB/c mice (4xlOV25 cm^ flask) were stimulated for 
10 minutes with 100 U/ml IFN-y and 100 ng/ml LPS in the absence/presence of 50 pM 
sPG. Dual phosphorylated ERK MAP kinases were detected by Western Blotting of 
total protein lysates.
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Figure 4 .1 3 .  E ffect o f  sPG on tim ecourse  of IFN-y 4- LPS-induced ERK  
MAP kinase activation .
Murine peritoneal macrophages (4xlOV25 cm^ flask) were stimulated with 100 U/ml 
IFN-y and 100 ng/ml LPS for the times indicated in the absence/presence of 50 pM sPG. 
Total protein lysates were purified, separated by SDS PAGE and blotted on to 
nitrocellulose. The blot was probed with anti-pTyr-pThr ERK 1/2 antibody to detect 
dual-phosphorylated active ERKl and ERK2 (pERK; A, upper panel). N .B. The film 
was underexposed to enable differences at intermediate timepoints to be detected. The 
blot was stripped and re probed with an antibody against total ERK protein as a gel 
loading control (wERK; A, lower panel). Densitometric values (B) are phospho- 






Figure 4 .1 4 .  E ffects  o f  sPG and sPG3 on p38 MAP kinase activation  in 
J774 ce lls .
J774 cells (4x10^/25 cm^ flask) were stimulated with 100 U/ml IFN-y and 1 pg/ml LPS 
for 20 minutes in the absence/presence of 50 pM sPG or sPG3. Total protein lysates 
were purified, separated by SDS PAGE and blotted on to nitrocellulose. The blot was 
probed with anti-pTyr-pThr p38 antibody to detect dual-phosphorylated active p38 
(upper panel). The blot was stripped and re probed with an antibody against total p38 
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Figure 4 .1 5 .  E ffects  o f  sPG on p38 and JNK MAP kinase activation  in  
murine peritoneal m acrophages.
BALB/c peritoneal macrophages (4xlOV25 cm^ flask) were stimulated with 100 U/ml 
IFN-y and 100 ng/ml LPS for 10 minutes in the absence/presence of 50 pM sPG. Total 
protein lysates were purified, separated by SDS PAGE and blotted on to nitrocellulose. 
The blots were probed with anti-pTyr-pThr p38 (A) or JNK (B) antibodies to detect 
dual-phosphorylated active MAP kinase (upper panels). The blots were stripped and 
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Figure 4.16. Effect of inhibition of ERK MAP kinases on sPG-mediated 
suppression of IL-12 p40 production by J774 cells.
J774 cells (2xlOVwell in a 96-well plate) were pre-incubated with 20 |aM PD 098059 
(PD) prior to stimulation with 1 |ag/ml LPS in the absence/presence of 50 \iM sPG. IL- 
12 p40 in 24 hour culture supernatants was assayed by ELISA. * p < 0.05
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Figure 4.17. Effect of inhibition of ERK MAP kinases on sPG-mediated 
suppression of IL-12 p40 production by murine peritoneal macrophages.
BALB/c peritoneal macrophages (2xlOVwell in a 96-well plate) were pre-incubated 
with 20 pM PD 098059 (PD) for 1 hour prior to stimulation with 100 U/ml IFN-y and 
100 ng/ml LPS in the absence/presence of 50 pM sPG. IL-12 p40 in 24 hour culture 
supernatants was assayed by ELISA. ** p < 0.01
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Figure 4.18. Effect of inhibition of ERK MAP kinases on sPG-mediated 
suppression of IL-12 p70 production by murine peritoneal macrophages.
BALB/c peritoneal macrophages (2xl0Vwell in a 96-well plate) were pre-incubated 
with 20 jLiM PD 098059 (PD) or 1 pM U0126 for 1 hour prior to stimulation with 100 
U/ml IFN-y and 100 ng/ml LPS in the presence/absence of 50 pM sPG. IL-12 p70 in 24 
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Figure 4.19. Model for suppression of macrophage IL-12 production by 
Leishmania LPG.
Leishmania LPG binds to macrophages and transduces signals resulting in the enhanced 
activation of ERK MAP kinases, which negatively regulate LPS-induced IL-12 p40 
production, possibly by disrupting p38 MAP kinase signalling. Production of the p35 
subunit of IL-12 may also be suppressed by sPG.
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Chapter 5 -  Modulation of macrophage cytokine production 




5:1:1 Filarial nematodes and disease.
Filarial nematodes are arthropod-transmitted parasites of vertebrates. Eight 
species infect humans, and three - Wuchereria bancrofti, Bmgia malayi, and Onchocerca 
volvulus - are of major clinical importance. It is currently estimated that -140 million 
people are infected with these three filarial nematodes and more than a billion people are 
at risk (WHO 2000a). Filarial nematodes cause a range of diseases known collectively as 
filariasis, which includes lymphatic filariasis and onchocerciasis (WHO 2000a). 
Lymphatic filariasis is caused principally by W. bancrofti and Brugia sp. parasites. 
Visible manifestations of this disease include swollen limbs and genitals, hence this 
disease is commonly known as elephantiasis. This is accompanied by internal damage to 
the kidneys and lymphatic system. Localised acute inflammation can also occur alongside 
chronic lymphoedema, as a result of the host’s immune response to the parasite or due to 
bacterial infection of areas where lymphatic damage has occurred and normal defences 
have been partially lost. Infection with O. volvulus can result in chronic debilitating skin 
lesions and blindness.
Parasites are transmitted to mammalian hosts by mosquitoes (W. bancrofti and B. 
malayi) or blackflies (O. volvulus). They develop inside the vector from microfilariae to 
infective larvae, before migrating to the mouthparts from where they are transferred into 
a new host when the insect feeds (see Figure 5.1; reviewed by Raj an and Gundlapalli, 
1997). In hosts such as humans, W. bancrofti and B. malayi worms continue to grow in 
the lymphatic vessels where they can survive for more than 5 years (Vanamail et a l,
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1996). They reproduce sexually to produce millions of microfilariae that circulate in the 
blood and are picked up by the insect vector to continue the cycle.
In regions where infection is endemic, parasites are generally acquired in 
childhood, but disease may take many years to manifest itself. Asymptomatic infection is 
characterised by the presence of thousands of microfilariae in the bloodstream and adult 
worms in the lymphatics. Some individuals may appear outwardly healthy although they 
have hidden lymphatic pathology and kidney damage.
5:1:2 Immunosuppression of hosts.
The longevity of survival in the host may, at least in part, reflect the ability of 
parasites to induce defects in host immune responsiveness, including modulation of both 
parasite-specific and more generalised B and T cell responses, with a bias towards a type 
2 T helper (Th2) cell response (Nutman et a l, 1987a and b; Ottesen, 1984; Kwa and 
Mak, 1984; Haque and Capron, 1986; King and Nutman, 1991; Maizels and Lawrence, 
1991). For example, Mahanty and Nutman (1995) showed that in humans, filarial 
infection reduces the ability of peripheral blood mononuclear cells to proliferate and 
produce IFN-y in response to parasite antigen, and increases the production of IL-10. This 
aids the survival of the parasite in the host for long periods. Induction of a Thl response 
results in inflammation and elephantiasis, which is detrimental to the parasite as well as 
the host.
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Exposure of experimental animals to filarial antigens results in a brief period of 
vigorous responsiveness, followed by induction of a state of hyporesponsiveness of 
lymphocytes (Weiss, 1978; Soboslay et al, 1991). Responses to non-parasite antigens 
may or may not be normal (Mahanty and Nutman, 1995; Stewart et a l, 1999). 
Hyporesponsiveness generally occurs around the onset of patency and was thus originally 
attributed to microfilariae, which are released at this time (Maizels and Lawrence, 1991). 
Although microfilarial molecules have been shown to inhibit lymphocyte proliferation 
(Wadee et al, 1987), some studies have reported lymphocyte hyporesponsiveness prior to 
the onset of patency (Weiss, 1978; Soboslay et al, 1991), suggesting that molecules 
released by adult worms must be responsible.
5:1:3 Excretory-secretory products.
Filarial nematodes release a number of proteins into their environment, some of 
which are biologically active and are considered to play roles in the maintenance of 
infection and parasite survival (Harnett and Parkhouse, 1995). These include proteinases, 
pro tease inhibitors and antioxidants, and a homologue of the human pro-inflammatory 
cytokine macrophage inhibitory factor (MIF) which is chemotactic for macrophages 
(Pastrana et al, 1998). Sera from infected humans or animals possess similar inhibitory 
properties to those observed with active infection, including suppression of lymphocyte 
proliferation (Weiss, 1978; Piessens et a l, 1980; Lammie et a l, 1984; Haque et a l, 
1983). Such serum samples contain excretory-secretory (ES) molecules released by 
worms (Weil, 1990; Bradley and Unnasch, 1996). ES products in the bloodstream have 
ample opportunity to interact with host lymphocytes and are therefore strong candidates
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for mediators of immunosuppression. Indeed, ES products in the bloodstream of humans 
are more readily detected in patients with detectable microfilariae (Harnett et a l, 1999a) 
who generally represent the most hyporesponsive category of infected individual 
(Maizels and Lawrence, 1991). Furthermore, studies with the rodent filarial nematode 
Acanthocheilonema viteae indicate that there is a large increase in production of ES just 
prior to the onset of patency (Harnett et al, 1989).
Dasgupta et a l (1987) showed that in filariasis patients, cellular unresponsiveness 
was related to the presence of circulating parasite antigen, and Marley et a l  (1995) 
demonstrated an inverse relationship between ES levels and total antibody in the 
bloodstream of humans infected with W. bancrofti. Studies in rodents revealed a 
correlation between chronic infection with B. pahangi or A. viteae, which is accompanied 
by the presence of large quantities of parasite antigen in the host circulation (Wenger et 
al, 1988; Harnett et a l, 1989; Harnett et a l, 1990), and inhibition of specific 
proliferative responses by sera (Lammie et al, 1984; Weiss, 1978).
Direct evidence of an immunomodulatory role for ES came from observations that 
ES products from W. bancrofti microfilariae inhibited leukocyte migration in patients 
with clinical filariasis (Prasad and Harinath, 1987). Similarly, ES products from 
microfilariae and adult female worms of O. volvulus suppressed proliferative responses of 
lymphocytes from onchocerciasis patients (Elkhalifa er a/., 1991). Furthermore, injection 
of ES into B. pahangi-infeclQd dogs resulted in loss of antigen-driven cellular 
proliferative responses (Miller et al, 1991). The major ES product of the rodent filarial 
nematode Acanthocheilonema viteae, ES-62, has also been demonstrated to inhibit 
lymphocyte proliferation (Harnett and Harnett, 1993; Harnett et al, 1998).
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A common feature of ES products, and indeed a variety of pathogen products, is 
the presence of phosphorylcholine (PC) attached to N-linked carbohydrates (Houston et 
al, 1997; Harnett and Harnett, 1999). This PC has been suggested to be responsible for 
many of the immunomodulatory activities of ES products. Indeed, inhibition of 
phytohaemaglutinin-induced T cell proliferation in vitro by a PC-containing product of B. 
malayi was mimicked by PC conjugated to BSA (Lai et a l, 1990). Similarly, the 
inhibitory effects on B cells of ES-62, which contains PC, could be mimicked by PC- 
BSA (Harnett and Harnett, 1993; Deehan et a l, 1998). ES-62 and PC-BSA have 
therefore been used to investigate the immunomodulatory effects of filarial ES products 
and determine the involvement of the PC moiety.
5:1:4 Immunomodulation by ES-62, an ES product of Acanthocheilonema viteae.
ES-62 is a 62 kDa, PC-containing glycoprotein produced by the rodent filarial 
nematode Acanthocheilonema viteae (reviewed by Harnett and Harnett, 1999). Harnett 
and colleagues have previously demonstrated the effects of ES-62 on lymphocyte 
activation via their antigen (Ag) receptors and the differentiation of dendritic cells 
(Harnett and Harnett, 1993; Deehan et al, 1997; Deehan et al, 1998; Harnett et al, 1998; 
Whelan et a l, 2000). They have shown that ES-62 inhibits Ag receptor-driven B cell 
proliferation (Harnett and Harnett, 1993) by inducing abortive, non-productive activation 
of certain signalling elements, such as protein tyrosine kinases (PTKs) and mitogen- 
activated protein (MAP) kinases, thereby desensitising cells to subsequent sustained 
proliferative signalling via the B cell Ag receptor complex (BCR) (Deehan et al, 1998). 
ES-62 also achieves this inhibition of BCR-mediated proliferation by suppressing
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phosphoinositide-3-kinase (PI-3-K) (Deehan et al, 1997), and down-regulating protein 
kinase C (PKC) isoforms by stimulating their proteolytic degradation and disrupting their 
normal activation and nuclear translocation (Deehan et al, 1998).
Similarly, ES-62 inhibited anti-CD3-stimulated activation of the human Jurkat T 
cell line by disrupting coupling of the T cell receptor (TCR) to PTKs, phospholipase D 
(PLD), PKC and Ras-MAP kinase signalling cascades (Harnett et al, 1998). As with B 
cells, ES-62 pre-incubation induced abortive signalling in T cells and desensitisation to 
subsequent activation via the Ag receptor. ES-62 has also been shown to bias the immune 
response to a Th2 phenotype. Whelan et a l (2000) demonstrated that ES-62 directs the 
maturation of dendritic cells with the capacity to induce Th2 responses. T cells activated 
by bone marrow-derived dendritic cells which had been matured in the presence of ES-62 
produced increased IL-4 but decreased IFN-y, compared with T cells activated by 
dendritic cells matured in the absence of ES-62 or in the presence of LPS. The induction 
of a Th2 response was further demonstrated by the detection of ES-62-specific IgGl, but 
not the Th 1 -induced Ig isotype IgG2a, in sera from mice injected with ES-62 (Whelan et 
al, 2000). PC blocks the production of IgG2a antibodies against other epitopes on the 
ES-62 molecule by an IL-10-dependent mechanism (Houston et al, 2000).
5:1:5 Aim of this study.
ES-62 thus targets a number of cells of the immune system. The aim of this study 
was to examine its effects on the function of a cell not studied to date -  the macrophage. 
In particular, the consequence of ES-62 treatment for production of IL-12, the key
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cytokine driving the development of Thl responses, was assessed, to determine whether 
modulation of IL - 1 2  by ES-62 could contribute to the generation of a Th2 response to 
filarial parasites. Production of the pro-inflammatory cytokines IL - 6  and TNF-a and the 
toxic mediator NO by macrophages stimulated in the presence of ES-62 was also 




5:2:1 Effects of ES-62 on cytokine and NO production by macrophages.
To establish whether ES-62 targets macrophage function, the effects of treatment 
of murine peritoneal macrophages with ES-62 on cytokine and NO production were 
investigated.
5:2:1:1 Effects of ES-62 on IL-12, IL-6, and TNF-a production.
Thioglycollate-elicited murine peritoneal macrophages were pre-incubated with 
various concentrations of ES-62 for 18 hours prior to stimulation with IFN-y and LPS for 
24 hours. IFN-y + LPS-induced levels of both IL-12 p40 and TNF-a in culture 
supernatants were reduced by ES-62 pre-treatment in a dose-dependent manner (Figure 
5.2). Concentrations of up to 100 ng/ml had little effect on either IL-12 p40 or TNF-a, 
but pre-treatment with 1-5 gg/ml ES-62 effectively abolished IL-12 p40 production 
(Figure 5.2A) and reduced TNF-a induction by more than 50% (Figure 5.2B). A 
concentration of 2  pg/ml ES-62, which has previously been shown to give optimal 
suppression of B cell proliferation (Harnett and Harnett, 1993), and is within the range of 
concentrations of PC-containing ES products found in filariasis patients (Lai et al, 1987), 
was selected for subsequent experiments.
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Shorter pre-incubation with ES-62 and even simultaneous addition with IFN-y + 
LPS also resulted in suppression of macrophage cytokine production (Figure 5.3). ES-62 
appears to induce a state of macrophage hyporesponsiveness since washing of cells after 
ES-62 pre-incubation prior to IFN-y + LPS stimulation still resulted in inhibition of IL-12 
p40 production (Figure 5.3). Furthermore, transfer of culture supernatant from ES-62-pre- 
treated cells to resting macrophages just prior to stimulation resulted in normal IL-12 p40 
production (Figure 5.3), suggesting that suppression occurs as a direct result of ES-62 
treatment rather than via the induction of another inhibitory factor.
To further investigate the effects of ES-62 on cytokine production by 
macrophages, BALB/c peritoneal macrophages were pre-treated with 2 jig/ml ES-62 for 
18 hours prior to stimulation with IFN-y and/or LPS, and IL-12, TNF-a and IL - 6  levels in 
24 hour culture supernatants were measured by ELISA. In the absence of LPS stimulation 
i.e. resting or IFN-y-treated cells, ES-62 stimulated low but significant levels of IL-12 
p40, IL - 6  and TNF-a (Figure 5.4A, C and D). In contrast, ES-62 pre-treatment resulted in 
inhibition of IFN-y + LPS-induced IL-12 p40 (94%), IL - 6  (72%) and TNF-a (57%) 
production; LPS-induced TNF-a was also reduced by 63% (Figure 5.4A, C and D).
IL-12 p70 heterodimer was also measured to establish whether ES-62 reduces 
active IL-12 or simply p40 monomer production. IFN-y + LPS treatment induced 
approximately 20-fold lower p70 compared with p40, and this was practically abolished 
by ES-62 treatment (Figure 5.4B). Similar results were obtained with total spleen cells, 
splenic macrophages, bone marrow-derived macrophages and macrophages from the 129 
mouse strain (Figure 5.5).
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Interestingly, the amount of each cytokine produced following ES-62 pre­
treatment was identical in the four stimulation groups (non-stimulated, IFN-y alone, LPS 
alone, and IFN-y and LPS in combination; Figures 5.4 and 5.5). This suggests that ES-62 
treatment induces low levels of production of these cytokines before establishing a state 
of hyporesponsiveness of macrophages to full activation by IFN-y + LPS. Timecourse 
experiments confirmed that these cytokines are produced during the ES-62 pre-incubation 
(Figure 5.6 A) but not further stimulated by IFN-y + LPS (Figure 5.6B).
IL-12 and TNF-a mRNA were quantified by real-time PCR (TaqMan). Compared 
with control cells, the level of IFN-y + LPS-induced IL-12 p40 transcripts was reduced by 
pre-treatment with ES-62 (Figure 5.7), but not as significantly as protein levels (Figure 
5.4A), while TNF-a mRNA levels were not significantly reduced by ES-62 pre-treatment 
(Figure 5.7C). Thus ES-62 must regulate production of IL-12 p40 at transcriptional and 
translational/post-translational stages, and TNF-a predominantly at a translational/post- 
translational level. Interestingly, mRNA for the constitutively-expressed p35 subunit of 
IL-12 was also modulated (Figure 5.7B). IFN-y + LPS stimulated p35 transcript levels, 
but pre-exposure to ES-62 prevented this. Thus, ES-62 achieves inhibition of active IL-12 
p70 production by targeting both subunits of this heterodimer. Consistent with the ELISA 
data, ES-62 treatment alone induced the transient expression of low levels of IL-12 and 
TNF-a transcripts (Figure 5.8).
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5:2:1:2 Effects of ES-62 on NO production and cell viability.
To verify whether ES-62 specifically targets production of these cytokines or 
inhibits macrophage responses in general, NO release was measured by Griess Reaction. 
In contrast to cytokine production, ES-62 had no effect on NO release from these cells 
(Figure 5.9A). In addition, cell viability was unaffected as determined by MTT assay 
(Figure 5.9B).
5:2:1:3 Exposure to ES-62 in vivo by release from osmotic pumps.
Exposure of mice to parasite products can be mimicked in vivo using osmotic 
pumps, which release their contents at a constant rate. This offers a more physiological 
alternative to serial injection experiments, and is less traumatic for the mice. ALZET 
osmotic pumps containing ES-62 were implanted subcutaneously on the backs of five 
BALB/c mice (see Materials and Methods); five control mice had PBS-containing pumps 
inserted. Mice were sacrificed after two weeks; peritoneal macrophages were removed 
and rested before culture with IFN-y and/or LPS. Cytokine and NO levels were measured 
in 24 hour culture supernatants. In agreement with the in vitro data, exposure to ES-62 in 
vivo at a rate of 0.05 |ig/hr resulted in the suppression of IFN-y + LPS-induced IL-12 (p40 
and p70) and TNF-a production (Figure 5.10A and B), while having no effect on NO 
(Figure 5.IOC). In contrast with the in vitro exposure, low-level cytokine production by 
ES-62-treated but subsequently non-stimulated macrophages was not observed. This is 
not surprising however; this low-level induction probably occurred in vivo prior to
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removal of macrophages. Nevertheless, it is clear that ES-62 induces a state of sustained 
hyporesponsiveness of macrophages to full activation.
Since the pumps release their contents at a constant flow rate, it is possible to 
adjust the concentration of ES-62 that the mice are exposed to by varying the 
concentration of ES-62 inserted into the pump. Thus, in a separate experiment, IFN-y + 
LPS-induced IL-12 and TNF-a production by peritoneal macrophages from mice exposed 
to different concentrations of ES-62 was measured. Suppression of IL-12 p40 and TNF-a 
by ES-62 was dose-dependent and a delivery rate of 0.1 gg/hour was optimal for 
inhibition of both cytokines (Figure 5.11). Interestingly, IL-12 was more significantly 
inhibited than TNF-a at lower ES-62 concentrations.
5:2:2 Modulation of signal transduction pathways by ES-62.
Having clearly demonstrated that ES-62 suppresses the production of IL-12, IL - 6  
and TNF-a, the next step in this investigation was to dissect the signalling mechanisms 
underlying this modulation of macrophage function, drawing on the findings concerning 
the regulation of IFN-y/LPS-induced cytokine production detailed in the earlier chapters.
5:2:2:1 Effects of ES-62 on tyrosine phosphorylation.
Tyrosine kinases and tyrosine phosphatases are important regulators of early 
receptor-triggered signalling events. These proteins are themselves regulated by tyrosine
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phosphorylation as well as regulating their downstream targets by catalysing this 
modification. Therefore, tyrosine phosphorylation is an important regulatory mechanism. 
Several of these molecules have been reported to be activated upon stimulation with IFN- 
y and/or LPS, including the Src family members Lyn, Hck and Fgr, as well as Vav and 
She (Stefanova et al, 1993; Crowley et al, 1997).
The effects of ES-62 treatment on tyrosine phosphorylation were analysed by 
Western Blotting using the anti-phospho-tyrosine antibody 4G10. ES-62 dramatically 
altered patterns of tyrosine phosphorylation of proteins from peritoneal macrophages 
(Figure 5.12). ES-62 alone induced tyrosine phosphorylation which was further enhanced 
following stimulation with LPS or IFN-y + LPS. Tyrosine phosphorylation of proteins of 
approximately 55, 57, 60, 69, 72, 144, 149, 167 and 186 kDa was enhanced by ES-62 
treatment. A protein of approximately 72 kDa was particularly highly phosphorylated by 
treatment with ES-62. Enhanced tyrosine phosphorylation was maintained throughout an 
8  hour timecourse of IFN-y + LPS stimulation (Figure 5.13).
5:2:2:2 Effects of ES-62 on activation of MAP kinases.
In chapter 3, ERK MAP kinases were demonstrated to be required for IL - 6  and 
TNF-a production, but to negatively regulate IL-12 p40 transcription. Furthermore, in 
chapter 4, ERKs were found to be responsible for suppression of IL-12 p40 production by 
Leishmania phosphoglycan. It is possible that a similar mechanism is employed by ES-62 
to inhibit IL-12 production. Therefore, the effects of ES-62 treatment on activation of
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ERK MAP kinases and cytokine production in the absence of ERK activation were 
investigated.
To establish whether ERK MAP kinases are targeted by ES-62, ERKl (p44) and 
ERK2 (p42) activation in cells treated with ES-62 and IFN-y + LPS was assessed by 
Western Blotting, using antibodies specific for active, dual-phosphorylated ERK MAP 
kinases. ES-62 differentially regulated the ERK isoforms over a timecourse of IFN-y + 
LPS stimulation, following ES-62 pre-incubation (Figure 5.14). IFN-y + LPS induced 
dominant ERKl activation at early timepoints, peaking at 4 hours and thereafter returning 
to near basal levels; ERK2 activation also peaked at 4 hours. Levels of active ERKl were 
suppressed by ES-62 pre-treatment at early timepoints (up to 4 hours) but were 
subsequently slightly elevated. In contrast, although ERK2 activation was initially 
suppressed, it was dramatically enhanced at later timepoints (4 and 8  hours) by ES-62 
treatment. Activation of neither ERK isoform above basal levels was detected during the 
ES-62 pre-incubation period (not shown).
5:2:2:3 Effects of inhibition of ERK MAP kinases on modulation of cytokine 
production by ES-62.
To investigate whether ES-62 regulates ERK activity to modulate cytokine 
production, peritoneal macrophages were pre-ineubated with ES-62 in the presence or 
absence of PD 098059 for 18 hours prior to IFN-y/LPS stimulation and cytokine 
production was measured as before. Whereas PD 098059 alone did not stimulate IL-12 or 
TNF-a production, it was synergistic with ES-62 for stimulation of IL-12 (both p40 and
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p70), but practically abolished ES-62-induced TNF-a production (Figure 5.15A, B and 
D). Inhibition of IFN-y + LPS-induced IL-12 p40 production by ES-62 was abolished by 
pre-incubation with PD 098059 (Figure 5.15A), resulting in only a partial restoration of 
p70 production (Figure 5.15B). Inhibition of IFN-y + LPS-induced TNF-a production by 
ES-62 was unaltered by PD 098059 treatment (Figure 5.15D). Neither stimulation of IL - 6  
by ES-62 alone, nor suppression of IFN-y + LPS-induced IL - 6  production by ES-62, were 
affected by inhibition of ERK activation (Figure 5.15C).
These data demonstrate multiple and various roles for ERK MAP kinases in the 
regulation of cytokine production by ES-62. While ERK activity prevents excessive IL- 
12 production in response to ES-62 alone, it is required for low level production of TNF- 
a. Subsequently, it appears to provide a mechanism for ES-62-induced prevention of full 
stimulation of IL-12 production by IFN-y + LPS. In contrast, it is not involved in the 
suppression of TNF-a production; neither does it play any role in modulation of IL - 6  
production.
The effects of ES-62 on p38 and INK MAP kinase activation were also 
investigated. 10 minutes after stimulation of peritoneal macrophages with LPS or IFN-y+ 
LPS, activation of both p38 and INK MAP kinases was suppressed in ES-62-pre-treated 
cells compared with control cells (Figure 5.16). This suggests that ES-62 may achieve 
inhibition of cytokine induction by also suppressing p38 and INK MAP kinase activation.
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5:2:2:4 Effects of ES-62 on transcription factor synthesis, nuclear translocation and 
promoter binding.
The targeting of transcription factors by ES-62 was investigated by examining the 
synthesis, nuclear translocation and binding to promoter sequences of Ets and members 
of the IRF and NF-kB families by Western Blotting and EMSA.
ES-62 induced rapid synthesis of IRF-1, which was detectable by 10 minutes after 
treatment (Figure 5.17). This early stimulation of IRF-1 continued up to 2 hours but was 
reduced again to near basal levels by 4 hours after treatment. Following a lag phase of 4 -  
8  hours, there was further induction of IRF-1, this time resulting in a large and sustained 
increase in IRF-1 levels, which remained higher than in non-ES-62-treated cells 
following IFN-y and LPS stimulation for at least 1 hour (Figure 5.18). By 2 hours after 
IFN-y + LPS stimulation, IRF-1 induction was equivalent in ES-62 treated and untreated 
cells. In contrast, IRF-2 levels were not altered by ES-62 treatment and remained constant 
throughout the stimulation timecourse (Figure 5.18). Levels of Ets-2 in ES-62-pre-treated 
macrophages were also higher than in control cells for at least 1 hour after IFN-y + LPS 
stimulation (Figure 5.18).
Production of the p65 isoform of NF-kB was not targeted by ES-62 (Figure 5.18). 
However, the kinetics of IFN-y + LPS-induced nuclear translocation and binding of NF- 
kB to a promoter consensus sequence were altered by ES-62 pre-treatment (Figure 5.19). 
At early timepoints following IFN-y 4- LPS stimulation, NF-kB binding (p65/p50 and c- 
Rel/p50) was enhanced in ES-62 pre-treated cells. At 4 hours, binding of both NF-kB  
heterodimers and p50 homodimer was detected in ES-62-treated and -untreated cells.
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Stimulation with IFN-y + LPS resulted in an additional band at this timepoint, the identity 
of which was not determined; this band was absent from the ES-62-treated sample. By 8  
hours, NF-kB binding (heterodimers) was suppressed in ES-62-treated cells compared 
with control cells.
Evidence for the effects of ES-62 on IL-12 production via modulation of 
transcription factor binding to the FI site on the IL-12 promoter was also obtained by 
EMSA studies. A timecourse of treatment with ES-62 alone showed that during the ES- 
62 pre-incubation the pattern of transcription factor binding to an oligonucleotide probe 
representing a portion of the FI site was rapidly and dramatically altered (Figure 5.20). 
Similarly, large and sustained differences in binding patterns were observed following 
IFN-y + LPS stimulation (Figure 5.21), with enhanced binding of higher molecular 
weight complexes in extracts from ES-62 pre-treated cells. This might represent the 
additional binding of inhibitors of transcription.
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5:3 Discussion.
This investigation has examined the immunomodulatory effects of the filarial 
nematode excretory-secretory product ES-62 on the activation of macrophages by IFN-y 
and LPS. Although treatment of peritoneal, splenic and bone marrow-derived 
macrophages with ES-62 alone induced low levels of IL-12, IL - 6  and TNF-a production, 
ES-62 pre-treatment resulted in inhibition of IFN-y + LPS-induced production of these 
cytokines (Figures 5.2 - 5.5). The data show a two-stage regulation of cytokine 
production by ES-62; an initial stimulatory phase during the ES-62 pre-incubation, 
followed by induction of hyporesponsiveness of macrophages to subsequent full 
activation by IFN-y + LPS (Figure 5.6). Interestingly, this mirrors the abortive, yet non­
productive, activation of signalling elements by ES-62 that desensitises B and T cells to 
subsequent activation via their Ag receptors (Deehan et al, 1998; Harnett et al, 1998).
ES-62 treatment did not affect macrophage viability (Figure 5.9B), indicating that 
it does not suppress cytokine production by simply killing cells. Furthermore, the ability 
of macrophages to produce NO was not altered by treatment with ES-62 (Figure 5.9A). 
Although it would appear that the INGS enzyme is not targeted by ES-62, it is however 
likely that NO production in the intact host would be suppressed due to reduced 
production of IFN-y, the major stimulator of iNOS. Thus, ES-62 does not cause a 
generalised repression of macrophage function; rather, it specifically inhibits the IFN-y + 
LPS-mediated induction of IL-12, IL - 6  and TNF-a. Since IL - 6  and TNF-a play critical 
roles in the activation of T and B cells (reviewed by Hirano, 1992 and Mannel and 
Echtenacher, 2000), suppression of their production by ES-62 is likely to contribute to the 
hyporesponsiveness of lymphocytes observed during filarial infection. Suppression of IL-
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12, the key cytokine driving the development of Thl responses, is also consistent with 
previous observations that ES-62 biases the immune response to a Th2 phenotype 
(Whelan et al, 2000). Therefore, these data, in agreement with previous reports (Harnett 
and Harnett, 1993; Harnett et al, 1998; Whelan et al, 2000), suggest that ES-62 is both 
immunosuppressive (anti-inflammatory) and immunomodulatory (causing a Th2 bias).
The use of osmotic pumps to deliver ES-62 to mice offers an alternative to 
repeated dosing by serial injection, and mimics natural, constant release of the parasite 
product during infection, as well as minimising animal handling and stress, which can 
influence the immune response. The demonstration that exposure to ES-62 in vivo by 
release from osmotic pumps results in suppression of IFN-y + LPS-induced IL-12 and 
TNF-a production by peritoneal macrophages (Figures 5.10 and 5.11) confirmed that the 
in vitro data are physiologically relevant, and supported the hypothesis that exposure to 
ES-62 induces a state of hyporesponsiveness. In contrast however, unstimulated 
macrophages that had been pre-exposed to ES-62 did not produce the low levels of 
cytokine production seen in the in vitro experiments. It is likely that this ES-62-induced 
cytokine, which remains in the culture supernatants of macrophages exposed to ES-62 in 
vitro, is secreted in vivo in the mice exposed to ES-62 by release from osmotic pumps 
prior to the removal of macrophages, and is therefore subsequently not detected in culture 
supernatants. Nevertheless, taken together, the results clearly indicate that ES-62 strongly 
suppresses IL-12, IL - 6  and TNF-a induction by appropriate stimuli.
Suppression of IL-12 synthesis may be due to modulation of both transcription 
and translation/post-translational modification, since mRNA levels for the IL-12 p40 
subunit were not as dramatically reduced by ES-62 treatment as protein in culture
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supernatants (Figures 5.7 compared with Figure 5.4). The modulation of p35 transcript 
levels by ES-62 (Figure 5.7) is particularly interesting, since p35 has not been studied as 
widely as its counterpart, p40. Although constitutively expressed, p35 expression can be 
regulated at multiple levels, including transcription, translation and by post-translational 
modification (Babik et a l, 1999; Snijders et al, 1996). One important mechanism of 
regulation of p35 production is the generation of different transcripts (Babik et al, 1999). 
Transcription can initiate from several start sites, resulting in the generation of transcripts 
for functional p35 protein, but also some message that cannot be translated completely. In 
unstimulated cells, transcripts that encode incomplete protein predominate and hence 
protein levels are suppressed. Upon LPS stimulation however, there is an increase in the 
proportion of functional transcripts and hence efficient protein production. ES-62 may 
target the factors that determine which transcription start site is used to bias the 
production of transcripts to those that do not encode functional protein, thereby reducing 
p35 subunit generation and hence contributing to the suppression of bioactive p70 
production.
In contrast to IL-12, transcription of TNF-a was not regulated by ES-62 (Figure 
5.7). ES-62 must therefore exert its inhibitory action on the IFN-y + LPS-mediated 
induction of this cytokine at a later stage of synthesis e.g. translation, post-translational 
modification, release from the cell. The proteolytic cleavage of the membrane-bound 
form to release soluble TNF-a is an important regulatory step (Kriegler et a l, 1988) 
which may be targeted by ES-62.
It has previously been shown that ES-62 targets the ERK MAP kinases of B and T 
cells in a Ras-independent manner to achieve its modulation of the function of these cells
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(Deehan et ai, 1998; Harnett et ai, 1998). In this study, treatment with ES-62 was shown 
to alter ERK activation in macrophages, but in a complex manner, with differential 
modulation of the two ERK isoforms (Figure 5.14).
The differential involvement of the ERKs in mediating cytokine suppression by 
ES-62 was also demonstrated. There was evidence that ES-62 targets ERKs to regulate 
the production of IL-12 and TNF-a, but not IL - 6  (Figure 5.15). Use of the inhibitor of the 
MEK^ERK pathway, PD 098059, demonstrated opposing roles for these MAP kinases 
in the stimulation of low levels of IL-12 and TNF-a by ES-62 alone, and indicated that 
ERKs mediate suppression of IFN-y + LPS-induced IL-12, but play no role in the 
suppression of TNF-a or modulation of IL - 6  production (Figure 5.15). This was 
consistent with the demonstration in chapter 3 that ERK MAP kinases transduce negative 
and positive regulatory signals to regulate induction of IL-12 and TNF-a respectively, but 
are not involved in the regulation of IL - 6  production. The partial restoration of ES-62- 
suppressed p70 levels by pre-treatment with PD 098059, is consistent with the 
suppression of the p35 subunit by ES-62 (Figure 5.7) and the observation that induction 
of this subunit is not regulated by ERK MAP kinases (Figure 3.27). Therefore, PD 
098059 treatment restores the inhibition of p40 but not the p35 subunit, thereby limiting 
p70 production. A model for the inhibition of IL-12 production is presented in Figure 
5.22.
The apparent inconsistency in the opposing roles of ERKs in mediating regulation 
of IL-12 and TNF-a production, which are both inhibited by ES-62, might reflect 
differential temporal regulation (since TNF-a is produced earlier than IL-12; see Figures 
3.4 and 3.11), utilisation of a particular ERK isoform, or a combination of these and other
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factors. Therefore, unlike the suppression of IL-12 production by sPG, which was simply 
due to the sustained enhancement of both ERKl and ERK2 (see chapter 4), the inhibition 
of IFN-y + LPS-induced IL-12 production by ES-62 cannot be explained in terms of 
modulation of a single MAP kinase subfamily.
It is apparent that the regulation of cytokine production is achieved by the 
convergence of multiple signals, including members of MAP kinase subfamilies as well 
as other signalling molecules. Indeed it has been shown that co-ordination of the ERK, 
p38, INK and Big MAP kinase (BMK)/ERK5 pathways is responsible for regulation of 
TNF-a promoter activation (Zhu et a l, 2000). Modulation of a particular MAP kinase 
isoform may have a critical or limited effect on cytokine production. It is therefore likely 
that ES-62 achieves regulation of each cytokine through differential targeting of MAP 
kinase family members. In Chapter 3, p38 activity was shown to be necessary for 
induction by LPS of both IL-12 subunits, IL - 6  and TNF-a. It has also been reported that 
p38 MAP kinase signals stabilise IL - 6  mRNA (Winzen et a l, 1999) and that JNK MAP 
kinases are required for translation of TNF-a mRNA after LPS induction (Swantek et al, 
1997). Therefore, ES-62 may reduce the production of these cytokines by suppressing the 
activation of the p38 and JNK MAP kinase subfamilies. Indeed, ES-62 suppressed the 
early induction of p38 and JNK MAP kinases by LPS/IFN-y + LPS (Figure 5.16). Thus, 
the suppression of tnese distinctly regulated cytokines by ES-62 is likely to occur via the 
modulation of multiple signals, including ERK and p38 MAP kinases, and the integration 
of these signals at different stages of bioactive cytokine synthesis.
Treatment of macrophages with ES-62 also altered the expression and activation 
of a number of other signalling molecules, providing further information about the
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regulation of cytokine production by ES-62. Tyrosine phosphorylation of a number of 
proteins was enhanced, in particular a protein of approximately 72 kDa (Figures 5.12 and 
5.13). These proteins are likely to be tyrosine kinases that associate with receptors 
following ligand binding to form large intracellular signalling complexes. Thus, the 
enhanced tyrosine phosphorylation could represent recruitment to the receptor to which 
ES-62 binds or association with TLR4 to disrupt LPS signalling. One candidate molecule 
is Bruton’s tyrosine kinase (Btk) which has been shown to negatively regulate IL-12 
production (Mukhopadhyay et al, 1999a). This molecule has recently been shown to play 
a role in the clearance of filarial infection by modulating macrophage function 
(Mukhopadhyay et al, 1999b). Btk-deficient X-immunodeficient (xid) mice produced 
increased IFN-y and displayed delayed clearance of injected microfilariae compared to 
normal mice, and these effects were rescued by transfer of peritoneal macrophages from 
normal to deficient mice. Therefore, one possible mechanism for the suppression of IL-12 
production by ES-62 would be the upregulation of Btk activity by the enhancement of its 
tyrosine phosphorylation. This would bias the immune response towards a Th2 
phenotype, favouring survival of the parasite.
ES-62 clearly modulates the synthesis and binding of multiple transcription 
factors to promoter sequences (Figures 5.17 -  5.21), including members of the NF-kB 
family which regulate production of IL-12, IL - 6  and TNF-a, and therefore represent an 
obvious target for ES-62-mediated suppression. Binding to a portion of the FI site of the 
IL-12 p40 promoter was also significantly altered (Figures 5.20 and 5.21), with enhanced 
binding of higher molecular weight complexes. This could represent the additional 
binding of inhibitory molecules in the FI complex. Interestingly, analysis of the sequence 
of the ES-62 protein revealed the presence of leucine rich regions, which are typically
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involved in protein-protein interactions. It is possible therefore that ES-62 itself interacts 
with transcription factors, such as leucine zipper proteins like C/EBP and NF-IL6 , and 
binds to DNA.
The phosphorylcholine (PC) component of ES-62 has been suggested to be 
responsible for many of the immunomodulatory properties of ES-62, since PC-BSA and 
PC-choline mimicked the effects of intact ES-62 in B and T cells (Harnett and Harnett, 
1993; Deehan et al, 1998). PC-containing molecules produced by a diverse range of 
organisms, including bacteria, fungi and protozoa, as well as filarial and gastrointestinal 
nematodes, enable detection of pathogens by the host, but can also function to promote 
pathogen survival via modulation of host immune responses (Harnett and Harnett, 1999). 
PC is therefore of great significance in pathogenic infection. Whether the effects of ES- 
62 on macrophage function demonstrated here can be ascribed to this moiety remains to 
be investigated. However, these results are clearly relevant to studies of macrophage 
function during filarial infection and may yet have much wider implications in the 
investigation of pathogenic disease.
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5:4 Summary of this study.
ES-62, the major excretory-secretory product of the rodent filarial nematode A. 
viteae, has previously been shown to modulate lymphocyte activation and the 
differentiation of dendritic cells. In this study the effects of ES-62 on macrophage 
activation were investigated. The results demonstrate that ES-62 pre-exposure prevents 
full activation of macrophages by IFN-y + EPS, resulting in the suppression of IL-12, IL- 
6  and TNF-a production, without affecting NO release. This modulation is achieved by 
targeting different levels of cytokine synthesis, and involves the disruption of various 
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Figure 5.1. Filarial nematode lifecycle.
Typical lifecycle of Wuchereria bancrofti and Brugia malayi parasites. Adult worms live 
in the lymphatics of the human host where they reproduce sexually, releasing thousands 
of microfilariae into the bloodstream. These LI larvae are ingested by mosquitoes when 
they take a bloodmeal. They shed their acellular sheath, penetrate the midgut and 
migrate into the flight muscles where they develop into L2 larvae. About two weeks 
later, L3 larvae migrate through the salivary glands to the proboscis. At this stage they 
can infect humans by injection into the skin when the mosquito feeds. They migrate into 
the lymphatics where they moult and mature to L4 larvae, before further maturing and 
differentiating to form adult worms. The development from microfilariae to adult worms 
can take several months and adult worms can live for many years.











=1 0 . 5 -
0
T
I I ‘ " I' ' ' 1







1 , 1 0 . 0  H
C







1 I  ■ I ■ ■ I
O  UO CM T-
T
o  §  I  I
ES-62 (ng/ml) °
IFN-y + LPS
Figure 5.2. Dose-dependent effects of ES-62 on IFN-y + LPS-induced IL-12 and 
TNF-oc production.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xlOVwell in a 96- 
well plate) were pre-treated with ES-62 at the indicated concentrations for 18 hours prior 
to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS for 24 hours. IL-12 p40 and 
TNF-a in culture supernatants were measured by ELISA. * p < 0.05, ** p < 0.01
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Figure 5.3. Effects of ES-62 treatment on IL-12 p40 production.
Thioglycollate-elicited peritoneal macrophages (2 xlOVwell in a 96-well plate) were pre­
incubated with/without 2 gg/ml ES-62 for 18 hours as indicated prior to stimulation with 
100 U/ml IFN-y and 100 ng/ml LPS for 24 hours.
Immediately before IFN-y + LPS addition, cells were treated as indicated:
 ^2 pg/ml ES-62 was added to culture.
^  Culture supernatants from ES-62 pre-treated macrophages were removed and replaced 
with fresh medium immediately prior to stimulation with IFN-y + LPS.
Culture supernatants from ES-62-pre-treated macrophages were transferred to resting 
macrophages immediately prior to stimulation with IFN-y + LPS.








































Figure 5.4. Effects of ES-62 on IL-12, IL-6 and TNF-oc production by peritoneal 
macrophages.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xlOVwell in a 96- 
well plate) were left untreated or pre-incub ate d with 2 pg/ml ES-62 for 18 hours prior to 
stimulation with 100 U/ml IFN-y and/or 100 ng/ml LPS for 24 hours. Culture 
supernatants were assayed for IL-12 p40 (p40 monomer, active p70 heterodimer, 
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Figure 5.5. Effects of ES-62 on IL-12 production by macrophages from various 
sources.
Total spleen cells (A), splenic macrophages (B) and bone marrow-derived macrophages 
(C) from BALB/c mice, and thioglycollate-elicited peritoneal macrophages from 129 
mice (D) (2xlOVwell in a 96-well plate) were left untreated or pre-incubated with 2 
pg/ml ES-62 for 18 hours prior to stimulation with 100 U/ml IFN-y and/or 100 ng/ml 
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Figure 5.6. Timecourses of IL-12 p40 production following ES-62 treatment.
A. Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xlOVwell in a 
96-well plate) were treated with 2 pg/ml ES-62 for the times indicated and IL-12 p40 in 
culture supernatants was measured by ELISA.
B. Thioglycollate-elicited peritoneal macrophages (2xlOVwell in a 96-well plate) were 
left untreated or pre-treated with 2 pg/ml ES-62 for 18 hours and then stimulated with 
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Figure 5.7. Effects of ES-62 on induction of IL-12 p40, p35 and TNF-a mRNA by 
IFN-y + LPS.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4xlOV25 cm^ flask) 
were pre-incubated with 2 |ag/ml ES-62 for 18 hours prior to stimulation with 100 U/ml 
IFN-y and 100 ng/ml LPS for 8  hours. Total RNA was purified from cells and IL-12 p40, 
IL-12 p35 and TNF-a transcripts were assayed by real-time PCR (TaqMan). Levels are 
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Figure 5.8. Induction of IL-12 p40, p35 and TNF-a mRNA by ES-62.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4xl0V25 cm^ flask) 
were treated with 2 pg/ml ES-62 for the times indicated. Total RNA was purified from 
cells and IL-12 p40, IL-12 p35 and TNF-a transcripts were assayed by real-time PCR 










I  0 .7 5 -
o  N LO
g  0 .5 0 -
t=












□  control 
S  ES-62
Figure 5.9. Effects of ES-62 on NO production and cell viability.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (2xl0Vwell in a 96- 
well plate) were left untreated or pre-incubated with 2 pg/ml ES-62 for 18 hours prior to 
stimulation with 100 U/ml IFN-y and/or 100 ng/ml LPS for 24 hours. NO levels in 
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Figure 5.10. Effects of in vivo exposure to ES-62 on IL-12, TNF-a and NO 
production.
BALB/c mice (5 mice in each group) were exposed to ES-62 (0.05 pg/hr) or PBS 
(control) by constant release from osmotic pumps for two weeks. Peritoneal 
macrophages were removed and stimulated with 100 U/ml IFN-y and/or 100 ng/ml LPS 
(2x10^ cells/well in a 96-well plate) for 24 hours. IL-12 p40 and TNF-a in culture 
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Figure 5.11. Dose-dependent effects of in vivo exposure to ES-62.
Peritoneal macrophages from mice (5 mice per group) exposed to PBS or different 
concentrations of ES-62 in vivo by release from osmotic pumps were stimulated in vitro 
with 100 U/ml IFN-y and 100 ng/ml LPS (2x10^ cells/well in a 96-well plate). IL-12 
p40 and TNF-a in 24 hour culture supernatants were measured by ELISA. * p < 0.05,
















Figure 5 .1 2 .  E ffec t  o f  ES-62 on tyrosine phosphorylation o f macrophage  
proteins.
Thioglycollate-elicited peritoneal macrophages from 129 mice (4xlOV25 cm^ flask) 
were pre-treated with 2 pg/ml ES-62 for 18 hours prior to stimulation with 100 U/ml 
IFN-y and 100 ng/ml LPS for 10 minutes. Total protein lysates were separated by SDS 
PAGE and transferred to nitrocellulose. Blots were probed with the anti-phospho- 
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Figure 5 .1 3 .  E ffect  o f  ES-62 on a tim ecourse o f  tyrosine  
phosphorylation.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4xlOV25 cm^ 
flask) were pre-treated with 2 pg/ml ES-62 for 18 hours prior to stimulation with 100 
U/ml IFN-y and 100 ng/ml LPS for the times indicated. Total protein lysates were 
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Figure 5 .1 4 .  E ffect  o f  ES-62 on ERK MAP kinase activation .
A. Peritoneal macrophages (4xlOV25 cm^ flask) were left untreated or treated with 2 
pg/ml ES-62 for 18 hours prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS 
for the times indicated. Total protein extracts were purified and assayed by Western 
Blotting for dual phosphorylated ERK MAP kinase (pERKl and pERK2; upper panel); 
antibodies against total ERK proteins were used to check protein loading (lower panel).
B. Densitometric analysis of phospho-ERK blot, normalised against total ERK. Dotted 
line represents unstimulated cells.
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Figure 5.15. Effects of inhibition of ERK MAP kinases on modulation of IL-12, IL- 
6 and TNF-a production by ES-62.
Peritoneal macrophages (2xl0Vwell in a 96-well plate) were treated with/without 2 
pg/ml ES-62 in the absence/presence of 20 pM PD 098059 for 18 hours prior to 
stimulation with 100 U/ml IFN-y and 100 ng/ml LPS for 24 hours. IL-12 p40, bioactive 
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Figure 5 .1 6 .  E ffects  o f  ES-62 on activation  of p38 and JNK MAP kinases
Peritoneal macrophages (4x10^/25 cm^ flask) were left untreated or treated with 2 pg/ml 
ES-62 for 18 hours prior to stimulation with 100 U/ml IFN-y and 100 ng/ml LPS 10 
minutes. Total protein extracts were purified and assayed by Western Blotting for dual 
phosphorylated p38 (A) and JNK (B) MAP kinases (upper panel of each pair); 
antibodies against total p38 (A) and non-specific protein (B) were used to confirm equal 
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Figure 5 .1 7 .  E ffect  o f  ES-62 on lRF-1 synthesis .
Peritoneal macrophages (4xlOV25 cm^ flask) were stimulated with 2 pg/ml ES-62 for 
the times indicated. Total protein lysates were purified and assayed by Western 
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Figure 5 .1 8 .  E ffect  o f  ES-62 on transcription factors synthesis .
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4xlOV25 cm^ 
flask) were pre-treated with 2 pg/ml ES-62 for 18 hours prior to stimulation with 100 
U/ml IFN-y and 100 ng/ml LPS for the times indicated. Total protein lysates were 
separated by SDS PAGE and transferred to nitrocellulose. Blots were probed with 
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Figure 5 .1 9 .  E ffect o f  ES-62 on N F -kB binding.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4x10^25 cm^ 
flask) were pre-treated with 2 pg/ml ES-62 for 18 hours prior to stimulation with 100 
U/ml IFN-y and 100 ng/ml LPS for the times indicated. Nuclear protein extracts were 
assayed by EMSA for binding to a ^^P-labelled oligonucleotide probe that represents an 
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Figure 5 .2 0 .  E ffect  o f  ES-62 on binding o f transcription factors to the 
IL-12 p40 promoter.
Peritoneal macrophages (4x10^/25 cm^ flask) were stimulated with 2 pg/ml ES-62 for 
the times indicated. Nuclear protein extracts were assayed by EMSA for binding 
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Figure 5 .2 1 .  E ffec t o f  ES-62 on IFN-y + LPS-induced binding of  
transcription factors to the IL-12 p40 promoter.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4xlOV25 cm^ 
flask) were pre-treated with 2 pg/ml ES-62 for 18 hours prior to stimulation with 100 
U/ml IFN-y and 100 ng/ml LPS for the times indicated. Nuclear protein extracts were 
assayed by EMSA for binding to a ^^P-labelled oligonucleotide probe that represents a 
portion of the IL-12 p40 promoter. Arrows indicate binding complexes.
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Figure 5.22. Model for suppression of IFN-y + LPS-induced IL-12 production by 
ES-62.
Stimulation of macrophages with IFN-y and LPS results in the activation of ERK and 
p38 MAP kinases. ES-62 inhibits the transcription of the IL-12 p40 gene in an ERK- 
dependent manner. It also suppresses the activation of p38 MAP kinase, which is 
required for the transcription of both IL-12 subunits. Reduced levels of both p40 and 
p35 protein limit the production of bioactive IL-12.
227
Chapter 6 -  General Discussion.
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6:1 Regulation of cytokine and iNOS induction in LPS-stimulated macrophages.
Pro-inflammatory cytokines produced by activated macrophages are key 
mediators of innate immunity against invading microorganisms, and are also important 
for initiating and directing the development of adaptive immune responses. One of the 
aims of this study was to investigate the signalling mechanisms underlying the induction 
of cytokine production resulting from activation of macrophages with LPS. The roles of 
p38 and ERK MAP kinases in induction of IL-12, IL - 6  and TNF-a were dissected using 
specific inhibitors of these signalling molecules, and are summarised in Table 6.1 and 
Figure 6.1.
p38 was shown to be a key mediator of LPS signalling; activation of this MAP 
kinase is required for the synthesis of both subunits of IL-12, as well as IL-6 , TNF-a and 
iNOS. In contrast, only TNF-a and iNOS induction are ERK-dependent. Furthermore, 
transcription of the IL-12 p40 gene is negatively regulated by ERK MAP kinases, which 
appear to act, at least in part, by suppressing the positive p38-mediated signals. The 
suppression of synthesis of p40, which is in any case produced in vast excess over the 
p35 subunit, is likely to serve to achieve an appropriate balance between the formation of 
bioactive IL-12 p70 and antagonistic p40 homodimers. IL-12 and iNOS, but not TNF-a, 
are regulated primarily at the level of transcription. Given that p38 but not ERK MAP 
kinases are required for IL-12 p35 and IL - 6  induction and the homology between their 
genes, it is likely that regulation of IL - 6  production by p38 MAP kinases, like IL-12 p35, 
occurs at the level of transcription or mRNA stability. Similarly, the recent report that 
p38 MAP kinase signals stabilise IL - 6  mRNA (Winzen et al, 1999) suggests that IL-12 
p35 transcripts could also be regulated in this way. Although LPS stimulation does result
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in dramatic induction of TNF-a mRNA, transcription of the TNF-a gene does not appear 
to be regulated by the ERK MAP kinases, which must therefore mediate translation or 
release of TNF-a protein. In contrast, p38 MAP kinase does appear to regulate TNF-a 
transcription or message stability, although it is also likely to act at later stages of TNF-a 
synthesis.
The physiological relevance of these observations was underlined by the 
demonstration that these signalling cascades are targeted by pathogen molecules to 
subvert macrophage activation and cytokine production.
Leishm ania  sp. parasites evade destruction by the host immune system by 
suppressing IL-12 production by macrophages, thus preventing the establishment of a 
Thl response and the generation of NO. A number of other intracellular pathogens 
including the yeast H istoplasm a capsulatum , measles virus and human 
immunodeficiency virus also inhibit IL-12 production (reviewed by Mosser and Karp, 
1999). The Leishm ania  surface molecule lipophosphoglycan (LPG) has been 
demonstrated to mediate this suppression (Piedrafita et a l, 1999). In this study, sPG, a 
synthetic version of the repeating disaccharide component of LPG, was shown to 
selectively inhibit the induction of IL-12 by LPS. This inhibition is achieved by 
enhancing ERK MAP kinase activation and thereby suppressing transcription of the IL- 
12 p40 gene. The enhancement of ERK activity by sPG had no effect on TNF-a or iNOS 
induction, indicating that although they are necessary, ERK MAP kinases are not 
sufficient for induction of these macrophage mediators, but require additional signals to 
achieve upregulation of production.
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Similarly, inhibition of IFN - 7  + LPS-induced IL-12 production by the ES product 
of the filarial nematode A. viteae (ES-62) appears to be achieved via modulation of ERK 
activation, although by a more complex mechanism than that employed by sPG. 
Suppression of IL-12 p40 generation occurred at the transcriptional level, but mRNA 
production was not as dramatically reduced as protein, indicating that ES-62 also targets 
translation, post-translational modification or assembly of bio active IL-12. Reduced 
transcription of the IL-12 p35 gene further contributes to the inhibition of bioactive IL-12 
generation. ES-62 also suppresses the induction of IL - 6  and TNF-a production. 
Transcription of the TNF-a gene was not altered by ES-62, suggesting that translation or 
release of protein trom macrophages must be targeted by ES-62. Therefore, these results 
(summarised in Table 6.2 and Figure 6.2) support the idea that inhibition is achieved by 
modulation of multiple signals.
Taken together, these data demonstrate how the same signal can result in the 
uncoordinated induction of multiple factors using a limited set of signalling molecules. 
Thus, regulation of cytokine and iNOS production is achieved by different combinations 
of common mediators, enabling either independent or collective induction of these factors 
by the host. This also provides an opportunity for selective modulation of macrophage 
function by pathogens, which by targeting different pathways or steps in a pathway can 
alter the induction of a single or multiple immune mediators.
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6:2 Future Work.
The data presented demonstrate crucial roles for MAP kinases in the regulation of 
production of macrophage immune mediators, with differential roles in IL-12, IL-6 , TNF- 
a and iNOS synthesis. Further investigation of the mechanisms involved would be 
interesting, in particular, the ERK-mediated regulation of IL-12 p40. The data indicate 
that ERK MAP kinases target the IRE family of transcription factors to achieve regulation 
of IL-12 p40 induction. IL-12 p40 promoter constructs could be used to identify the 
regions of the promoter required for ERK regulation.
The pathway upstream of ERK activation could also be investigated. Preliminary 
evidence suggests that phosphoinositide-3-kinase (PI-3K) might be responsible for the 
ERK-mediated suppression of IL-12 p40. This enzyme catalyses the conversion of PI- 
(4 ,5 )P2  to PI-(3 ,4 ,5 )P3 , resulting in the activation of PKC which has been implicated in 
the activation of MEKl, and hence PI-3K could mediate ERK activation by LPS. Indeed, 
stimulation of macrophages following pre-incubation for 1 hour with the PI-3K inhibitor 
wortmannin, like PD 098059 pre-incubation, resulted in enhanced IL-12 p40 production 
(Figure 6.3).
Similarly, macrophages cultured in calcium-free medium produced more IL-12 
p40 (Figure 6.4), suggesting that calcium fluxes may also regulate IL-12 production. 
Indeed, calcium has also been implicated in the activation of the ERK pathway in many 
systems (Chao et a l, 1992; Rosen et a l,  1994; Zohn et a l, 1995). Furthermore, 
Leishmania infection of monocytes has been shown to result in elevated intracellular 
calcium levels resulting from increased permeability of plasma membrane Ca^ "^  channels
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(Olivier et al, 1992) and this could therefore provide a link to the suppression of IL-12 
production by sPG. Consistent with this, blocking of calcium influx using EGTA has 
previously been shown to prevent suppression of IL-12 p40 production following ligation 
of macrophage receptors (including CR3 which binds LPG), without affecting other 
cytokines such as IL-10 and TNF-a (Sutterwala et al, 1997).
The role of INK MAP kinases in the induction of cytokines and iNOS cannot be 
investigated by inhibitor studies as there is at present no known selective inhibitor of 
these MAP kinases. However, JNK-deficient macrophages could be used to dissect the 
roles of this MAP kinase subfamily in macrophage activation. These could be obtained 
either by transient transfection with dominant negative INK or antisense 
oligonucleotides, or from knock-out animals. In this way, JNKs have previously been 
implicated in the regulation of IL-12, TNF-a and NO (Swantek et a l, 1997; Constant et 
al, 2 0 0 0 ).
Further investigation is required to understand how ES-62 achieves its selective 
inhibition of macrophage functions, including more detailed study of MAP kinase 
activation e.g. role of p38 and INK MAP kinases. ES-62 disrupts antigen receptor 
signalling in B and T lymphocytes, resulting in enhanced tyrosine phosphorylation and 
the uncoupling of MAP kinase cascades from antigen receptors (Deehan et a l, 1997, 
Harnett et a l, 1998). As demonstrated in this study, ES-62 has similar effects on 
signalling molecules in macrophages. It has also been shown to target other signalling 
molecules in lymphocytes, including PI-3K, PKC and phospholipase C (PLC) (reviewed 
by Harnett and Harnett, 1999); the effects of ES-62 on these molecules could also be
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investigated in macrophages. The roles of transcription factors such as NF-kB and IRF 
family members could also be further analysed.
The results described in chapter 5 suggest that ES-62 either subverts LPS-receptor 
signalling or alternatively, initiates a signalling pathway that negatively regulates LPS 
signalling. TaqMan analysis of TLR4 mRNA showed that transcription of this LPS 
receptor is not altered by ES-62 (Figure 6.5). However, the membrane expression of 
TLR4 may be suppressed, thereby preventing the transduction of LPS signals. This 
possibility could be investigated by flow cytometry. Alternatively, preliminary evidence 
in human PBMC-derived dendritic cells suggests that ES-62 could inhibit cytokine 
production by down-regulating CD 14 expression at the cell surface (R. Callard, personal 
communication to W. Harnett). Disruption of LPS binding could explain why 
macrophages were defective for induction of cytokines by LPS, but still able to produce 
NO, since iNOS induction was more dependent on IFN-y than LPS signals. This would be 
similar to the situation in B cells where ES-62 uncouples various signalling pathways 
from the BCR, including the ERK MAP kinase cascade, to prevent proliferation 
(reviewed by Harnett and Harnett, 1999).
Preliminary experiments suggest that ES-62 may also function inside the cell 
since it is present in macrophage cytoplasmic and nuclear protein fractions (not shown). 
ES-62 shares homology with aminopeptidases and indeed, has been demonstrated to 
possess aminopeptidase activity (Harnett et al, 1999b), although the function of this is at 
present unknown. An E. coli aminopeptidase (PepA/CarP/XerB) has been shown to bind 
DNA (Charlier et a l, 1995); hence it would be interesting to determine whether ES-62 
achieves immunomodulation by binding to promoter sequences. The presence of leucine
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rich repeats suggests that ES-62 could form dimers with leucine zipper transcription 
factors such as C/EBP and NF-IL 6 , which are known to regulate pro-inflammatory 
cytokine induction.
The ES-62 receptor is at present unknown, but BiaCore analysis indicated that 
ES-62 binds to monocyte membrane fractions with receptor-like affinity and in a PC- 
dependent manner (W. Harnett, personal communication). PC has been detected in a wide 
range of prokaryotic and eukaryotic pathogens including both Gram positive and negative 
bacteria, fungi, protozoa such as Leishmania major and Trypanosoma cruzi, several 
gastrointestinal nematodes and all species of filarial nematodes examined (Harnett and 
Harnett, 1999). It therefore seems likely that ES-62 could be recognised via binding of 
PC to pattern recognition receptors, such as the TLRs. Furthermore, the presence of 
leucine rich repeats (LRRs) in the ES-62 protein suggests that it could associate with 
other proteins, such as TLRs which also have LRRs.
Preliminary evidence from Far Western Blotting analysis using ES-62 conjugated 
to biotin indicated that ES-62 binds to several proteins from a variety of cell types 
including monocytic and B and T cell lines, including a protein of approximately 82 kDa 
(not shown). This band was again detected when the blot was stripped and reprobed with 
an anti-TLR2 antibody, suggesting that ES-62 may achieve immunomodulation by 
signalling through TLR2. This receptor is present on many different cell types (Muzio et 
ai, 2 0 0 0 ), suggesting that a common mechanism may operate to disrupt the normal 
activation of both innate and adaptive immune cells following antigen binding. 
Interestingly, TaqMan analysis showed that TLR2 expression is transiently enhanced by 
treatment with ES-62 alone (Figure 6.5).
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In Drosophila development, Toll receptor signalling is initiated by the binding of 
an endogenous protein encoded by the spaetzle gene (reviewed by Anderson, 1998). A 
mammalian homologue of Spaetzle has not yet been identified, but the binding of 
endogenous factors to Toll-like receptors fits with the Danger Theory of immune system 
activation. Macrophages and dendritic cells could be activated by the binding of an 
endogenous ligand to TLR4 (mimicked by LPS in the in vitro system) as a result of 
damage caused by the parasite. The presence of ES-62 would prevent the detection of this 
alarm signal, thereby suppressing cytokine induction, and resulting in suppression of host 
immunity and a bias of the T helper cell response towards a type 2 phenotype.
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6:3 Concluding Remarks.
The development of therapies for treatment of infection requires the 
understanding both of normal mechanisms of host immune regulation and of evasion of 
immune responses by invading pathogens. The use of the two parasite molecules (sPG 
and ES-62) in this investigation not only enabled the study of subversion of cytokine 
production by parasites, but also revealed information about how MAP kinase isoforms 
regulate cytokine synthesis by macrophages. Furthermore, such immunomodulatory 
pathogen molecules are themselves potential therapeutic agents for the control of immune 
diseases. For example, since ES-62 biases T helper cell responses towards a type 2 
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Table 6.1. Roles of ERK and p38 MAP kinases in induction of cytokines and iNOS 
by stimulation of macrophages with LPS.
Induction of both subunits of IL-12, as well as IL-6 , TNF-a and iNOS, by stimulation of 
macrophages with LPS in the presence/absence of IFN-y requires signals mediated by 
p38 MAP kinase. ERK MAP kinase signals are also required for synthesis of TNF-a and 
iNOS, but negatively regulate IL-12 p40 production. Regulation is likely to occur at 
multiple levels including transcription, message stability, translation, post-translational 
modification and release from the cell.
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Figure 6.1. Roles of MAP kinases in the induction of cytokines and iNOS by LPS.
Stimulation of macrophages with LPS results in activation of ERK, p38 and JNKMAP 
kinases. The roles of the ERK and p38 MAP kinases in the induction of IL-12, IL-6 , 
TNF-a and iNOS are indicated. The involvement of the JNKs is not clear due to the 
unavailability of a selective inhibitor of these MAP kinases.
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Table 6.2. Suppression of cytokine production by ES-62.
ES-62 suppresses the induction of IL-12, IL - 6  and TNF-a by macrophages activated with 
IFN-y + LPS. The table summarises the level of synthesis of each cytokine that is 
targeted by ES-62 and whether this effect is mediated by ERK MAP kinases.
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Figure 6.2. Suppression of cytokine induction by ES-62.
Stimulation of macrophages with IFN-y + LPS results in induction of IL-12, IL-6 , TNF-a 
and iNOS expression. ES-62 suppresses bioactive IL-12 production by reducing the 
synthesis of both the p40 and the p35 subunits. It also inhibits IL- 6  and TNF-a induction, 
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Figure 6.3. Effect of PI-3 kinase inhibition on IL-12 production and macrophage 
viability.
J774 cells (2xlOVwell in a 96-well plate) were stimulated with 100 U/ml IFN-y and/or 
100 ng/ml LPS in the presence/absence of 5 nM wortmannin, an inhibitor of PI-3 
kinase. IL-12 p40 in 24 hour culture supernatants was measured by ELISA and cell 





















I  0.15 H
oN 
LO







m edium  IFN-y LPS IFN-y
LPS
m edium  IFN-y LPS IFN-y 
LPS
□  normal medium ^  Ca^+ free medium
C 0.4  1
^  0 .2 - 
9
CL
1.8 mM CaClg ^ 4-
normal Ca^+ free  
m edium  medium
IFN-y + LPS
Figure 6.4. Stimulation of macrophages in calcium-free medium.
Murine peritoneal macrophages (2xl0Vwell in a 96-well plate) were cultured in normal 
medium, calcium-free medium, or calcium-free medium with the calcium replaced by 
addition of 1.8 mM CaClg, prior to stimulation with 100 U/ml IFN-y and/or 100 ng/ml 
LPS for 24 hours. IL-12 p40 in culture supernatants was measured by ELISA and cell 
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Figure 6.5. Effect of ES-62 treatment on TLR2 and TLR4 mRNA levels.
Thioglycollate-elicited peritoneal macrophages from BALB/c mice (4x10^ cells/25 cm^ 
flask) were treated with 2 pg/ml ES-62 for the times indicated. Total RNA was purified 
from cells and TLR2 and TLR4 transcripts were assayed by real-time PCR (TaqMan). 
mRNA levels are expressed relative to HPRT mRNA.
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